{"protocolSection":{"identificationModule":{"nctId":"NCT03819049","orgStudyIdInfo":{"id":"CR108580"},"secondaryIdInfos":[{"id":"VAC52416BAC1001","type":"OTHER","domain":"Janssen Research & Development, LLC"},{"id":"2020-000657-27","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Janssen Research & Development, LLC","class":"INDUSTRY"},"briefTitle":"A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health","officialTitle":"A Randomized, Observer-blind, First-in-Human Phase 1/2a Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health"},"statusModule":{"statusVerifiedDate":"2026-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-06-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-06-08","type":"ACTUAL"},"completionDateStruct":{"date":"2024-12-18","type":"ACTUAL"},"studyFirstSubmitDate":"2019-01-25","studyFirstSubmitQcDate":"2019-01-25","studyFirstPostDateStruct":{"date":"2019-01-28","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-05-30","resultsFirstSubmitQcDate":"2024-05-30","resultsFirstPostDateStruct":{"date":"2024-06-25","type":"ACTUAL"},"dispFirstSubmitDate":"2022-06-03","dispFirstSubmitQcDate":"2022-06-03","dispFirstPostDateStruct":{"date":"2022-06-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-06-04","lastUpdatePostDateStruct":{"date":"2026-06-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the safety, reactogenicity, and immunogenicity of 3 different doses of ExPEC10V and to select the optimal dose for further clinical development (Cohort 1). Cohort 2 is aimed to expand the dataset supporting the short- and long-term safety and immunogenicity of the optimal dose of ExPEC10V, selected from the primary analysis results of Cohort 1. Cohort 2 will include participants in stable health with a history of urinary tract infection (UTI) in the past 5 years and will be included in the study to support the plan for late stage development of ExPEC vaccine.","detailedDescription":"ExPEC10V (JNJ-69968054) is a 10-valent vaccine candidate in development for prevention of invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease (IED) in adults 60 years of age and older. ExPEC10V consists of O-antigen polysaccharides (PSs) of the ExPEC serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B and O75 separately bioconjugate to the carrier protein, a genetically detoxified form of exotoxin A (EPA) derived from Pseudomonas aeruginosa. Since, mechanism of action of conjugate vaccines in prevention of invasive disease is not expected to be affected by antibiotic resistance mechanisms, ExPEC10V vaccine may provide protection against IED caused by drug resistant and susceptible ExPEC serotypes. The study consists of two cohorts. Cohort 1 is comprised of three periods: a screening period (28 days), an observer-blind follow-up period (181 days) with vaccination on Day 1, and an open-label long term follow up (LTFU) period (from Day 182 until 5 years \\[Day 1826\\] post-vaccination). Cohort 2 is also comprised of three periods: a screening period (28 days), a double-blind follow-up period (181 days) with vaccination on Day 1, and a double-blind LTFU period (from Day 182 until 1 years \\[Day 366\\] post-vaccination). The end of Cohort 1 is considered as the Year 5 visit (Day 1826) for the last participant. The end of Cohort 2 is considered as the Year 1 visit (Day 366) for the last participant. Key immunogenicity assessments will include the assessment of ExPEC10V and ExPEC4V serotype-specific total immunoglobulin G antibody levels elicited by the vaccine and ExPEC10V and ExPEC4V serotype-specific functional antibodies. Key safety assessments include solicited local and systemic AEs, unsolicited AEs, SAEs, physical examinations, vital sign measurements, and, for Cohort 1 only, clinical laboratory tests. The total duration of the study is up to 5 years."},"conditionsModule":{"conditions":["Extraintestinal Pathogenic Escherichia Coli Prevention"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"OTHER","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":836,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1: ExPEC10V (Low Dose)","type":"EXPERIMENTAL","description":"Participants will be randomized to receive a single intramuscular (IM) injection of low dose ExPEC10V on Day 1.","interventionNames":["Biological: ExPEC10V"]},{"label":"Cohort 1: ExPEC10V (Medium dose)","type":"EXPERIMENTAL","description":"Participants will be randomized to receive a single IM injection of medium dose ExPEC10V on Day 1.","interventionNames":["Biological: ExPEC10V"]},{"label":"Cohort 1: ExPEC10V (High dose)","type":"EXPERIMENTAL","description":"Participants will be randomized to receive a single IM injection of high dose ExPEC10V on Day 1.","interventionNames":["Biological: ExPEC10V"]},{"label":"Cohort 1: ExPEC4V","type":"EXPERIMENTAL","description":"Participants will be randomized to receive a single IM injection of ExPEC4V on Day 1.","interventionNames":["Biological: ExPEC4V"]},{"label":"Cohort 1: Prevnar 13","type":"EXPERIMENTAL","description":"Participants will be randomized to receive a single IM injection of Prevnar 13 on Day 1.","interventionNames":["Biological: Prevnar 13"]},{"label":"Cohort 2: ExPEC10V","type":"EXPERIMENTAL","description":"Participants will be randomized to receive a single IM injection of selected dose of ExPEC10V on Day 1. The ExPEC10V dose used in Cohort 2 will be based on the primary analysis (Day 30) results of Cohort 1.","interventionNames":["Biological: ExPEC10V"]},{"label":"Cohort 2: Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will be randomized to receive a single IM injection of matching placebo on Day 1.","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"ExPEC10V","description":"Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \\[low or medium or high\\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.","armGroupLabels":["Cohort 1: ExPEC10V (High dose)","Cohort 1: ExPEC10V (Low Dose)","Cohort 1: ExPEC10V (Medium dose)","Cohort 2: ExPEC10V"],"otherNames":["VAC52416"]},{"type":"BIOLOGICAL","name":"ExPEC4V","description":"Participants will receive a single IM injection of ExPEC4V on Day 1.","armGroupLabels":["Cohort 1: ExPEC4V"],"otherNames":["JNJ-63871860"]},{"type":"BIOLOGICAL","name":"Prevnar 13","description":"Participants will receive a single IM injection of Prevnar 13 on Day 1.","armGroupLabels":["Cohort 1: Prevnar 13"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Participants will receive single IM injection of matching placebo on Day 1.","armGroupLabels":["Cohort 2: Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Cohort 1: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) for 14 Days After Vaccination on Day 1","description":"Number of participants with solicited local AEs for 14 days after vaccination on Day 1 were reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local (injection site) AEs included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site). All solicited AEs at the injection site (local) were considered related to the study vaccine administration.","timeFrame":"Up to 14 days post vaccination on Day 1 (from Day 1 up to Day 15)"},{"measure":"Cohort 1: Number of Participants With Solicited Systemic Adverse Events (AEs) Collected for 14 Days After Vaccination on Day 1","description":"Number of participants with solicited systemic AEs 14 days after vaccination on Day 1 were reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. Solicited systemic AEs included fatigue, headache, nausea, fever and myalgia, for which participants were specifically questioned and which were noted by participants in their participant diary for 14 days post-vaccination (day of vaccination and the subsequent 14 days).","timeFrame":"Up to 14 days post vaccination on Day 1 (from Day 1 up to Day 15)"},{"measure":"Cohort 1: Number of Participants With Unsolicited Adverse Events (AEs) up to 29 Days After Vaccination on Day 1","description":"Number of participants with unsolicited AEs up to 29 days after vaccination on Day 1 were reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. Unsolicited AEs were all AEs for which the participant is not specifically questioned in the participant diary.","timeFrame":"Up to 29 days post vaccination on Day 1 (from Day 1 up to Day 30)"},{"measure":"Cohort 1: Number of Participants With Serious Adverse Events (SAEs) up to Day 181","description":"Number of participants with SAEs up to Day 181 were reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","timeFrame":"Day 1 (post vaccination) up to Day 181"},{"measure":"Cohort 2: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) Collected for 14 Days After Vaccination on Day 1","description":"Number of participants with solicited local AEs for 14 days after vaccination on Day 1 were reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local (injection site) AEs included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site). All solicited AEs at the injection site (local) were considered related to the study vaccine administration.","timeFrame":"Up to 14 days post vaccination on Day 1 (from Day 1 up to Day 15)"},{"measure":"Cohort 2: Number of Participants With Solicited Systemic Adverse Events (AEs) Collected for 14 Days After Vaccination on Day 1","description":"Number of participants with solicited systemic AEs 14 days after vaccination on Day 1 were reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. Solicited systemic AEs included fatigue, headache, nausea, fever and myalgia, for which participants were specifically questioned and which were noted by participants in their participant diary for 14 days post-vaccination (day of vaccination and the subsequent 14 days).","timeFrame":"Up to 14 days post vaccination on Day 1 (from Day 1 up to Day 15)"},{"measure":"Cohort 2: Number of Participants With Unsolicited Adverse Events (AEs) 29 Days After Vaccination on Day 1","description":"Number of participants with unsolicited AEs up to 29 days after vaccination on Day 1 were reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. Unsolicited AEs were all AEs for which the participant is not specifically questioned in the participant diary.","timeFrame":"Up to 29 days post vaccination on Day 1 (from Day 1 up to Day 30)"},{"measure":"Cohort 2: Number of Participants With Serious Adverse Events (SAEs) up to Day 181","description":"Number of participants with SAEs up to Day 181 were reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","timeFrame":"Day 1 (post vaccination) up to Day 181"},{"measure":"Cohort 1: Geometric Mean Titers (GMTs) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex Electrochemiluminescent (ECL) Based Immunoassay on Day 15","description":"GMTs of serotype-specific total IgG serum antibodies as measured by multiplex ECL based immunoassay were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and exotoxin protein A (EPA) were determined in serum from collected blood samples. Lower limit of quantification (LLOQ) values for O1A: 69149, O2: 65287, O4: 67356, O6A: 150748, O8: 72196, O15: 66910, O16: 71586, O18A: 70519, O25B: 61990, O75: 133019, and EPA: 66165. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"Day 15"},{"measure":"Cohort 1: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype Specific Antibodies as Measured by Multiplex ECL Based Immunoassay on Day 15","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by multiplex ECL based immunoassay on Day 15 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples by multiplex ECL based immunoassay. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 15 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 15"},{"measure":"Cohort 1: Percentage of Participants With a Greater Than or Equal to (>=) 2-Fold and >=4-Fold Increase From Baseline in Serotype Specific Serum Antibody Titers as Measured by Multiplex ECL Based Immunoassay on Day 15","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase (FI) from baseline in serotype specific serum antibody titers as measured by multiplex ECL based immunoassay on Day 15 was reported. The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Day 15 for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA was calculated as the ratio of titer values of serum antibody on Day 15 and pre-vaccination (on day 1) that is Day 15/Day 1. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 15"},{"measure":"Cohort 1: Geometric Mean Titers (GMT) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex Opsonophagocytic Assay (MOPA) on Day 15","description":"GMTs of serotype-specific total IgG serum antibodies as measured by MOPA were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples. LLOQ values were: O1A: 53, O2: 51, O4: 29, O6A: 47, O8: 196, O15: 37, O16: 54, O18A: 12, O25B: 65, and O75: 37. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"Day 15"},{"measure":"Cohort 1: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype Specific Antibodies as Measured by MOPA on Day 15","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by MOPA on Day 15 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples by MOPA. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 15 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination), Day 15"},{"measure":"Cohort 1: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by MOPA on Day 15","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by MOPA on Day 15 was reported. The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Day 15 for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, and O75 was calculated as the ratio of titer values of serum antibody on Day 15 and pre-vaccination (on day 1) that is, Day 15/Day 1. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 15"},{"measure":"Cohort 2: Geometric Mean Titers (GMTs) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex ECL Based Immunoassay on Day 30","description":"GMTs of serotype-specific total IgG serum antibodies as measured by multiplex ECL based immunoassay were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples. LLOQ values for O1A: 69149, O2: 65287, O4: 67356, O6A: 150748, O8: 72196, O15: 66910, O16: 71586, O18A: 70519, O25B: 61990, O75: 133019, and EPA: 66165. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"At Day 30"},{"measure":"Cohort 2: Geometric Mean Ratio (GMR) of Fold Changes From Baseline For Serotype-specific Antibodies Measured by Multiplex ECL Based Immunoassay on Day 30","description":"GMR of fold changes from baseline for serotype-specific antibodies as measured by multiplex ECL based immunoassay on Day 30 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples by multiplex ECL based immunoassay. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 30 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 30"},{"measure":"Cohort 2: Percentage of Participants With a >=2-Fold and >=4-Fold Increase From Baseline in Serotype Specific Serum Antibody Titers as Measured by Multiplex ECL Based Immunoassay on Day 30","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by multiplex ECL based immunoassay on Day 30 was reported. The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Day 30 for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA was calculated as the ratio of titer values of serum antibody on Day 30 and pre-vaccination (on day 1) that is, Day 30/Day 1. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 30"},{"measure":"Cohort 2: Geometric Mean Titer (GMT) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex Opsonophagocytic Assay (MOPA) on Day 30","description":"GMTs of serotype-specific total IgG serum antibodies as measured by MOPA were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75 were determined in serum from collected blood samples. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. LLOQ values were O1A: 33, O2: 42, O4: 12, O6A: 62, O15: 75, O16: 17, O18A: 44, O25B: 58, O75: 14. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"At Day 30"},{"measure":"Cohort 2: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype Specific Antibodies as Measured by MOPA on Day 30","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by MOPA on Day 30 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples by MOPA. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 30 and pre-vaccination (on Day 1). For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 30"},{"measure":"Cohort 2: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibodies Titers Measured by MOPA on Day 30","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibodies titers as measured by MOPA on Day 30 was reported. The fold (\\>=2-fold and \\>=4-fold increase from baseline to Day 30 for the serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 was calculated as the ratio of titer values of serum antibodies on Day 30 and pre-vaccination (on day 1 that is, Day 30/Day 1. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 30"}],"secondaryOutcomes":[{"measure":"Cohort 1: Correlation Between the Multiplex ECL-Based Immunoassay and the MOPA Functional Titers by Serotypes on Day 15","description":"Correlation between the multiplex ECL-based immunoassay and the MOPA functional titers by serotypes (O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B and O75) on Day 15 were analyzed. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"Day 15"},{"measure":"Cohort 1: Geometric Mean Titers (GMTs) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex ECL Based Immunoassay on Days 30 and 181","description":"GMTs of serotype-specific total IgG serum antibodies as measured by multiplex ECL based immunoassay on Days 30 and 181 were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples. LLOQ values for O1A: 69149, O2: 65287, O4: 67356, O6A: 150748, O8: 72196, O15: 66910, O16: 71586, O18A: 70519, O25B: 61990, O75: 133019, and EPA: 66165. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"Days 30 and 181"},{"measure":"Cohort 1: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype-specific Antibodies Measured by Multiplex ECL Based Immunoassay on Days 30 and 181","description":"GMR of fold changes from baseline for serotype specific antibodies measured by multiplex ECL based immunoassay on Days 30 and 181 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples by ECL based immunoassay. GMR of fold change from baseline was calculated as the ratio of GMTs on Days 30 and 181 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Days 30 and 181"},{"measure":"Cohort 1: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase From Baseline in Serotype-specific Serum Antibody Titers as Measured by Multiplex ECL Based Immunoassay on Days 30 and 181","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype (ST)-specific serum antibody titers as measured by multiplex ECL based immunoassay on Days 30 and 181 was reported. The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Days 30 and 181 for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA was calculated as the ratio of titer values of serum antibody on Day 30 and Day 181 and pre-vaccination (on Day 1 that is, Day 30/Day 1 and Day 181/Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Day 1 (pre-vaccination) and Days 30 and 181"},{"measure":"Cohort 1: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype Specific Antibodies as Measured by MOPA on Days 30 and 181","description":"GMRs for each O-antigen (serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75) were determined using a validated MOPA. For sample pairs with available validated MOPA results from both Day 1 and Day 30, or Day 1 and 181, GMR from baseline for serotype specific antibodies was calculated as the ratio of GMTs on Days 30 or 181 and pre-vaccination (on Day 1). For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Days 30 and 181"},{"measure":"Cohort 1: Geometric Mean Titers (GMTs) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by MOPA on Days 30 and 181","description":"GMTs of serotype-specific total IgG serum antibodies as measured by MOPA on Days 30 and 181 were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A,O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. LLOQ values were O1A: 33, O2: 42, O4: 12, O6A: 62, O15: 75, O16: 17, O18A: 44, O25B: 58, O75: 14. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"Days 30 and 181"},{"measure":"Cohort 1: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by MOPA on Days 30 and 181","description":"For sample pairs with available validated MOPA results, for each O-antigen (serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75), the fold increase was calculated as the ratio of validated MOPA results on Days 30 or 181 and pre-vaccination (Day 30/Day 1 and 181/Day 1). The percentage of participants with \\>=2-fold and \\>=4-fold increase in serotype-specific serum antibody titers was calculated. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Day 1 (pre-vaccination) and Days 30 and 181"},{"measure":"Cohort 1: Number of Participants With Serious Adverse Events (SAEs) Related to Study Vaccine or Study Procedure From Day 182 up to End of Study (Day 1826)","description":"Number of participants with SAEs related to study vaccine or study procedure was reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent understudy. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","timeFrame":"From Day 182 up to end of study (Day 1826)"},{"measure":"Cohort 1: Geometric Mean Titers (GMTs) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex ECL Based Immunoassay on Days 366, 731, 1096, 1461 and 1826","description":"GMTs of serotype-specific total IgG serum antibodies as measured by ECL based immunoassay were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples. LLOQ values for O1A: 69149, O2: 65287, O4: 67356, O6A: 150748, O8: 72196, O15: 66910, O16: 71586, O18A: 70519, O25B: 61990, O75: 133019, and EPA: 66165. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"Days 366, 731, 1096, 1461 and 1826"},{"measure":"Cohort 1: Percentage of Participants With a >=2-Fold and >=4-Fold Increase From Baseline in Serotype Specific Serum Antibody Titers as Measured by Multiplex ECL Based Immunoassay on Days 366, 731, 1096, 1461 and 1826","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by multiplex ECL based immunoassay on Days 366, 731, 1096, 1461, and 1826 was reported. The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Days 366, 731, 1096, 1461, and 1826 for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA was calculated as the ratio of titer values of serum antibody on Days 366, 731, 1096, 1461 and 1826 and pre-vaccination (on day 1) that is, Day 366/Day 1, 731/Day 1, 1096/Day 1, 1461/Day 1 and 1826/Day 1. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Days 366, 731, 1096, 1461, 1826"},{"measure":"Cohort 1: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype-specific Antibodies Measured by Multiplex ECL Based Immunoassay on Days 366, 731, 1096, 1461 and 1826","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by multiplex ECL based immunoassay on Days 366, 731, 1096, 1461 and 1826 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples by ECL based immunoassay. GMR of fold change from baseline was calculated as the ratio of GMTs on Days 366, 731, 1096, 1461 and 1826 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Days 366, 731, 1096, 1461, 1826"},{"measure":"Cohort 1: Geometric Mean Titer (GMT) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by MOPA on Days 366, 731, 1096, and 1461","description":"GMTs of serotype-specific total IgG serum antibodies as measured by MOPA were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Data was planned to be analyzed for specified arms only. LLOQ values for O1A: 33, O2: 42, O4: 12, O6A: 62, O15: 75, O16: 17, O18A: 44, O25B: 58, O75: 14. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"Days 366, 731, 1096, 1461"},{"measure":"Cohort 1: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype Specific Antibodies as Measured by MOPA on Days 366, 731, 1096, and 1461","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by MOPA on Days 366, 731, 1096, 1461 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples by MOPA. GMR of fold change from baseline was calculated as the ratio of GMTs on Days 366, 731, 1096, 1461 and pre-vaccination (on Day 1). For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Days 366, 731, 1096, 1461"},{"measure":"Cohort 1: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by MOPA on Days 366, 731, 1096, and 1461","description":"The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Days 366, 731, 1096, and 1461 for the serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75 was calculated as the ratio of titer values of serum antibody on Days 366, 731, 1096, 1461 and pre-vaccination (on day 1) that is, Day 366/Day 1, 731/Day 1, 1096/Day 1, 1461/Day 1. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Days 366, 731, 1096, and 1461"},{"measure":"Cohort 2: Correlation Between the Multiplex ECL-Based Immunoassay and the MOPA Functional Titers by Serotype on Day 30","description":"Correlation between the multiplex ECL-based immunoassay and the MOPA functional titers by serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75 on Day 30 was analyzed. Data was planned to be analyzed for specified arms only. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype.","timeFrame":"Day 30"},{"measure":"Cohort 2: Geometric Mean Titers (GMTs) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex ECL Based Immunoassay on Days 15 and 181","description":"GMTs of serotype-specific total IgG serum antibodies as measured by ECL based immunoassay were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples. Data was planned to be analyzed for specified arms only. LLOQ values for O1A: 69149, O2: 65287, O4: 67356, O6A: 150748, O8: 72196, O15: 66910, O16: 71586, O18A: 70519, O25B: 61990, O75: 133019, and EPA: 66165. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"At Days 15 and 181"},{"measure":"Cohort 2: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype-specific Antibodies Measured by Multiplex ECL Based Immunoassay on Days 15 and 181","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by multiplex ECL based immunoassay on Days 15 and 181 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, and O75 were determined in serum from collected blood samples by ECL based immunoassay. GMR of fold change from baseline was calculated as the ratio of GMTs on Days 15 and 181 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination), Days 15 and 181"},{"measure":"Cohort 2: Percentage of Participants With a >= 2-Fold Increase in Serotype-specific Serum Antibody Titers Measured by Multiplex ECL Based Immunoassay on Days 15 and 181","description":"Percentage of participants with a \\>=2-fold increase from baseline in serotype specific serum antibody titers as measured by multiplex ECL based immunoassay on Days 15 and 181 were reported. The fold (\\>=2-fold increase from baseline to Days 15 and 181) for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, and O75 was calculated as the ratio of titer values of serum antibody on Days 15 and 181 and pre-vaccination (on Day 1 that is Day 15/Day 1 and Day 181/Day 1).","timeFrame":"Baseline (Day 1, pre-vaccination), Days 15 and 181"},{"measure":"Cohort 2: Percentage of Participants With a >= 4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by Multiplex ECL Based Immunoassay on Days 15 and 181","description":"Percentage of participants with a \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by multiplex ECL based immunoassay on Days 15 and 181 were reported. The fold (\\>=4-fold increase from baseline to Days 15 and 181) for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, and O75 was calculated as the ratio of titer values of serum antibody on Days 15 and 181 and pre-vaccination (on Day 1 that is Day 15/Day 1 and Day 181/Day 1).","timeFrame":"Baseline (Day 1, pre-vaccination), Days 15 and 181"},{"measure":"Cohort 2: Geometric Mean Titers (GMTs) of Serotype-specific Total IgG Serum Antibodies Against Specified Antigens Measured by MOPA on Day 181","description":"GMTs of serotype-specific total IgG serum antibodies as measured by MOPA were reported. Serotypes: O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75 were determined in serum from collected blood samples. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. LLOQ values for O1A: 33, O2: 42, O4: 12, O6A: 62, O15: 75, O16: 17, O18A: 44, O25B: 58, O75: 14. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"At Day 181"},{"measure":"Cohort 2: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by MOPA on Day 181","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by MOPA on Day 181 was reported. The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Day 181 for the serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 was calculated as the ratio of titer values of serum antibody on Day 181 and pre-vaccination (on Day 1) that is, Day 181/Day 1. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 181"},{"measure":"Cohort 2: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype-specific Antibodies Measured by MOPA on Day 181","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by MOPA on Day 181 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples by MOPA. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 181 and pre-vaccination (on Day 1). For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination), Day 181"},{"measure":"Cohort 2: Number of Participants With Serious Adverse Events (SAEs) Related to Study Vaccine or Study Procedure From Day 182 up to End of Study (Day 1826)","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","timeFrame":"From Day 182 up to end of study (Day 1826)"},{"measure":"Cohort 2: Geometric Mean Titers (GMTs) of Serotype-specific Antibodies Against Specified Antigens Measured by Multiplex ECL Based Immunoassay on Day 366","description":"GMTs of serotype-specific antibodies as measured by ECL based immunoassay were reported. GMTs for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 were determined. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"At Day 366"},{"measure":"Cohort 2: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by Multiplex ECL Based Immunoassay on Day 366","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by multiplex ECL based immunoassay on Day 366 was reported. The fold (\\>=2-fold and \\>=4- fold) increase from baseline to Day 366 for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 was calculated as the ratio of titer values of serum antibodies on Day 366 and pre-vaccination (on day 1) that is, Day 366/ Day 1. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination), Day 366"},{"measure":"Cohort 2: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype-specific Antibodies Measured by Multiplex ECL Based Immunoassay on Day 366","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by multiplex ECL based immunoassay on Day 366 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 were determined in serum from collected blood samples by ECL based immunoassay. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 366 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination), Day 366"},{"measure":"Cohort 2: Geometric Mean Titers (GMTs) of Serotype-specific Total IgG Serum Antibodies Against Specified Antigens Measured by MOPA on Day 366","description":"GMTs of serotype-specific total IgG serum antibodies as measured by MOPA were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75 were determined in serum from collected blood samples. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. LLOQ values for O1A: 33, O2: 42, O4: 12, O6A: 62, O15: 75, O16: 17, O18A: 44, O25B: 58, O75: 14. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","timeFrame":"At Day 366"},{"measure":"Cohort 2: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype-specific Antibodies Measured by MOPA on Day 366","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by MOPA on Day 366 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples by MOPA. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 366 and pre-vaccination (on Day 1). For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination), Day 366"},{"measure":"Cohort 2: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by MOPA on Day 366","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by MOPA on Day 366 was reported. The \\>=2-fold and \\>=4-fold increase from baseline to Day 366 for the serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 was calculated as the ratio of titer values of serum antibody on Day 366 and pre-vaccination (on day 1) that is, Day 366/Day 1. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","timeFrame":"Baseline (Day 1, pre-vaccination), Day 366"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must have a body mass index (BMI) of greater than (\\>) 18.5 or less than 40 kilogram per meter square (kg/m\\^2)\n* Before randomization, a woman must be: postmenopausal - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause; or not intending to conceive by any methods\n* Must be healthy or medically stable\n* Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study\n* Willing and able to adhere to the lifestyle restrictions specified in this protocol\n* Agrees not to donate blood until 12 weeks after receiving the study vaccine\n\nExclusion Criteria:\n\n* Acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature greater than equal to \\>=38.0 degree Celsius (100.4 degree Fahrenheit) within 24 hours prior to the administration of study vaccine, or, applicable for Cohort 2 only, an ongoing or suspected symptomatic urinary tract infection (UTI); enrollment at a later date is permitted (provided the screening window of 28 days is respected)\n* History of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)\n* Known allergies, hypersensitivity, or intolerance to ExPEC10V or its excipients\n* Applicable for Cohort 1 only: known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the active control vaccines)\n* Contraindication to intramuscular (IM) injections and blood draws example, bleeding disorders\n* Abnormal function of the immune system\n* Has had major psychiatric illness and/or drug substance or alcohol abuse in the past 12 months","healthyVolunteers":true,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Research & Development, LLC Clinical Trial","affiliation":"Janssen Research & Development, LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Optimal Research 2","city":"Huntsville","state":"Alabama","zip":"35802","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"Optimal Research","city":"Melbourne","state":"Florida","zip":"32934","country":"United States","geoPoint":{"lat":28.08363,"lon":-80.60811}},{"facility":"Qps-Mra, Llc","city":"Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Optimal Research 1","city":"Peoria","state":"Illinois","zip":"61614","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Synexus Clinical Research US Inc 4","city":"Evansville","state":"Indiana","zip":"47714","country":"United States","geoPoint":{"lat":37.97476,"lon":-87.55585}},{"facility":"Johnson County Clin-Trials","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Synexus Clinical Research US Inc 2","city":"Richfield","state":"Minnesota","zip":"55432","country":"United States","geoPoint":{"lat":44.8833,"lon":-93.283}},{"facility":"Synexus Clinical Research US Inc 3","city":"Manhattan","state":"New York","zip":"10017","country":"United States","geoPoint":{"lat":40.78343,"lon":-73.96625}},{"facility":"Rochester Clinical Research, Inc","city":"Rochester","state":"New York","zip":"14609","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Synexus Clinical Research US Inc 1","city":"Akron","state":"Ohio","zip":"44311","country":"United States","geoPoint":{"lat":41.08144,"lon":-81.51901}},{"facility":"Synexus Clinical Research US Inc","city":"Columbus","state":"Ohio","zip":"43212","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Coastal Carolina Research Center","city":"North Charleston","state":"South Carolina","zip":"29405","country":"United States","geoPoint":{"lat":32.85462,"lon":-79.97481}},{"facility":"Anima","city":"Alken","zip":"3570","country":"Belgium","geoPoint":{"lat":50.87553,"lon":5.30558}},{"facility":"ATC Pharma","city":"Liège","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"Clinical Pharmacology Unit","city":"Merksem","zip":"2170","country":"Belgium","geoPoint":{"lat":51.24623,"lon":4.44903}},{"facility":"CHU Nantes","city":"Nantes","zip":"44093","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Hopital Cochin","city":"Paris","zip":"75014","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"APHP - Hopital Bichat - Claude Bernard","city":"Paris","zip":"75018","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"CHU Lyon Sud","city":"Pierre-Bénite","zip":"69495","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"facility":"Chu Rennes Hopital Pontchaillou","city":"Rennes","zip":"35000","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"CHRU Tours Hopital Bretonneau","city":"Tours","zip":"37000","country":"France","geoPoint":{"lat":47.39484,"lon":0.70398}},{"facility":"EB Flevo Research","city":"Almere Stad","zip":"1311 RL","country":"Netherlands","geoPoint":{"lat":52.37025,"lon":5.21413}},{"facility":"PRA Health Sciences","city":"Groningen","zip":"NZ 9728","country":"Netherlands","geoPoint":{"lat":53.21917,"lon":6.56667}},{"facility":"Hosp. Del Mar","city":"Barcelona","zip":"08003","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hosp Reina Sofia","city":"Córdoba","zip":"14004","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"facility":"Hosp. Univ. de La Princesa","city":"Madrid","zip":"28006","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hosp. Univ. La Paz","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hosp. Univ. Marques de Valdecilla","city":"Santander","zip":"39008","country":"Spain","geoPoint":{"lat":43.46589,"lon":-3.80493}},{"facility":"Hosp. Virgen Macarena","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}}]},"referencesModule":{"references":[{"pmid":"38877036","type":"DERIVED","citation":"Fierro CA, Sarnecki M, Spiessens B, Go O, Day TA, Davies TA, van den Dobbelsteen G, Poolman J, Abbanat D, Haazen W. A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI. NPJ Vaccines. 2024 Jun 14;9(1):106. doi: 10.1038/s41541-024-00885-1."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials\\\\transparency.\n\nAs noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu","url":"https://www.janssen.com/clinical-trials/transparency"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection of ExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"FG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"FG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"FG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"FG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."},{"id":"FG005","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"FG006","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"104"},{"groupId":"FG001","numSubjects":"102"},{"groupId":"FG002","numSubjects":"104"},{"groupId":"FG003","numSubjects":"53"},{"groupId":"FG004","numSubjects":"54"},{"groupId":"FG005","numSubjects":"280"},{"groupId":"FG006","numSubjects":"139"}]},{"type":"Vaccinated","achievements":[{"groupId":"FG000","numSubjects":"104"},{"groupId":"FG001","numSubjects":"102"},{"groupId":"FG002","numSubjects":"104"},{"groupId":"FG003","numSubjects":"52"},{"groupId":"FG004","numSubjects":"54"},{"groupId":"FG005","numSubjects":"278"},{"groupId":"FG006","numSubjects":"138"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"103"},{"groupId":"FG001","numSubjects":"100"},{"groupId":"FG002","numSubjects":"35"},{"groupId":"FG003","numSubjects":"52"},{"groupId":"FG004","numSubjects":"17"},{"groupId":"FG005","numSubjects":"268"},{"groupId":"FG006","numSubjects":"136"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"69"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"37"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"3"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"17"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"50"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"29"},{"groupId":"FG005","numSubjects":"9"},{"groupId":"FG006","numSubjects":"1"}]},{"type":"Randomized but not vaccinated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set (FAS) included all randomized participants with a vaccine administration documented.","groups":[{"id":"BG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"BG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"BG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"BG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"BG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."},{"id":"BG005","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"BG006","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."},{"id":"BG007","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"104"},{"groupId":"BG003","value":"52"},{"groupId":"BG004","value":"54"},{"groupId":"BG005","value":"278"},{"groupId":"BG006","value":"138"},{"groupId":"BG007","value":"832"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"66.2","spread":"5.77"},{"groupId":"BG001","value":"66.4","spread":"5.17"},{"groupId":"BG002","value":"65.1","spread":"5.15"},{"groupId":"BG003","value":"64.8","spread":"4.56"},{"groupId":"BG004","value":"65.9","spread":"5.44"},{"groupId":"BG005","value":"68.7","spread":"6.16"},{"groupId":"BG006","value":"69.1","spread":"7.21"},{"groupId":"BG007","value":"67.3","spread":"6.13"}]}]}]},{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"18-64 years","categories":[{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"63"},{"groupId":"BG003","value":"32"},{"groupId":"BG004","value":"29"},{"groupId":"BG005","value":"90"},{"groupId":"BG006","value":"48"},{"groupId":"BG007","value":"367"}]}]},{"title":"From 65 to 84 years","categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"41"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"25"},{"groupId":"BG005","value":"185"},{"groupId":"BG006","value":"88"},{"groupId":"BG007","value":"459"}]}]},{"title":"85 years and above","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"31"},{"groupId":"BG004","value":"28"},{"groupId":"BG005","value":"220"},{"groupId":"BG006","value":"111"},{"groupId":"BG007","value":"559"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"39"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"26"},{"groupId":"BG005","value":"58"},{"groupId":"BG006","value":"27"},{"groupId":"BG007","value":"273"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"38"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"113"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"86"},{"groupId":"BG003","value":"46"},{"groupId":"BG004","value":"47"},{"groupId":"BG005","value":"237"},{"groupId":"BG006","value":"117"},{"groupId":"BG007","value":"703"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"16"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"3"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"3"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"51"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"93"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"90"},{"groupId":"BG003","value":"48"},{"groupId":"BG004","value":"50"},{"groupId":"BG005","value":"261"},{"groupId":"BG006","value":"129"},{"groupId":"BG007","value":"762"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"10"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"BELGIUM","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"40"},{"groupId":"BG006","value":"24"},{"groupId":"BG007","value":"64"}]}]},{"title":"FRANCE","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"39"},{"groupId":"BG006","value":"21"},{"groupId":"BG007","value":"60"}]}]},{"title":"NETHERLANDS","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"40"},{"groupId":"BG006","value":"11"},{"groupId":"BG007","value":"51"}]}]},{"title":"SPAIN","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"30"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"42"}]}]},{"title":"UNITED STATES","categories":[{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"104"},{"groupId":"BG003","value":"52"},{"groupId":"BG004","value":"54"},{"groupId":"BG005","value":"129"},{"groupId":"BG006","value":"70"},{"groupId":"BG007","value":"615"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Cohort 1: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) for 14 Days After Vaccination on Day 1","description":"Number of participants with solicited local AEs for 14 days after vaccination on Day 1 were reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local (injection site) AEs included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site). All solicited AEs at the injection site (local) were considered related to the study vaccine administration.","populationDescription":"Full analysis set (FAS) included all randomized participants with a vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 14 days post vaccination on Day 1 (from Day 1 up to Day 15)","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"104"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"40"}]}]}]},{"type":"PRIMARY","title":"Cohort 1: Number of Participants With Solicited Systemic Adverse Events (AEs) Collected for 14 Days After Vaccination on Day 1","description":"Number of participants with solicited systemic AEs 14 days after vaccination on Day 1 were reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. Solicited systemic AEs included fatigue, headache, nausea, fever and myalgia, for which participants were specifically questioned and which were noted by participants in their participant diary for 14 days post-vaccination (day of vaccination and the subsequent 14 days).","populationDescription":"FAS included all randomized participants with a vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 14 days post vaccination on Day 1 (from Day 1 up to Day 15)","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"104"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"47"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"26"}]}]}]},{"type":"PRIMARY","title":"Cohort 1: Number of Participants With Unsolicited Adverse Events (AEs) up to 29 Days After Vaccination on Day 1","description":"Number of participants with unsolicited AEs up to 29 days after vaccination on Day 1 were reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. Unsolicited AEs were all AEs for which the participant is not specifically questioned in the participant diary.","populationDescription":"FAS included all randomized participants with a vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 29 days post vaccination on Day 1 (from Day 1 up to Day 30)","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"104"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"15"}]}]}]},{"type":"PRIMARY","title":"Cohort 1: Number of Participants With Serious Adverse Events (SAEs) up to Day 181","description":"Number of participants with SAEs up to Day 181 were reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","populationDescription":"FAS included all randomized participants with a vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 (post vaccination) up to Day 181","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"104"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]}]},{"type":"PRIMARY","title":"Cohort 2: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) Collected for 14 Days After Vaccination on Day 1","description":"Number of participants with solicited local AEs for 14 days after vaccination on Day 1 were reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local (injection site) AEs included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site). All solicited AEs at the injection site (local) were considered related to the study vaccine administration.","populationDescription":"FAS included all randomized participants with a vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 14 days post vaccination on Day 1 (from Day 1 up to Day 15)","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"138"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"22"}]}]}]},{"type":"PRIMARY","title":"Cohort 2: Number of Participants With Solicited Systemic Adverse Events (AEs) Collected for 14 Days After Vaccination on Day 1","description":"Number of participants with solicited systemic AEs 14 days after vaccination on Day 1 were reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. Solicited systemic AEs included fatigue, headache, nausea, fever and myalgia, for which participants were specifically questioned and which were noted by participants in their participant diary for 14 days post-vaccination (day of vaccination and the subsequent 14 days).","populationDescription":"FAS included all randomized participants with a vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 14 days post vaccination on Day 1 (from Day 1 up to Day 15)","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"138"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"53"}]}]}]},{"type":"PRIMARY","title":"Cohort 2: Number of Participants With Unsolicited Adverse Events (AEs) 29 Days After Vaccination on Day 1","description":"Number of participants with unsolicited AEs up to 29 days after vaccination on Day 1 were reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. Unsolicited AEs were all AEs for which the participant is not specifically questioned in the participant diary.","populationDescription":"FAS included all randomized participants with a vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 29 days post vaccination on Day 1 (from Day 1 up to Day 30)","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"138"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"36"}]}]}]},{"type":"PRIMARY","title":"Cohort 2: Number of Participants With Serious Adverse Events (SAEs) up to Day 181","description":"Number of participants with SAEs up to Day 181 were reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","populationDescription":"FAS included all randomized participants with a vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 (post vaccination) up to Day 181","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"138"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"PRIMARY","title":"Cohort 1: Geometric Mean Titers (GMTs) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex Electrochemiluminescent (ECL) Based Immunoassay on Day 15","description":"GMTs of serotype-specific total IgG serum antibodies as measured by multiplex ECL based immunoassay were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and exotoxin protein A (EPA) were determined in serum from collected blood samples. Lower limit of quantification (LLOQ) values for O1A: 69149, O2: 65287, O4: 67356, O6A: 150748, O8: 72196, O15: 66910, O16: 71586, O18A: 70519, O25B: 61990, O75: 133019, and EPA: 66165. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"Per-protocol immunogenicity (PPI) analysis set: all randomized and vaccinated participants for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\"(Number of participants analyzed)signifies participants evaluable for this endpoint and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Day 15","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"classes":[{"title":"Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5350535.1","lowerLimit":"4644976.0","upperLimit":"6163266.7"},{"groupId":"OG001","value":"6358232.9","lowerLimit":"5664895.6","upperLimit":"7136429.1"},{"groupId":"OG002","value":"6421446.5","lowerLimit":"5730738.4","upperLimit":"7195403.5"},{"groupId":"OG003","value":"6930697.9","lowerLimit":"5823442.2","upperLimit":"8248484.7"},{"groupId":"OG004","value":"1606747.3","lowerLimit":"1205014.3","upperLimit":"2142411.9"}]}]},{"title":"Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4873016.8","lowerLimit":"4116237.9","upperLimit":"5768931.0"},{"groupId":"OG001","value":"4787891.5","lowerLimit":"4034593.8","upperLimit":"5681837.2"},{"groupId":"OG002","value":"6537864.9","lowerLimit":"5861510.6","upperLimit":"7292263.1"},{"groupId":"OG003","value":"6196015.3","lowerLimit":"4955643.7","upperLimit":"7746845.5"},{"groupId":"OG004","value":"447845.4","lowerLimit":"343614.9","upperLimit":"583692.7"}]}]},{"title":"Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2906299.6","lowerLimit":"2339299.2","upperLimit":"3610729.8"},{"groupId":"OG001","value":"2778764.0","lowerLimit":"2281609.7","upperLimit":"3384246.4"},{"groupId":"OG002","value":"4140729.8","lowerLimit":"3480255.9","upperLimit":"4926546.7"},{"groupId":"OG003","value":"503269.8","lowerLimit":"409184.0","upperLimit":"618989.3"},{"groupId":"OG004","value":"545556.7","lowerLimit":"415552.0","upperLimit":"716233.0"}]}]},{"title":"Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4349111.4","lowerLimit":"3780753.5","upperLimit":"5002910.0"},{"groupId":"OG001","value":"5150333.2","lowerLimit":"4384440.1","upperLimit":"6050015.8"},{"groupId":"OG002","value":"5834052.6","lowerLimit":"5130881.4","upperLimit":"6633591.3"},{"groupId":"OG003","value":"5051389.0","lowerLimit":"4030377.7","upperLimit":"6331051.9"},{"groupId":"OG004","value":"984170.4","lowerLimit":"805275.1","upperLimit":"1202807.9"}]}]},{"title":"Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5082460.4","lowerLimit":"4435261.0","upperLimit":"5824100.0"},{"groupId":"OG001","value":"5605655.1","lowerLimit":"4917150.4","upperLimit":"6390564.9"},{"groupId":"OG002","value":"6071895.4","lowerLimit":"5414031.1","upperLimit":"6809697.4"},{"groupId":"OG003","value":"1738652.7","lowerLimit":"1408103.9","upperLimit":"2146796.9"},{"groupId":"OG004","value":"1391481.0","lowerLimit":"1093370.5","upperLimit":"1770872.3"}]}]},{"title":"Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5151217.3","lowerLimit":"4393448.3","upperLimit":"6039684.0"},{"groupId":"OG001","value":"4635317.8","lowerLimit":"3976055.4","upperLimit":"5403891.3"},{"groupId":"OG002","value":"5414798.2","lowerLimit":"4732722.1","upperLimit":"6195174.6"},{"groupId":"OG003","value":"898897.3","lowerLimit":"694569.8","upperLimit":"1163333.7"},{"groupId":"OG004","value":"1202517.7","lowerLimit":"893109.0","upperLimit":"1619118.0"}]}]},{"title":"Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4298055.1","lowerLimit":"3664533.7","upperLimit":"5041099.1"},{"groupId":"OG001","value":"3972656.6","lowerLimit":"3378225.9","upperLimit":"4671682.9"},{"groupId":"OG002","value":"5675420.6","lowerLimit":"4957603.9","upperLimit":"6497170.6"},{"groupId":"OG003","value":"759403.5","lowerLimit":"619027.4","upperLimit":"931612.4"},{"groupId":"OG004","value":"732969.6","lowerLimit":"586564.3","upperLimit":"915917.3"}]}]},{"title":"Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3532498.2","lowerLimit":"2965791.1","upperLimit":"4207492.4"},{"groupId":"OG001","value":"3585987.4","lowerLimit":"3008355.6","upperLimit":"4274529.8"},{"groupId":"OG002","value":"4522807.6","lowerLimit":"3883477.9","upperLimit":"5267388.9"},{"groupId":"OG003","value":"1015034.0","lowerLimit":"840693.0","upperLimit":"1225529.4"},{"groupId":"OG004","value":"1100583.1","lowerLimit":"846592.3","upperLimit":"1430775.0"}]}]},{"title":"Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1426991.8","lowerLimit":"1113308.2","upperLimit":"1829058.4"},{"groupId":"OG001","value":"2265970.3","lowerLimit":"1766736.9","upperLimit":"2906273.8"},{"groupId":"OG002","value":"2044257.9","lowerLimit":"1617260.1","upperLimit":"2583994.0"},{"groupId":"OG003","value":"2174362.2","lowerLimit":"1533603.8","upperLimit":"3082837.4"},{"groupId":"OG004","value":"267879.1","lowerLimit":"204166.3","upperLimit":"351474.3"}]}]},{"title":"Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2932034.9","lowerLimit":"2454267.7","upperLimit":"3502807.9"},{"groupId":"OG001","value":"3107132.4","lowerLimit":"2627869.3","upperLimit":"3673802.2"},{"groupId":"OG002","value":"3963138.0","lowerLimit":"3450884.5","upperLimit":"4551430.9"},{"groupId":"OG003","value":"1336846.1","lowerLimit":"1060936.4","upperLimit":"1684509.5"},{"groupId":"OG004","value":"1363797.1","lowerLimit":"1041800.4","upperLimit":"1785315.7"}]}]},{"title":"Serotype EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1170226.6","lowerLimit":"829684.5","upperLimit":"1650543.4"},{"groupId":"OG001","value":"1496999.3","lowerLimit":"1016330.1","upperLimit":"2204999.2"},{"groupId":"OG002","value":"1542536.8","lowerLimit":"1099718.5","upperLimit":"2163662.7"},{"groupId":"OG003","value":"1448761.2","lowerLimit":"868026.8","upperLimit":"2418023.4"},{"groupId":"OG004","value":"NA","lowerLimit":"NA","upperLimit":"74582.5","comment":"Geometric mean and lower limit of 95% CI could not be estimated as the value was below the LLOQ that is 66165."}]}]}]},{"type":"PRIMARY","title":"Cohort 1: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype Specific Antibodies as Measured by Multiplex ECL Based Immunoassay on Day 15","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by multiplex ECL based immunoassay on Day 15 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples by multiplex ECL based immunoassay. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 15 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 15","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"classes":[{"title":"Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.41","lowerLimit":"3.690","upperLimit":"5.259"},{"groupId":"OG001","value":"5.33","lowerLimit":"4.429","upperLimit":"6.406"},{"groupId":"OG002","value":"5.26","lowerLimit":"4.381","upperLimit":"6.323"},{"groupId":"OG003","value":"6.00","lowerLimit":"4.472","upperLimit":"8.061"},{"groupId":"OG004","value":"1.26","lowerLimit":"1.086","upperLimit":"1.452"}]}]},{"title":"Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.54","lowerLimit":"8.014","upperLimit":"11.360"},{"groupId":"OG001","value":"10.05","lowerLimit":"8.374","upperLimit":"12.056"},{"groupId":"OG002","value":"12.31","lowerLimit":"10.564","upperLimit":"14.334"},{"groupId":"OG003","value":"12.80","lowerLimit":"9.343","upperLimit":"17.530"},{"groupId":"OG004","value":"1.01","lowerLimit":"0.953","upperLimit":"1.064"}]}]},{"title":"Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.28","lowerLimit":"5.103","upperLimit":"7.718"},{"groupId":"OG001","value":"5.49","lowerLimit":"4.528","upperLimit":"6.656"},{"groupId":"OG002","value":"9.17","lowerLimit":"7.610","upperLimit":"11.054"},{"groupId":"OG003","value":"1.06","lowerLimit":"1.005","upperLimit":"1.127"},{"groupId":"OG004","value":"1.27","lowerLimit":"1.081","upperLimit":"1.491"}]}]},{"title":"Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.55","lowerLimit":"3.039","upperLimit":"4.141"},{"groupId":"OG001","value":"4.48","lowerLimit":"3.731","upperLimit":"5.389"},{"groupId":"OG002","value":"5.11","lowerLimit":"4.408","upperLimit":"5.918"},{"groupId":"OG003","value":"4.31","lowerLimit":"3.336","upperLimit":"5.576"},{"groupId":"OG004","value":"1.04","lowerLimit":"0.990","upperLimit":"1.088"}]}]},{"title":"Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.34","lowerLimit":"2.892","upperLimit":"3.855"},{"groupId":"OG001","value":"3.27","lowerLimit":"2.791","upperLimit":"3.826"},{"groupId":"OG002","value":"3.90","lowerLimit":"3.362","upperLimit":"4.534"},{"groupId":"OG003","value":"1.07","lowerLimit":"1.033","upperLimit":"1.116"},{"groupId":"OG004","value":"1.06","lowerLimit":"0.999","upperLimit":"1.128"}]}]},{"title":"Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.94","lowerLimit":"4.966","upperLimit":"7.104"},{"groupId":"OG001","value":"5.32","lowerLimit":"4.468","upperLimit":"6.339"},{"groupId":"OG002","value":"6.20","lowerLimit":"5.248","upperLimit":"7.329"},{"groupId":"OG003","value":"1.01","lowerLimit":"0.971","upperLimit":"1.055"},{"groupId":"OG004","value":"1.46","lowerLimit":"1.223","upperLimit":"1.753"}]}]},{"title":"Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.04","lowerLimit":"4.300","upperLimit":"5.912"},{"groupId":"OG001","value":"4.59","lowerLimit":"3.822","upperLimit":"5.502"},{"groupId":"OG002","value":"7.02","lowerLimit":"5.904","upperLimit":"8.342"},{"groupId":"OG003","value":"1.11","lowerLimit":"0.987","upperLimit":"1.254"},{"groupId":"OG004","value":"1.08","lowerLimit":"1.010","upperLimit":"1.155"}]}]},{"title":"Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.79","lowerLimit":"3.220","upperLimit":"4.456"},{"groupId":"OG001","value":"3.64","lowerLimit":"3.043","upperLimit":"4.344"},{"groupId":"OG002","value":"4.84","lowerLimit":"4.132","upperLimit":"5.675"},{"groupId":"OG003","value":"1.04","lowerLimit":"0.995","upperLimit":"1.087"},{"groupId":"OG004","value":"1.13","lowerLimit":"1.027","upperLimit":"1.241"}]}]},{"title":"Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.80","lowerLimit":"4.761","upperLimit":"7.071"},{"groupId":"OG001","value":"9.51","lowerLimit":"7.463","upperLimit":"12.126"},{"groupId":"OG002","value":"8.24","lowerLimit":"6.529","upperLimit":"10.394"},{"groupId":"OG003","value":"11.02","lowerLimit":"7.889","upperLimit":"15.388"},{"groupId":"OG004","value":"1.02","lowerLimit":"0.932","upperLimit":"1.127"}]}]},{"title":"Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.33","lowerLimit":"2.013","upperLimit":"2.701"},{"groupId":"OG001","value":"2.38","lowerLimit":"2.055","upperLimit":"2.756"},{"groupId":"OG002","value":"3.06","lowerLimit":"2.622","upperLimit":"3.563"},{"groupId":"OG003","value":"1.14","lowerLimit":"1.026","upperLimit":"1.274"},{"groupId":"OG004","value":"1.03","lowerLimit":"0.945","upperLimit":"1.131"}]}]},{"title":"Serotype EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.31","lowerLimit":"8.61","upperLimit":"14.86"},{"groupId":"OG001","value":"12.31","lowerLimit":"9.11","upperLimit":"16.62"},{"groupId":"OG002","value":"11.84","lowerLimit":"9.01","upperLimit":"15.55"},{"groupId":"OG003","value":"12.68","lowerLimit":"8.28","upperLimit":"19.43"},{"groupId":"OG004","value":"0.99","lowerLimit":"0.97","upperLimit":"1.01"}]}]}]},{"type":"PRIMARY","title":"Cohort 1: Percentage of Participants With a Greater Than or Equal to (>=) 2-Fold and >=4-Fold Increase From Baseline in Serotype Specific Serum Antibody Titers as Measured by Multiplex ECL Based Immunoassay on Day 15","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase (FI) from baseline in serotype specific serum antibody titers as measured by multiplex ECL based immunoassay on Day 15 was reported. The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Day 15 for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA was calculated as the ratio of titer values of serum antibody on Day 15 and pre-vaccination (on day 1) that is Day 15/Day 1. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 15","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"classes":[{"title":"Serotype O1A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.2","lowerLimit":"68.90","upperLimit":"85.82"},{"groupId":"OG001","value":"84.7","lowerLimit":"76.01","upperLimit":"91.17"},{"groupId":"OG002","value":"82.0","lowerLimit":"73.05","upperLimit":"88.97"},{"groupId":"OG003","value":"81.3","lowerLimit":"67.37","upperLimit":"91.05"},{"groupId":"OG004","value":"9.8","lowerLimit":"3.26","upperLimit":"21.41"}]}]},{"title":"Serotype O1A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.4","lowerLimit":"46.20","upperLimit":"66.28"},{"groupId":"OG001","value":"62.","lowerLimit":"51.88","upperLimit":"71.84"},{"groupId":"OG002","value":"65.0","lowerLimit":"54.82","upperLimit":"74.27"},{"groupId":"OG003","value":"66.7","lowerLimit":"51.59","upperLimit":"79.60"},{"groupId":"OG004","value":"5.9","lowerLimit":"1.23","upperLimit":"16.24"}]}]},{"title":"Serotype O2: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","lowerLimit":"86.24","upperLimit":"97.17"},{"groupId":"OG001","value":"93.9","lowerLimit":"87.15","upperLimit":"97.72"},{"groupId":"OG002","value":"99.0","lowerLimit":"94.55","upperLimit":"99.97"},{"groupId":"OG003","value":"89.6","lowerLimit":"77.34","upperLimit":"96.53"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"6.98"}]}]},{"title":"Serotype O2: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.2","lowerLimit":"74.42","upperLimit":"89.88"},{"groupId":"OG001","value":"83.7","lowerLimit":"74.84","upperLimit":"90.37"},{"groupId":"OG002","value":"92.0","lowerLimit":"84.84","upperLimit":"96.48"},{"groupId":"OG003","value":"81.3","lowerLimit":"67.37","upperLimit":"91.05"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"6.98"}]}]},{"title":"Serotype O4: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","lowerLimit":"67.82","upperLimit":"84.98"},{"groupId":"OG001","value":"81.6","lowerLimit":"72.53","upperLimit":"88.74"},{"groupId":"OG002","value":"91.0","lowerLimit":"83.60","upperLimit":"95.80"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"},{"groupId":"OG004","value":"9.8","lowerLimit":"3.26","upperLimit":"21.41"}]}]},{"title":"Serotype O4: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.4","lowerLimit":"54.21","upperLimit":"73.64"},{"groupId":"OG001","value":"63.3","lowerLimit":"52.93","upperLimit":"72.78"},{"groupId":"OG002","value":"80.0","lowerLimit":"70.82","upperLimit":"87.33"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"3.9","lowerLimit":"0.48","upperLimit":"13.46"}]}]},{"title":"Serotype O6A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.3","lowerLimit":"62.48","upperLimit":"80.72"},{"groupId":"OG001","value":"77.6","lowerLimit":"68.01","upperLimit":"85.36"},{"groupId":"OG002","value":"86.0","lowerLimit":"77.63","upperLimit":"92.13"},{"groupId":"OG003","value":"77.1","lowerLimit":"62.69","upperLimit":"87.97"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"6.98"}]}]},{"title":"Serotype O6A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","lowerLimit":"32.79","upperLimit":"52.81"},{"groupId":"OG001","value":"53.1","lowerLimit":"42.71","upperLimit":"63.22"},{"groupId":"OG002","value":"66.0","lowerLimit":"55.85","upperLimit":"75.18"},{"groupId":"OG003","value":"52.1","lowerLimit":"37.19","upperLimit":"66.71"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"6.98"}]}]},{"title":"Serotype O8: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","lowerLimit":"63.54","upperLimit":"81.59"},{"groupId":"OG001","value":"73.5","lowerLimit":"63.59","upperLimit":"81.88"},{"groupId":"OG002","value":"74.0","lowerLimit":"64.27","upperLimit":"82.26"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"3.9","lowerLimit":"0.48","upperLimit":"13.46"}]}]},{"title":"Serotype O8: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.6","lowerLimit":"31.86","upperLimit":"51.82"},{"groupId":"OG001","value":"38.8","lowerLimit":"29.10","upperLimit":"49.15"},{"groupId":"OG002","value":"51.0","lowerLimit":"40.80","upperLimit":"61.14"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"6.98"}]}]},{"title":"Serotype O15: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.1","lowerLimit":"80.17","upperLimit":"93.71"},{"groupId":"OG001","value":"82.7","lowerLimit":"73.69","upperLimit":"89.56"},{"groupId":"OG002","value":"87.0","lowerLimit":"78.80","upperLimit":"92.89"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"21.6","lowerLimit":"11.29","upperLimit":"35.32"}]}]},{"title":"Serotype O15: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","lowerLimit":"51.18","upperLimit":"70.91"},{"groupId":"OG001","value":"63.3","lowerLimit":"52.93","upperLimit":"72.78"},{"groupId":"OG002","value":"68.0","lowerLimit":"57.92","upperLimit":"76.98"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"9.8","lowerLimit":"3.26","upperLimit":"21.41"}]}]},{"title":"Serotype O16: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.1","lowerLimit":"77.84","upperLimit":"92.21"},{"groupId":"OG001","value":"77.6","lowerLimit":"68.01","upperLimit":"85.36"},{"groupId":"OG002","value":"88.0","lowerLimit":"79.98","upperLimit":"93.64"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"},{"groupId":"OG004","value":"2.0","lowerLimit":"0.05","upperLimit":"10.45"}]}]},{"title":"Serotype O16: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.4","lowerLimit":"53.19","upperLimit":"72.73"},{"groupId":"OG001","value":"57.1","lowerLimit":"46.75","upperLimit":"67.10"},{"groupId":"OG002","value":"73.0","lowerLimit":"63.20","upperLimit":"81.39"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"6.98"}]}]},{"title":"Serotype O18A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.3","lowerLimit":"62.48","upperLimit":"80.72"},{"groupId":"OG001","value":"71.4","lowerLimit":"61.42","upperLimit":"80.10"},{"groupId":"OG002","value":"84.0","lowerLimit":"75.32","upperLimit":"90.57"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"3.9","lowerLimit":"0.48","upperLimit":"13.46"}]}]},{"title":"Serotype O18A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.5","lowerLimit":"38.45","upperLimit":"58.67"},{"groupId":"OG001","value":"41.8","lowerLimit":"31.95","upperLimit":"52.23"},{"groupId":"OG002","value":"61.0","lowerLimit":"50.73","upperLimit":"70.60"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"2.0","lowerLimit":"0.05","upperLimit":"10.45"}]}]},{"title":"Serotype O25B: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"82.2","lowerLimit":"73.30","upperLimit":"89.08"},{"groupId":"OG001","value":"87.8","lowerLimit":"79.59","upperLimit":"93.51"},{"groupId":"OG002","value":"84.8","lowerLimit":"76.24","upperLimit":"91.26"},{"groupId":"OG003","value":"87.5","lowerLimit":"74.75","upperLimit":"95.27"},{"groupId":"OG004","value":"3.9","lowerLimit":"0.48","upperLimit":"13.46"}]}]},{"title":"Serotype O25B: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.4","lowerLimit":"48.18","upperLimit":"68.14"},{"groupId":"OG001","value":"75.5","lowerLimit":"65.79","upperLimit":"83.64"},{"groupId":"OG002","value":"69.7","lowerLimit":"59.65","upperLimit":"78.53"},{"groupId":"OG003","value":"79.2","lowerLimit":"65.01","upperLimit":"89.53"},{"groupId":"OG004","value":"2.0","lowerLimit":"0.05","upperLimit":"10.45"}]}]},{"title":"Serotype O75: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","lowerLimit":"40.36","upperLimit":"60.60"},{"groupId":"OG001","value":"49.0","lowerLimit":"38.74","upperLimit":"59.28"},{"groupId":"OG002","value":"68.0","lowerLimit":"57.92","upperLimit":"76.98"},{"groupId":"OG003","value":"6.3","lowerLimit":"1.31","upperLimit":"17.20"},{"groupId":"OG004","value":"2.0","lowerLimit":"0.05","upperLimit":"10.45"}]}]},{"title":"Serotype O75: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","lowerLimit":"13.36","upperLimit":"30.01"},{"groupId":"OG001","value":"25.5","lowerLimit":"17.24","upperLimit":"35.31"},{"groupId":"OG002","value":"33.0","lowerLimit":"23.92","upperLimit":"43.12"},{"groupId":"OG003","value":"4.2","lowerLimit":"0.51","upperLimit":"14.25"},{"groupId":"OG004","value":"2.0","lowerLimit":"0.05","upperLimit":"10.45"}]}]},{"title":"Serotype EPA: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.1","lowerLimit":"79.00","upperLimit":"92.96"},{"groupId":"OG001","value":"83.7","lowerLimit":"74.84","upperLimit":"90.37"},{"groupId":"OG002","value":"85.0","lowerLimit":"76.47","upperLimit":"91.35"},{"groupId":"OG003","value":"81.3","lowerLimit":"67.37","upperLimit":"91.05"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"6.98"}]}]},{"title":"Serotype EPA: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.3","lowerLimit":"64.60","upperLimit":"82.44"},{"groupId":"OG001","value":"74.5","lowerLimit":"64.69","upperLimit":"82.76"},{"groupId":"OG002","value":"77.0","lowerLimit":"67.51","upperLimit":"84.83"},{"groupId":"OG003","value":"72.9","lowerLimit":"58.15","upperLimit":"84.72"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"6.98"}]}]}]},{"type":"PRIMARY","title":"Cohort 1: Geometric Mean Titers (GMT) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex Opsonophagocytic Assay (MOPA) on Day 15","description":"GMTs of serotype-specific total IgG serum antibodies as measured by MOPA were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples. LLOQ values were: O1A: 53, O2: 51, O4: 29, O6A: 47, O8: 196, O15: 37, O16: 54, O18A: 12, O25B: 65, and O75: 37. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Day 15","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"classes":[{"title":"Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"654.3","lowerLimit":"512.4","upperLimit":"835.4"},{"groupId":"OG001","value":"764.2","lowerLimit":"590.3","upperLimit":"989.5"},{"groupId":"OG002","value":"1129.5","lowerLimit":"842.3","upperLimit":"1514.7"},{"groupId":"OG003","value":"1377.3","lowerLimit":"851.8","upperLimit":"2227.0"},{"groupId":"OG004","value":"244.6","lowerLimit":"177.9","upperLimit":"336.1"}]}]},{"title":"Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5538.4","lowerLimit":"3884.7","upperLimit":"7896.2"},{"groupId":"OG001","value":"5359.8","lowerLimit":"3689.3","upperLimit":"7786.7"},{"groupId":"OG002","value":"12473.2","lowerLimit":"9082.9","upperLimit":"17129.0"},{"groupId":"OG003","value":"9629.4","lowerLimit":"5960.7","upperLimit":"15555.9"},{"groupId":"OG004","value":"363.5","lowerLimit":"274.0","upperLimit":"482.3"}]}]},{"title":"Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"376.3","lowerLimit":"278.6","upperLimit":"508.2"},{"groupId":"OG001","value":"322.9","lowerLimit":"239.7","upperLimit":"434.9"},{"groupId":"OG002","value":"505.7","lowerLimit":"374.6","upperLimit":"682.5"},{"groupId":"OG003","value":"102.9","lowerLimit":"74.1","upperLimit":"142.8"},{"groupId":"OG004","value":"102.5","lowerLimit":"79.3","upperLimit":"132.5"}]}]},{"title":"Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1495.9","lowerLimit":"1133.1","upperLimit":"1974.8"},{"groupId":"OG001","value":"2256.5","lowerLimit":"1725.5","upperLimit":"2951.0"},{"groupId":"OG002","value":"2217.2","lowerLimit":"1690.8","upperLimit":"2907.6"},{"groupId":"OG003","value":"2009.8","lowerLimit":"1344.6","upperLimit":"3004.0"},{"groupId":"OG004","value":"720.7","lowerLimit":"513.8","upperLimit":"1010.9"}]}]},{"title":"Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1249.2","lowerLimit":"979.3","upperLimit":"1593.5"},{"groupId":"OG001","value":"921.5","lowerLimit":"702.3","upperLimit":"1209.1"},{"groupId":"OG002","value":"1037.6","lowerLimit":"809.7","upperLimit":"1329.6"},{"groupId":"OG003","value":"712.9","lowerLimit":"527.1","upperLimit":"964.3"},{"groupId":"OG004","value":"931.3","lowerLimit":"720.7","upperLimit":"1203.4"}]}]},{"title":"Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3095.1","lowerLimit":"2194.3","upperLimit":"4365.6"},{"groupId":"OG001","value":"3018.4","lowerLimit":"2093.9","upperLimit":"4351.1"},{"groupId":"OG002","value":"3658.5","lowerLimit":"2528.2","upperLimit":"5294.1"},{"groupId":"OG003","value":"650.2","lowerLimit":"431.5","upperLimit":"979.8"},{"groupId":"OG004","value":"831.9","lowerLimit":"542.2","upperLimit":"1276.2"}]}]},{"title":"Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1532.2","lowerLimit":"1092.6","upperLimit":"2148.8"},{"groupId":"OG001","value":"1172.2","lowerLimit":"822.4","upperLimit":"1670.8"},{"groupId":"OG002","value":"1853.8","lowerLimit":"1353.2","upperLimit":"2539.6"},{"groupId":"OG003","value":"216.2","lowerLimit":"147.0","upperLimit":"317.9"},{"groupId":"OG004","value":"176.9","lowerLimit":"134.4","upperLimit":"232.9"}]}]},{"title":"Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"274.7","lowerLimit":"202.2","upperLimit":"373.2"},{"groupId":"OG001","value":"276.2","lowerLimit":"205.0","upperLimit":"372.0"},{"groupId":"OG002","value":"338.2","lowerLimit":"245.3","upperLimit":"466.3"},{"groupId":"OG003","value":"65.7","lowerLimit":"44.6","upperLimit":"96.9"},{"groupId":"OG004","value":"62.2","lowerLimit":"42.3","upperLimit":"91.6"}]}]},{"title":"Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"415.5","lowerLimit":"318.4","upperLimit":"542.3"},{"groupId":"OG001","value":"489.5","lowerLimit":"373.3","upperLimit":"641.9"},{"groupId":"OG002","value":"403.7","lowerLimit":"312.4","upperLimit":"521.6"},{"groupId":"OG003","value":"382.7","lowerLimit":"268.7","upperLimit":"545.0"},{"groupId":"OG004","value":"265.4","lowerLimit":"173.1","upperLimit":"406.8"}]}]},{"title":"Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.0","lowerLimit":"65.8","upperLimit":"107.1"},{"groupId":"OG001","value":"58.0","lowerLimit":"46.5","upperLimit":"72.3"},{"groupId":"OG002","value":"91.7","lowerLimit":"66.5","upperLimit":"126.5"},{"groupId":"OG003","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Geometric mean, lower and upper limit of 95% CI could not be estimated as the value was below the LLOQ (37)."},{"groupId":"OG004","value":"NA","lowerLimit":"NA","upperLimit":"45.3","comment":"Geometric mean and lower limit of 95% CI could not be estimated as the value was below the LLOQ (37)."}]}]}]},{"type":"PRIMARY","title":"Cohort 1: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype Specific Antibodies as Measured by MOPA on Day 15","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by MOPA on Day 15 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples by MOPA. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 15 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline (Day 1, pre-vaccination), Day 15","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"classes":[{"title":"Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.67","lowerLimit":"2.103","upperLimit":"3.389"},{"groupId":"OG001","value":"4.29","lowerLimit":"3.372","upperLimit":"5.469"},{"groupId":"OG002","value":"6.14","lowerLimit":"4.546","upperLimit":"8.287"},{"groupId":"OG003","value":"5.34","lowerLimit":"3.533","upperLimit":"8.059"},{"groupId":"OG004","value":"1.18","lowerLimit":"0.934","upperLimit":"1.484"}]}]},{"title":"Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.39","lowerLimit":"10.285","upperLimit":"20.126"},{"groupId":"OG001","value":"17.78","lowerLimit":"12.567","upperLimit":"25.168"},{"groupId":"OG002","value":"30.19","lowerLimit":"22.504","upperLimit":"40.490"},{"groupId":"OG003","value":"22.96","lowerLimit":"13.310","upperLimit":"39.589"},{"groupId":"OG004","value":"1.06","lowerLimit":"0.923","upperLimit":"1.228"}]}]},{"title":"Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.25","lowerLimit":"2.489","upperLimit":"4.240"},{"groupId":"OG001","value":"3.47","lowerLimit":"2.723","upperLimit":"4.420"},{"groupId":"OG002","value":"5.47","lowerLimit":"4.169","upperLimit":"7.178"},{"groupId":"OG003","value":"0.98","lowerLimit":"0.852","upperLimit":"1.127"},{"groupId":"OG004","value":"1.08","lowerLimit":"0.917","upperLimit":"1.263"}]}]},{"title":"Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","lowerLimit":"1.859","upperLimit":"2.858"},{"groupId":"OG001","value":"3.72","lowerLimit":"2.740","upperLimit":"5.046"},{"groupId":"OG002","value":"3.54","lowerLimit":"2.782","upperLimit":"4.510"},{"groupId":"OG003","value":"4.30","lowerLimit":"2.840","upperLimit":"6.514"},{"groupId":"OG004","value":"1.18","lowerLimit":"1.019","upperLimit":"1.368"}]}]},{"title":"Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","lowerLimit":"1.078","upperLimit":"1.468"},{"groupId":"OG001","value":"1.22","lowerLimit":"1.107","upperLimit":"1.339"},{"groupId":"OG002","value":"1.15","lowerLimit":"0.995","upperLimit":"1.324"},{"groupId":"OG003","value":"0.97","lowerLimit":"0.801","upperLimit":"1.170"},{"groupId":"OG004","value":"1.07","lowerLimit":"0.891","upperLimit":"1.282"}]}]},{"title":"Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.91","lowerLimit":"3.498","upperLimit":"6.884"},{"groupId":"OG001","value":"6.29","lowerLimit":"4.285","upperLimit":"9.247"},{"groupId":"OG002","value":"6.87","lowerLimit":"4.732","upperLimit":"9.980"},{"groupId":"OG003","value":"0.95","lowerLimit":"0.695","upperLimit":"1.289"},{"groupId":"OG004","value":"1.55","lowerLimit":"1.076","upperLimit":"2.246"}]}]},{"title":"Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.58","lowerLimit":"4.806","upperLimit":"9.018"},{"groupId":"OG001","value":"5.86","lowerLimit":"4.051","upperLimit":"8.485"},{"groupId":"OG002","value":"10.18","lowerLimit":"7.527","upperLimit":"13.755"},{"groupId":"OG003","value":"0.94","lowerLimit":"0.795","upperLimit":"1.113"},{"groupId":"OG004","value":"0.97","lowerLimit":"0.821","upperLimit":"1.157"}]}]},{"title":"Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.05","lowerLimit":"3.148","upperLimit":"5.204"},{"groupId":"OG001","value":"4.27","lowerLimit":"3.192","upperLimit":"5.721"},{"groupId":"OG002","value":"6.20","lowerLimit":"4.645","upperLimit":"8.279"},{"groupId":"OG003","value":"1.03","lowerLimit":"0.869","upperLimit":"1.217"},{"groupId":"OG004","value":"1.17","lowerLimit":"0.941","upperLimit":"1.458"}]}]},{"title":"Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","lowerLimit":"1.883","upperLimit":"2.903"},{"groupId":"OG001","value":"2.77","lowerLimit":"2.155","upperLimit":"3.557"},{"groupId":"OG002","value":"2.51","lowerLimit":"2.033","upperLimit":"3.096"},{"groupId":"OG003","value":"2.48","lowerLimit":"1.830","upperLimit":"3.367"},{"groupId":"OG004","value":"1.44","lowerLimit":"1.040","upperLimit":"1.997"}]}]},{"title":"Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","lowerLimit":"1.600","upperLimit":"2.299"},{"groupId":"OG001","value":"1.69","lowerLimit":"1.440","upperLimit":"1.991"},{"groupId":"OG002","value":"2.58","lowerLimit":"1.981","upperLimit":"3.355"},{"groupId":"OG003","value":"0.97","lowerLimit":"0.879","upperLimit":"1.064"},{"groupId":"OG004","value":"1.03","lowerLimit":"0.930","upperLimit":"1.133"}]}]}]},{"type":"PRIMARY","title":"Cohort 1: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by MOPA on Day 15","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by MOPA on Day 15 was reported. The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Day 15 for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, and O75 was calculated as the ratio of titer values of serum antibody on Day 15 and pre-vaccination (on day 1) that is, Day 15/Day 1. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 15","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"classes":[{"title":"Serotype O1A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.5","lowerLimit":"39.40","upperLimit":"59.64"},{"groupId":"OG001","value":"70.4","lowerLimit":"60.34","upperLimit":"79.21"},{"groupId":"OG002","value":"72.0","lowerLimit":"62.13","upperLimit":"80.52"},{"groupId":"OG003","value":"75.0","lowerLimit":"60.40","upperLimit":"86.36"},{"groupId":"OG004","value":"13.7","lowerLimit":"5.70","upperLimit":"26.26"}]}]},{"title":"Serotype O1A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","lowerLimit":"20.15","upperLimit":"38.57"},{"groupId":"OG001","value":"46.9","lowerLimit":"36.78","upperLimit":"57.29"},{"groupId":"OG002","value":"53.0","lowerLimit":"42.76","upperLimit":"63.06"},{"groupId":"OG003","value":"52.1","lowerLimit":"37.19","upperLimit":"66.71"},{"groupId":"OG004","value":"3.9","lowerLimit":"0.48","upperLimit":"13.46"}]}]},{"title":"Serotype O2: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","lowerLimit":"82.54","upperLimit":"95.15"},{"groupId":"OG001","value":"86.5","lowerLimit":"77.96","upperLimit":"92.59"},{"groupId":"OG002","value":"98.0","lowerLimit":"92.89","upperLimit":"99.75"},{"groupId":"OG003","value":"87.5","lowerLimit":"74.75","upperLimit":"95.27"},{"groupId":"OG004","value":"11.8","lowerLimit":"4.44","upperLimit":"23.87"}]}]},{"title":"Serotype O2: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.3","lowerLimit":"64.60","upperLimit":"82.44"},{"groupId":"OG001","value":"78.1","lowerLimit":"68.53","upperLimit":"85.92"},{"groupId":"OG002","value":"88.9","lowerLimit":"80.99","upperLimit":"94.32"},{"groupId":"OG003","value":"77.1","lowerLimit":"62.69","upperLimit":"87.97"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"6.98"}]}]},{"title":"Serotype O4: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.4","lowerLimit":"46.20","upperLimit":"66.28"},{"groupId":"OG001","value":"60.2","lowerLimit":"49.82","upperLimit":"69.96"},{"groupId":"OG002","value":"73.0","lowerLimit":"63.20","upperLimit":"81.39"},{"groupId":"OG003","value":"4.2","lowerLimit":"0.51","upperLimit":"14.25"},{"groupId":"OG004","value":"11.8","lowerLimit":"4.44","upperLimit":"23.87"}]}]},{"title":"Serotype O4: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","lowerLimit":"24.56","upperLimit":"43.75"},{"groupId":"OG001","value":"38.8","lowerLimit":"29.10","upperLimit":"49.15"},{"groupId":"OG002","value":"56.0","lowerLimit":"45.72","upperLimit":"65.92"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"},{"groupId":"OG004","value":"3.9","lowerLimit":"0.48","upperLimit":"13.46"}]}]},{"title":"Serotype O6A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","lowerLimit":"37.49","upperLimit":"57.70"},{"groupId":"OG001","value":"54.1","lowerLimit":"43.71","upperLimit":"64.20"},{"groupId":"OG002","value":"63.0","lowerLimit":"52.76","upperLimit":"72.44"},{"groupId":"OG003","value":"66.7","lowerLimit":"51.59","upperLimit":"79.60"},{"groupId":"OG004","value":"9.8","lowerLimit":"3.26","upperLimit":"21.41"}]}]},{"title":"Serotype O6A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","lowerLimit":"15.86","upperLimit":"33.26"},{"groupId":"OG001","value":"41.8","lowerLimit":"31.95","upperLimit":"52.23"},{"groupId":"OG002","value":"40.0","lowerLimit":"30.33","upperLimit":"50.28"},{"groupId":"OG003","value":"39.6","lowerLimit":"25.77","upperLimit":"54.73"},{"groupId":"OG004","value":"2.0","lowerLimit":"0.05","upperLimit":"10.45"}]}]},{"title":"Serotype O8: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","lowerLimit":"12.54","upperLimit":"28.91"},{"groupId":"OG001","value":"14.3","lowerLimit":"8.04","upperLimit":"22.81"},{"groupId":"OG002","value":"10.0","lowerLimit":"4.90","upperLimit":"17.62"},{"groupId":"OG003","value":"6.3","lowerLimit":"1.31","upperLimit":"17.20"},{"groupId":"OG004","value":"11.8","lowerLimit":"4.44","upperLimit":"23.87"}]}]},{"title":"Serotype O8: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","lowerLimit":"2.21","upperLimit":"12.48"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.64","upperLimit":"8.69"},{"groupId":"OG002","value":"4.0","lowerLimit":"1.10","upperLimit":"9.9"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"},{"groupId":"OG004","value":"3.9","lowerLimit":"0.48","upperLimit":"13.46"}]}]},{"title":"Serotype O15: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","lowerLimit":"50.73","upperLimit":"70.60"},{"groupId":"OG001","value":"67.0","lowerLimit":"56.73","upperLimit":"76.22"},{"groupId":"OG002","value":"70.0","lowerLimit":"60.02","upperLimit":"78.76"},{"groupId":"OG003","value":"12.5","lowerLimit":"4.73","upperLimit":"25.25"},{"groupId":"OG004","value":"28.0","lowerLimit":"16.23","upperLimit":"42.49"}]}]},{"title":"Serotype O15: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.0","lowerLimit":"31.26","upperLimit":"51.29"},{"groupId":"OG001","value":"53.6","lowerLimit":"43.19","upperLimit":"63.80"},{"groupId":"OG002","value":"57.0","lowerLimit":"46.71","upperLimit":"66.86"},{"groupId":"OG003","value":"8.3","lowerLimit":"2.32","upperLimit":"19.9"},{"groupId":"OG004","value":"14.0","lowerLimit":"5.82","upperLimit":"26.74"}]}]},{"title":"Serotype O16: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","lowerLimit":"66.74","upperLimit":"84.14"},{"groupId":"OG001","value":"70.4","lowerLimit":"60.34","upperLimit":"79.21"},{"groupId":"OG002","value":"85.0","lowerLimit":"76.47","upperLimit":"91.35"},{"groupId":"OG003","value":"8.3","lowerLimit":"2.32","upperLimit":"19.9"},{"groupId":"OG004","value":"9.8","lowerLimit":"3.26","upperLimit":"21.41"}]}]},{"title":"Serotype O16: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","lowerLimit":"45.22","upperLimit":"65.34"},{"groupId":"OG001","value":"51.0","lowerLimit":"40.72","upperLimit":"61.26"},{"groupId":"OG002","value":"76.0","lowerLimit":"66.43","upperLimit":"83.98"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"},{"groupId":"OG004","value":"3.9","lowerLimit":"0.48","upperLimit":"13.46"}]}]},{"title":"Serotype O18A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.3","lowerLimit":"59.34","upperLimit":"78.10"},{"groupId":"OG001","value":"66.3","lowerLimit":"56.07","upperLimit":"75.56"},{"groupId":"OG002","value":"77.0","lowerLimit":"67.51","upperLimit":"84.83"},{"groupId":"OG003","value":"6.3","lowerLimit":"1.31","upperLimit":"17.20"},{"groupId":"OG004","value":"7.8","lowerLimit":"2.18","upperLimit":"18.88"}]}]},{"title":"Serotype O18A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","lowerLimit":"35.60","upperLimit":"55.76"},{"groupId":"OG001","value":"44.9","lowerLimit":"34.83","upperLimit":"55.28"},{"groupId":"OG002","value":"58.0","lowerLimit":"47.71","upperLimit":"67.80"},{"groupId":"OG003","value":"4.2","lowerLimit":"0.51","upperLimit":"14.25"},{"groupId":"OG004","value":"5.9","lowerLimit":"1.23","upperLimit":"16.24"}]}]},{"title":"Serotype O25B: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","lowerLimit":"37.49","upperLimit":"57.70"},{"groupId":"OG001","value":"50.0","lowerLimit":"39.73","upperLimit":"60.27"},{"groupId":"OG002","value":"50.0","lowerLimit":"39.83","upperLimit":"60.17"},{"groupId":"OG003","value":"50.0","lowerLimit":"35.23","upperLimit":"64.77"},{"groupId":"OG004","value":"15.7","lowerLimit":"7.02","upperLimit":"28.59"}]}]},{"title":"Serotype O25B: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","lowerLimit":"16.70","upperLimit":"34.33"},{"groupId":"OG001","value":"33.7","lowerLimit":"24.44","upperLimit":"43.93"},{"groupId":"OG002","value":"31.0","lowerLimit":"22.13","upperLimit":"41.03"},{"groupId":"OG003","value":"35.4","lowerLimit":"22.16","upperLimit":"50.54"},{"groupId":"OG004","value":"5.9","lowerLimit":"1.23","upperLimit":"16.24"}]}]},{"title":"Serotype O75: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.0","lowerLimit":"26.64","upperLimit":"46.21"},{"groupId":"OG001","value":"28.6","lowerLimit":"19.9","upperLimit":"38.58"},{"groupId":"OG002","value":"38.0","lowerLimit":"28.48","upperLimit":"48.25"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"3.9","lowerLimit":"0.48","upperLimit":"13.46"}]}]},{"title":"Serotype O75: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"9.43","upperLimit":"24.68"},{"groupId":"OG001","value":"17.3","lowerLimit":"10.44","upperLimit":"26.31"},{"groupId":"OG002","value":"25.0","lowerLimit":"16.88","upperLimit":"34.66"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"6.98"}]}]}]},{"type":"PRIMARY","title":"Cohort 2: Geometric Mean Titers (GMTs) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex ECL Based Immunoassay on Day 30","description":"GMTs of serotype-specific total IgG serum antibodies as measured by multiplex ECL based immunoassay were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples. LLOQ values for O1A: 69149, O2: 65287, O4: 67356, O6A: 150748, O8: 72196, O15: 66910, O16: 71586, O18A: 70519, O25B: 61990, O75: 133019, and EPA: 66165. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At Day 30","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"129"}]}],"classes":[{"title":"Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"6341302.4","lowerLimit":"5889782.4","upperLimit":"6827436.7"},{"groupId":"OG001","value":"1762724.3","lowerLimit":"1505477.9","upperLimit":"2063927.4"}]}]},{"title":"Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"5957433.5","lowerLimit":"5487954.2","upperLimit":"6467075.6"},{"groupId":"OG001","value":"749984.6","lowerLimit":"628913.9","upperLimit":"894362.5"}]}]},{"title":"Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"3537556.6","lowerLimit":"3153145.2","upperLimit":"3968833.1"},{"groupId":"OG001","value":"805295.5","lowerLimit":"689894.4","upperLimit":"940000.1"}]}]},{"title":"Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"5461039.4","lowerLimit":"4992165.2","upperLimit":"5973951.2"},{"groupId":"OG001","value":"1944280.6","lowerLimit":"1664293.0","upperLimit":"2271371.1"}]}]},{"title":"Serotype O8","categories":[{"measurements":[{"groupId":"OG000","value":"6240213.6","lowerLimit":"5782238.7","upperLimit":"6734461.7"},{"groupId":"OG001","value":"2315932.9","lowerLimit":"2011986.2","upperLimit":"2665796.4"}]}]},{"title":"Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"5724175.1","lowerLimit":"5301709.2","upperLimit":"6180305.1"},{"groupId":"OG001","value":"1207724.5","lowerLimit":"1028556.8","upperLimit":"1418101.9"}]}]},{"title":"Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"5158063.5","lowerLimit":"4735530.7","upperLimit":"5618297.2"},{"groupId":"OG001","value":"1127584.4","lowerLimit":"1001022.6","upperLimit":"1270147.7"}]}]},{"title":"Serotype O18","categories":[{"measurements":[{"groupId":"OG000","value":"4046778.4","lowerLimit":"3656809.6","upperLimit":"4478334.1"},{"groupId":"OG001","value":"1365154.9","lowerLimit":"1196273.0","upperLimit":"1557878.4"}]}]},{"title":"Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"2117662.8","lowerLimit":"1843164.1","upperLimit":"2433042.1"},{"groupId":"OG001","value":"375570.5","lowerLimit":"316412.1","upperLimit":"445789.5"}]}]},{"title":"Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"3758021.3","lowerLimit":"3419541.0","upperLimit":"4130005.8"},{"groupId":"OG001","value":"1577900.4","lowerLimit":"1365705.2","upperLimit":"1823065.1"}]}]},{"title":"Serotype EPA","categories":[{"measurements":[{"groupId":"OG000","value":"780539.6","lowerLimit":"622435.7","upperLimit":"978803.3"},{"groupId":"OG001","value":"75018.0","lowerLimit":"NA","upperLimit":"91880.8","comment":"Lower limit of 95% CI could not be estimated as the value was below the LLOQ (66165)."}]}]}]},{"type":"PRIMARY","title":"Cohort 2: Geometric Mean Ratio (GMR) of Fold Changes From Baseline For Serotype-specific Antibodies Measured by Multiplex ECL Based Immunoassay on Day 30","description":"GMR of fold changes from baseline for serotype-specific antibodies as measured by multiplex ECL based immunoassay on Day 30 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples by multiplex ECL based immunoassay. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 30 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 30","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"129"}]}],"classes":[{"title":"Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"4.40","lowerLimit":"3.958","upperLimit":"4.893"},{"groupId":"OG001","value":"1.02","lowerLimit":"0.955","upperLimit":"1.095"}]}]},{"title":"Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"8.18","lowerLimit":"7.255","upperLimit":"9.227"},{"groupId":"OG001","value":"0.98","lowerLimit":"0.909","upperLimit":"1.055"}]}]},{"title":"Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"5.31","lowerLimit":"4.726","upperLimit":"5.955"},{"groupId":"OG001","value":"1.09","lowerLimit":"1.014","upperLimit":"1.168"}]}]},{"title":"Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"3.64","lowerLimit":"3.289","upperLimit":"4.019"},{"groupId":"OG001","value":"1.06","lowerLimit":"0.993","upperLimit":"1.138"}]}]},{"title":"Serotype O8","categories":[{"measurements":[{"groupId":"OG000","value":"2.92","lowerLimit":"2.655","upperLimit":"3.221"},{"groupId":"OG001","value":"1.01","lowerLimit":"0.965","upperLimit":"1.058"}]}]},{"title":"Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"4.483","upperLimit":"5.565"},{"groupId":"OG001","value":"1.02","lowerLimit":"0.961","upperLimit":"1.077"}]}]},{"title":"Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"5.04","lowerLimit":"4.571","upperLimit":"5.561"},{"groupId":"OG001","value":"1.06","lowerLimit":"0.993","upperLimit":"1.126"}]}]},{"title":"Serotype O18","categories":[{"measurements":[{"groupId":"OG000","value":"3.40","lowerLimit":"3.088","upperLimit":"3.754"},{"groupId":"OG001","value":"1.07","lowerLimit":"1.017","upperLimit":"1.132"}]}]},{"title":"Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"5.59","lowerLimit":"4.866","upperLimit":"6.428"},{"groupId":"OG001","value":"1.04","lowerLimit":"0.963","upperLimit":"1.115"}]}]},{"title":"Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"2.33","lowerLimit":"2.136","upperLimit":"2.531"},{"groupId":"OG001","value":"1.04","lowerLimit":"0.979","upperLimit":"1.110"}]}]},{"title":"Serotype EPA","categories":[{"measurements":[{"groupId":"OG000","value":"8.06","lowerLimit":"6.73","upperLimit":"9.64"},{"groupId":"OG001","value":"1.02","lowerLimit":"0.97","upperLimit":"1.08"}]}]}]},{"type":"PRIMARY","title":"Cohort 2: Percentage of Participants With a >=2-Fold and >=4-Fold Increase From Baseline in Serotype Specific Serum Antibody Titers as Measured by Multiplex ECL Based Immunoassay on Day 30","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by multiplex ECL based immunoassay on Day 30 was reported. The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Day 30 for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA was calculated as the ratio of titer values of serum antibody on Day 30 and pre-vaccination (on day 1) that is, Day 30/Day 1. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this endpoint.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 30","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"129"}]}],"classes":[{"title":"Serotype O1A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"78.3","lowerLimit":"72.76","upperLimit":"83.17"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]},{"title":"Serotype O1A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"54.7","lowerLimit":"48.36","upperLimit":"60.84"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.24"}]}]},{"title":"Serotype O2: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"89.1","lowerLimit":"84.70","upperLimit":"92.67"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]},{"title":"Serotype O2: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"77.5","lowerLimit":"71.93","upperLimit":"82.46"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]},{"title":"Serotype O4: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"81.4","lowerLimit":"76.10","upperLimit":"85.95"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.48","upperLimit":"6.65"}]}]},{"title":"Serotype O4: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"58.9","lowerLimit":"52.64","upperLimit":"64.98"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]},{"title":"Serotype O6A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"73.3","lowerLimit":"67.41","upperLimit":"78.56"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.48","upperLimit":"6.65"}]}]},{"title":"Serotype O6A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"44.2","lowerLimit":"38.03","upperLimit":"50.48"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.24"}]}]},{"title":"Serotype O8: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"64.0","lowerLimit":"57.77","upperLimit":"69.82"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]},{"title":"Serotype O8: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"38.4","lowerLimit":"32.41","upperLimit":"44.61"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]},{"title":"Serotype O15: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"84.1","lowerLimit":"79.07","upperLimit":"88.35"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]},{"title":"Serotype O15: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"58.5","lowerLimit":"52.25","upperLimit":"64.60"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.24"}]}]},{"title":"Serotype O16: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"86.0","lowerLimit":"81.21","upperLimit":"90.03"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]},{"title":"Serotype O16: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"62.4","lowerLimit":"56.18","upperLimit":"68.33"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]},{"title":"Serotype O18: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"69.0","lowerLimit":"62.96","upperLimit":"74.58"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]},{"title":"Serotype O18: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"43.0","lowerLimit":"36.90","upperLimit":"49.31"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.24"}]}]},{"title":"Serotype O25B: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"78.3","lowerLimit":"72.76","upperLimit":"83.17"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.48","upperLimit":"6.65"}]}]},{"title":"Serotype O25B: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"56.6","lowerLimit":"50.30","upperLimit":"62.72"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]},{"title":"Serotype O75: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"51.2","lowerLimit":"44.89","upperLimit":"57.41"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.48","upperLimit":"6.65"}]}]},{"title":"Serotype O75: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"23.6","lowerLimit":"18.59","upperLimit":"29.31"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.48","upperLimit":"6.65"}]}]},{"title":"Serotype EPA: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"77.9","lowerLimit":"72.34","upperLimit":"82.82"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]},{"title":"Serotype EPA: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"65.5","lowerLimit":"59.36","upperLimit":"71.29"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.19","upperLimit":"5.49"}]}]}]},{"type":"PRIMARY","title":"Cohort 2: Geometric Mean Titer (GMT) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex Opsonophagocytic Assay (MOPA) on Day 30","description":"GMTs of serotype-specific total IgG serum antibodies as measured by MOPA were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75 were determined in serum from collected blood samples. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. LLOQ values were O1A: 33, O2: 42, O4: 12, O6A: 62, O15: 75, O16: 17, O18A: 44, O25B: 58, O75: 14. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this endpoint and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At Day 30","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"classes":[{"title":"Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"703.0","lowerLimit":"611.1","upperLimit":"808.7"},{"groupId":"OG001","value":"492.4","lowerLimit":"382.9","upperLimit":"633.2"}]}]},{"title":"Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3523.2","lowerLimit":"2950.7","upperLimit":"4206.7"},{"groupId":"OG001","value":"502.4","lowerLimit":"403.6","upperLimit":"625.4"}]}]},{"title":"Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"803.9","lowerLimit":"683.3","upperLimit":"945.7"},{"groupId":"OG001","value":"178.7","lowerLimit":"138.7","upperLimit":"230.4"}]}]},{"title":"Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1392.6","lowerLimit":"1196.9","upperLimit":"1620.3"},{"groupId":"OG001","value":"557.0","lowerLimit":"416.8","upperLimit":"744.3"}]}]},{"title":"Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2773.8","lowerLimit":"2347.4","upperLimit":"3277.6"},{"groupId":"OG001","value":"458.0","lowerLimit":"338.4","upperLimit":"619.9"}]}]},{"title":"Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1347.0","lowerLimit":"1132.2","upperLimit":"1602.5"},{"groupId":"OG001","value":"116.0","lowerLimit":"88.0","upperLimit":"152.8"}]}]},{"title":"Serotype O18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"516.3","lowerLimit":"446.2","upperLimit":"597.3"},{"groupId":"OG001","value":"168.2","lowerLimit":"128.8","upperLimit":"219.6"}]}]},{"title":"Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"159.8","lowerLimit":"135.4","upperLimit":"188.5"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"69.6","comment":"Geometric mean and lower limit of 95% CI could not be estimated as the value was below the LLOQ (58)."}]}]},{"title":"Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"257"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"201.0","lowerLimit":"169.5","upperLimit":"238.3"},{"groupId":"OG001","value":"52.2","lowerLimit":"39.2","upperLimit":"69.6"}]}]}]},{"type":"PRIMARY","title":"Cohort 2: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype Specific Antibodies as Measured by MOPA on Day 30","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by MOPA on Day 30 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples by MOPA. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 30 and pre-vaccination (on Day 1). For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this outcome measure and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 30","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"classes":[{"title":"Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","lowerLimit":"1.602","upperLimit":"2.054"},{"groupId":"OG001","value":"1.23","lowerLimit":"1.036","upperLimit":"1.451"}]}]},{"title":"Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.04","lowerLimit":"6.684","upperLimit":"9.681"},{"groupId":"OG001","value":"1.07","lowerLimit":"0.901","upperLimit":"1.265"}]}]},{"title":"Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.26","lowerLimit":"3.607","upperLimit":"5.033"},{"groupId":"OG001","value":"0.98","lowerLimit":"0.827","upperLimit":"1.162"}]}]},{"title":"Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","lowerLimit":"2.251","upperLimit":"2.939"},{"groupId":"OG001","value":"1.02","lowerLimit":"0.870","upperLimit":"1.192"}]}]},{"title":"Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.70","lowerLimit":"5.641","upperLimit":"7.958"},{"groupId":"OG001","value":"1.05","lowerLimit":"0.807","upperLimit":"1.376"}]}]},{"title":"Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.68","lowerLimit":"8.055","upperLimit":"11.639"},{"groupId":"OG001","value":"1.02","lowerLimit":"0.841","upperLimit":"1.227"}]}]},{"title":"Serotype O18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.88","lowerLimit":"2.482","upperLimit":"3.332"},{"groupId":"OG001","value":"0.93","lowerLimit":"0.805","upperLimit":"1.083"}]}]},{"title":"Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.05","lowerLimit":"1.813","upperLimit":"2.308"},{"groupId":"OG001","value":"0.94","lowerLimit":"0.841","upperLimit":"1.045"}]}]},{"title":"Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.21","lowerLimit":"2.744","upperLimit":"3.745"},{"groupId":"OG001","value":"1.18","lowerLimit":"0.973","upperLimit":"1.438"}]}]}]},{"type":"PRIMARY","title":"Cohort 2: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibodies Titers Measured by MOPA on Day 30","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibodies titers as measured by MOPA on Day 30 was reported. The fold (\\>=2-fold and \\>=4-fold increase from baseline to Day 30 for the serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 was calculated as the ratio of titer values of serum antibodies on Day 30 and pre-vaccination (on day 1 that is, Day 30/Day 1. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 30","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"classes":[{"title":"Serotype O1A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.5","lowerLimit":"35.40","upperLimit":"47.75"},{"groupId":"OG001","value":"22.9","lowerLimit":"13.67","upperLimit":"34.45"}]}]},{"title":"Serotype O1A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","lowerLimit":"13.36","upperLimit":"23.06"},{"groupId":"OG001","value":"2.9","lowerLimit":"0.35","upperLimit":"9.94"}]}]},{"title":"Serotype O2: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","lowerLimit":"75.68","upperLimit":"85.61"},{"groupId":"OG001","value":"18.6","lowerLimit":"10.28","upperLimit":"29.66"}]}]},{"title":"Serotype O2: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","lowerLimit":"57.37","upperLimit":"69.45"},{"groupId":"OG001","value":"4.3","lowerLimit":"0.89","upperLimit":"12.02"}]}]},{"title":"Serotype O4: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","lowerLimit":"58.56","upperLimit":"70.55"},{"groupId":"OG001","value":"14.3","lowerLimit":"7.07","upperLimit":"24.71"}]}]},{"title":"Serotype O4: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","lowerLimit":"39.54","upperLimit":"52.03"},{"groupId":"OG001","value":"4.3","lowerLimit":"0.89","upperLimit":"12.02"}]}]},{"title":"Serotype O6A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.3","lowerLimit":"47.97","upperLimit":"60.46"},{"groupId":"OG001","value":"17.1","lowerLimit":"9.18","upperLimit":"28.03"}]}]},{"title":"Serotype O6A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","lowerLimit":"27.24","upperLimit":"39.05"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.04","upperLimit":"7.70"}]}]},{"title":"Serotype O15: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.4","lowerLimit":"76.10","upperLimit":"85.95"},{"groupId":"OG001","value":"22.9","lowerLimit":"13.67","upperLimit":"34.45"}]}]},{"title":"Serotype O15: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.8","lowerLimit":"56.58","upperLimit":"68.71"},{"groupId":"OG001","value":"8.6","lowerLimit":"3.21","upperLimit":"17.73"}]}]},{"title":"Serotype O16: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.0","lowerLimit":"81.21","upperLimit":"90.03"},{"groupId":"OG001","value":"18.6","lowerLimit":"10.28","upperLimit":"29.66"}]}]},{"title":"Serotype O16: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.9","lowerLimit":"64.98","upperLimit":"76.40"},{"groupId":"OG001","value":"4.3","lowerLimit":"0.89","upperLimit":"12.02"}]}]},{"title":"Serotype O18: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.8","lowerLimit":"49.52","upperLimit":"61.97"},{"groupId":"OG001","value":"14.3","lowerLimit":"7.07","upperLimit":"24.71"}]}]},{"title":"Serotype O18: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","lowerLimit":"28.71","upperLimit":"40.64"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"5.13"}]}]},{"title":"Serotype O25B: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","lowerLimit":"35.02","upperLimit":"47.36"},{"groupId":"OG001","value":"5.7","lowerLimit":"1.58","upperLimit":"13.99"}]}]},{"title":"Serotype O25B: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","lowerLimit":"16.48","upperLimit":"26.83"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"5.13"}]}]},{"title":"Serotype O75: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.4","lowerLimit":"52.12","upperLimit":"64.55"},{"groupId":"OG001","value":"23.5","lowerLimit":"14.09","upperLimit":"35.38"}]}]},{"title":"Serotype O75: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.9","lowerLimit":"30.93","upperLimit":"43.11"},{"groupId":"OG001","value":"10.3","lowerLimit":"4.24","upperLimit":"20.07"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Correlation Between the Multiplex ECL-Based Immunoassay and the MOPA Functional Titers by Serotypes on Day 15","description":"Correlation between the multiplex ECL-based immunoassay and the MOPA functional titers by serotypes (O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B and O75) on Day 15 were analyzed. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity endpoint. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this outcome measure and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"correlation coefficient","timeFrame":"Day 15","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"classes":[{"title":"Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.62","lowerLimit":"0.49","upperLimit":"0.73"},{"groupId":"OG001","value":"0.51","lowerLimit":"0.35","upperLimit":"0.64"},{"groupId":"OG002","value":"0.63","lowerLimit":"0.49","upperLimit":"0.73"},{"groupId":"OG003","value":"0.57","lowerLimit":"0.34","upperLimit":"0.73"},{"groupId":"OG004","value":"0.51","lowerLimit":"0.27","upperLimit":"0.69"}]}]},{"title":"Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","lowerLimit":"0.61","upperLimit":"0.80"},{"groupId":"OG001","value":"0.74","lowerLimit":"0.63","upperLimit":"0.82"},{"groupId":"OG002","value":"0.64","lowerLimit":"0.51","upperLimit":"0.74"},{"groupId":"OG003","value":"0.74","lowerLimit":"0.58","upperLimit":"0.85"},{"groupId":"OG004","value":"0.59","lowerLimit":"0.38","upperLimit":"0.75"}]}]},{"title":"Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","lowerLimit":"0.58","upperLimit":"0.78"},{"groupId":"OG001","value":"0.65","lowerLimit":"0.52","upperLimit":"0.75"},{"groupId":"OG002","value":"0.61","lowerLimit":"0.47","upperLimit":"0.72"},{"groupId":"OG003","value":"-0.12","lowerLimit":"-0.39","upperLimit":"0.17"},{"groupId":"OG004","value":"0.47","lowerLimit":"0.22","upperLimit":"0.66"}]}]},{"title":"Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","lowerLimit":"0.31","upperLimit":"0.62"},{"groupId":"OG001","value":"0.53","lowerLimit":"0.37","upperLimit":"0.66"},{"groupId":"OG002","value":"0.60","lowerLimit":"0.46","upperLimit":"0.72"},{"groupId":"OG003","value":"0.67","lowerLimit":"0.48","upperLimit":"0.80"},{"groupId":"OG004","value":"0.15","lowerLimit":"-0.14","upperLimit":"0.40"}]}]},{"title":"Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","lowerLimit":"0.10","upperLimit":"0.46"},{"groupId":"OG001","value":"0.01","lowerLimit":"-0.19","upperLimit":"0.21"},{"groupId":"OG002","value":"0.20","lowerLimit":"0.00","upperLimit":"0.38"},{"groupId":"OG003","value":"-0.01","lowerLimit":"-0.29","upperLimit":"0.28"},{"groupId":"OG004","value":"0.15","lowerLimit":"-0.13","upperLimit":"0.41"}]}]},{"title":"Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","lowerLimit":"0.44","upperLimit":"0.70"},{"groupId":"OG001","value":"0.58","lowerLimit":"0.43","upperLimit":"0.70"},{"groupId":"OG002","value":"0.60","lowerLimit":"0.46","upperLimit":"0.71"},{"groupId":"OG003","value":"0.17","lowerLimit":"-0.12","upperLimit":"0.43"},{"groupId":"OG004","value":"0.41","lowerLimit":"0.15","upperLimit":"0.62"}]}]},{"title":"Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","lowerLimit":"0.64","upperLimit":"0.82"},{"groupId":"OG001","value":"0.67","lowerLimit":"0.54","upperLimit":"0.77"},{"groupId":"OG002","value":"0.69","lowerLimit":"0.58","upperLimit":"0.78"},{"groupId":"OG003","value":"0.52","lowerLimit":"0.28","upperLimit":"0.70"},{"groupId":"OG004","value":"0.48","lowerLimit":"0.24","upperLimit":"0.67"}]}]},{"title":"Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","lowerLimit":"0.58","upperLimit":"0.78"},{"groupId":"OG001","value":"0.65","lowerLimit":"0.52","upperLimit":"0.75"},{"groupId":"OG002","value":"0.72","lowerLimit":"0.61","upperLimit":"0.80"},{"groupId":"OG003","value":"0.39","lowerLimit":"0.12","upperLimit":"0.61"},{"groupId":"OG004","value":"0.55","lowerLimit":"0.32","upperLimit":"0.71"}]}]},{"title":"Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","lowerLimit":"0.40","upperLimit":"0.68"},{"groupId":"OG001","value":"0.57","lowerLimit":"0.42","upperLimit":"0.69"},{"groupId":"OG002","value":"0.54","lowerLimit":"0.38","upperLimit":"0.66"},{"groupId":"OG003","value":"0.46","lowerLimit":"0.21","upperLimit":"0.66"},{"groupId":"OG004","value":"-0.02","lowerLimit":"-0.29","upperLimit":"0.26"}]}]},{"title":"Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","lowerLimit":"0.45","upperLimit":"0.71"},{"groupId":"OG001","value":"0.45","lowerLimit":"0.27","upperLimit":"0.59"},{"groupId":"OG002","value":"0.64","lowerLimit":"0.51","upperLimit":"0.75"},{"groupId":"OG003","value":"0.51","lowerLimit":"0.26","upperLimit":"0.69"},{"groupId":"OG004","value":"0.35","lowerLimit":"0.08","upperLimit":"0.57"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Geometric Mean Titers (GMTs) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex ECL Based Immunoassay on Days 30 and 181","description":"GMTs of serotype-specific total IgG serum antibodies as measured by multiplex ECL based immunoassay on Days 30 and 181 were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples. LLOQ values for O1A: 69149, O2: 65287, O4: 67356, O6A: 150748, O8: 72196, O15: 66910, O16: 71586, O18A: 70519, O25B: 61990, O75: 133019, and EPA: 66165. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Days 30 and 181","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"classes":[{"title":"Day 30:Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5112484.0","lowerLimit":"4410187.9","upperLimit":"5926616.5"},{"groupId":"OG001","value":"6188073.3","lowerLimit":"5425498.1","upperLimit":"7057831.4"},{"groupId":"OG002","value":"6383997.2","lowerLimit":"5633938.0","upperLimit":"7233913.5"},{"groupId":"OG003","value":"6070942.6","lowerLimit":"4778712.5","upperLimit":"7712609.5"},{"groupId":"OG004","value":"1794173.8","lowerLimit":"1315930.3","upperLimit":"2446223.7"}]}]},{"title":"Day 30:Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4748963.2","lowerLimit":"4012632.8","upperLimit":"5620412.3"},{"groupId":"OG001","value":"4270069.6","lowerLimit":"3501400.5","upperLimit":"5207486.0"},{"groupId":"OG002","value":"6330528.7","lowerLimit":"5614246.1","upperLimit":"7138196.7"},{"groupId":"OG003","value":"5413245.9","lowerLimit":"4188560.3","upperLimit":"6996015.3"},{"groupId":"OG004","value":"484833.8","lowerLimit":"372182.7","upperLimit":"631581.8"}]}]},{"title":"Day 30:Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2849977.5","lowerLimit":"2298957.5","upperLimit":"3533067.3"},{"groupId":"OG001","value":"2286562.3","lowerLimit":"1855540.8","upperLimit":"2817705.3"},{"groupId":"OG002","value":"3835055.2","lowerLimit":"3183368.8","upperLimit":"4620152.0"},{"groupId":"OG003","value":"501717.6","lowerLimit":"417216.6","upperLimit":"603333.0"},{"groupId":"OG004","value":"585948.8","lowerLimit":"448200.5","upperLimit":"766032.1"}]}]},{"title":"Day 30:Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3914979.5","lowerLimit":"3360214.3","upperLimit":"4561335.5"},{"groupId":"OG001","value":"4675388.4","lowerLimit":"3910364.2","upperLimit":"5590082.1"},{"groupId":"OG002","value":"5328088.3","lowerLimit":"4595271.6","upperLimit":"6177768.6"},{"groupId":"OG003","value":"4648933.4","lowerLimit":"3601807.2","upperLimit":"6000482.7"},{"groupId":"OG004","value":"1018443.7","lowerLimit":"813194.1","upperLimit":"1275498.2"}]}]},{"title":"Day 30:Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5443708.3","lowerLimit":"4750360.8","upperLimit":"6238254.6"},{"groupId":"OG001","value":"5717188.1","lowerLimit":"4983597.2","upperLimit":"6558764.4"},{"groupId":"OG002","value":"6287045.5","lowerLimit":"5617980.2","upperLimit":"7035792.2"},{"groupId":"OG003","value":"1684506.5","lowerLimit":"1372618.1","upperLimit":"2067262.5"},{"groupId":"OG004","value":"1549931.5","lowerLimit":"1203616.5","upperLimit":"1995891.3"}]}]},{"title":"Day 30:Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4913158.9","lowerLimit":"4214268.5","upperLimit":"5727952.5"},{"groupId":"OG001","value":"4267640.2","lowerLimit":"3590342.0","upperLimit":"5072707.0"},{"groupId":"OG002","value":"5216657.6","lowerLimit":"4496071.7","upperLimit":"6052732.0"},{"groupId":"OG003","value":"900296.6","lowerLimit":"691458.3","upperLimit":"1172209.6"},{"groupId":"OG004","value":"1106266.6","lowerLimit":"821060.3","upperLimit":"1490543.2"}]}]},{"title":"Day 30:Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4376021.6","lowerLimit":"3720209.1","upperLimit":"5147443.3"},{"groupId":"OG001","value":"3525973.6","lowerLimit":"2932681.9","upperLimit":"4239290.3"},{"groupId":"OG002","value":"5410106.5","lowerLimit":"4684904.9","upperLimit":"6247565.9"},{"groupId":"OG003","value":"723757.2","lowerLimit":"621819.1","upperLimit":"842406.6"},{"groupId":"OG004","value":"819745.0","lowerLimit":"642584.7","upperLimit":"1045748.2"}]}]},{"title":"Day 30:Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3500329.1","lowerLimit":"2944423.4","upperLimit":"4161189.5"},{"groupId":"OG001","value":"3317876.1","lowerLimit":"2741547.6","upperLimit":"4015360.4"},{"groupId":"OG002","value":"4518450.7","lowerLimit":"3838422.1","upperLimit":"5318955.6"},{"groupId":"OG003","value":"1006196.4","lowerLimit":"830764.7","upperLimit":"1218673.8"},{"groupId":"OG004","value":"1121774.9","lowerLimit":"868211.3","upperLimit":"1449392.5"}]}]},{"title":"Day 30:Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1345602.7","lowerLimit":"1045822.6","upperLimit":"1731313.4"},{"groupId":"OG001","value":"2067379.5","lowerLimit":"1579663.8","upperLimit":"2705675.7"},{"groupId":"OG002","value":"1720048.6","lowerLimit":"1357130.9","upperLimit":"2180016.1"},{"groupId":"OG003","value":"1651715.3","lowerLimit":"1155425.4","upperLimit":"2361176.7"},{"groupId":"OG004","value":"285650.4","lowerLimit":"211348.9","upperLimit":"386073.0"}]}]},{"title":"Day 30:Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2827912.3","lowerLimit":"2357677.6","upperLimit":"3391934.5"},{"groupId":"OG001","value":"2640901.8","lowerLimit":"2178489.5","upperLimit":"3201466.9"},{"groupId":"OG002","value":"3569256.9","lowerLimit":"3057254.3","upperLimit":"4167005.2"},{"groupId":"OG003","value":"1180934.2","lowerLimit":"941313.5","upperLimit":"1481552.7"},{"groupId":"OG004","value":"1399568.8","lowerLimit":"1063013.9","upperLimit":"1842678.4"}]}]},{"title":"Day 30:Serotype EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1019260.3","lowerLimit":"727674.3","upperLimit":"1427687.4"},{"groupId":"OG001","value":"1306567.5","lowerLimit":"877517.2","upperLimit":"1945396.2"},{"groupId":"OG002","value":"1344648.1","lowerLimit":"957989.8","upperLimit":"1887367.1"},{"groupId":"OG003","value":"1107480.0","lowerLimit":"641693.9","upperLimit":"1911366.1"},{"groupId":"OG004","value":"NA","lowerLimit":"NA","upperLimit":"77381.5","comment":"Geometric mean and lower limit of 95% CI could not be estimated as the value was one-half of the LLOQ, that is, one -half of 66165."}]}]},{"title":"Day 181: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3583270.6","lowerLimit":"2911726.7","upperLimit":"4409695.6"},{"groupId":"OG001","value":"4537954.7","lowerLimit":"3685416.2","upperLimit":"5587709.0"},{"groupId":"OG002","value":"5046472.5","lowerLimit":"4245661.9","upperLimit":"5998330.9"},{"groupId":"OG003","value":"4468702.4","lowerLimit":"3299074.4","upperLimit":"6053001.2"},{"groupId":"OG004","value":"1523139.6","lowerLimit":"1054776.8","upperLimit":"2199474.2"}]}]},{"title":"Day 181: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2970482.1","lowerLimit":"2354313.7","upperLimit":"3747913.3"},{"groupId":"OG001","value":"3163734.9","lowerLimit":"2474677.1","upperLimit":"4044656.4"},{"groupId":"OG002","value":"4729234.1","lowerLimit":"3894909.1","upperLimit":"5742279.2"},{"groupId":"OG003","value":"4266510.5","lowerLimit":"3102445.5","upperLimit":"5867343.2"},{"groupId":"OG004","value":"490033.8","lowerLimit":"367540.7","upperLimit":"653351.1"}]}]},{"title":"Day 181: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1719377.7","lowerLimit":"1343456.0","upperLimit":"2200488.7"},{"groupId":"OG001","value":"1464137.0","lowerLimit":"1147541.0","upperLimit":"1868079.0"},{"groupId":"OG002","value":"2063300.4","lowerLimit":"1668018.7","upperLimit":"2552254.6"},{"groupId":"OG003","value":"501991.4","lowerLimit":"406178.0","upperLimit":"620406.3"},{"groupId":"OG004","value":"549904.9","lowerLimit":"410508.2","upperLimit":"736636.7"}]}]},{"title":"Day 181: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2742527.1","lowerLimit":"2289293.7","upperLimit":"3285491.5"},{"groupId":"OG001","value":"3187945.6","lowerLimit":"2581356.0","upperLimit":"3937077.1"},{"groupId":"OG002","value":"3447910.8","lowerLimit":"2852867.7","upperLimit":"4167066.4"},{"groupId":"OG003","value":"3334516.2","lowerLimit":"2533469.4","upperLimit":"4388842.5"},{"groupId":"OG004","value":"958424.9","lowerLimit":"745010.8","upperLimit":"1232973.1"}]}]},{"title":"Day 181: Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3792115.2","lowerLimit":"3159463.7","upperLimit":"4551449.0"},{"groupId":"OG001","value":"4351162.8","lowerLimit":"3653295.9","upperLimit":"5182338.9"},{"groupId":"OG002","value":"4752992.0","lowerLimit":"4056882.5","upperLimit":"5568545.1"},{"groupId":"OG003","value":"1757076.5","lowerLimit":"1418223.5","upperLimit":"2176891.0"},{"groupId":"OG004","value":"1637517.2","lowerLimit":"1193309.1","upperLimit":"2247081.3"}]}]},{"title":"Day 181: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3171754.0","lowerLimit":"2567192.7","upperLimit":"3918686.5"},{"groupId":"OG001","value":"3172409.9","lowerLimit":"2587224.3","upperLimit":"3889954.4"},{"groupId":"OG002","value":"3306905.3","lowerLimit":"2719748.6","upperLimit":"4020821.2"},{"groupId":"OG003","value":"919201.8","lowerLimit":"696966.2","upperLimit":"1212299.8"},{"groupId":"OG004","value":"948722.9","lowerLimit":"703688.5","upperLimit":"1279081.8"}]}]},{"title":"Day 181: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2952055.2","lowerLimit":"2380469.2","upperLimit":"3660887.5"},{"groupId":"OG001","value":"2527864.6","lowerLimit":"2047268.5","upperLimit":"3121280.6"},{"groupId":"OG002","value":"3713051.1","lowerLimit":"3064737.4","upperLimit":"4498508.8"},{"groupId":"OG003","value":"774950.8","lowerLimit":"638278.5","upperLimit":"940888.3"},{"groupId":"OG004","value":"720322.3","lowerLimit":"537574.2","upperLimit":"965195.6"}]}]},{"title":"Day 181: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2219012.5","lowerLimit":"1830470.2","upperLimit":"2690028.3"},{"groupId":"OG001","value":"2376169.7","lowerLimit":"1917314.2","upperLimit":"2944839.5"},{"groupId":"OG002","value":"2586344.3","lowerLimit":"2158196.6","upperLimit":"3099428.8"},{"groupId":"OG003","value":"943359.0","lowerLimit":"785332.4","upperLimit":"1133184.1"},{"groupId":"OG004","value":"1025511.9","lowerLimit":"773259.0","upperLimit":"1360054.9"}]}]},{"title":"Day 181: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"831345.5","lowerLimit":"623871.7","upperLimit":"1107816.5"},{"groupId":"OG001","value":"1144537.9","lowerLimit":"849494.3","upperLimit":"1542055.0"},{"groupId":"OG002","value":"939742.9","lowerLimit":"725097.2","upperLimit":"1217928.6"},{"groupId":"OG003","value":"794017.4","lowerLimit":"547313.1","upperLimit":"1151925.0"},{"groupId":"OG004","value":"239952.5","lowerLimit":"185411.5","upperLimit":"310537.2"}]}]},{"title":"Day 181: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1984426.0","lowerLimit":"1622665.9","upperLimit":"2426837.6"},{"groupId":"OG001","value":"1882478.8","lowerLimit":"1529846.4","upperLimit":"2316393.5"},{"groupId":"OG002","value":"2398218.7","lowerLimit":"2000407.3","upperLimit":"2875141.0"},{"groupId":"OG003","value":"1034083.5","lowerLimit":"835708.8","upperLimit":"1279546.9"},{"groupId":"OG004","value":"1159722.4","lowerLimit":"858094.1","upperLimit":"1567375.9"}]}]},{"title":"Day 181: Serotype EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"465763.6","lowerLimit":"312682.1","upperLimit":"693790.1"},{"groupId":"OG001","value":"561582.3","lowerLimit":"359386.0","upperLimit":"877537.3"},{"groupId":"OG002","value":"502960.6","lowerLimit":"354918.2","upperLimit":"712754.2"},{"groupId":"OG003","value":"584874.1","lowerLimit":"336014.2","upperLimit":"1018045.1"},{"groupId":"OG004","value":"NA","lowerLimit":"NA","upperLimit":"82330.5","comment":"Geometric mean and lower limit of 95% CI could not be estimated as the value was one-half of the LLOQ, that is, one -half of 66165."}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype-specific Antibodies Measured by Multiplex ECL Based Immunoassay on Days 30 and 181","description":"GMR of fold changes from baseline for serotype specific antibodies measured by multiplex ECL based immunoassay on Days 30 and 181 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples by ECL based immunoassay. GMR of fold change from baseline was calculated as the ratio of GMTs on Days 30 and 181 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Baseline (Day 1, pre-vaccination) and Days 30 and 181","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"classes":[{"title":"Day 30:Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.05","lowerLimit":"3.466","upperLimit":"4.740"},{"groupId":"OG001","value":"5.17","lowerLimit":"4.284","upperLimit":"6.242"},{"groupId":"OG002","value":"5.28","lowerLimit":"4.405","upperLimit":"6.325"},{"groupId":"OG003","value":"5.54","lowerLimit":"4.082","upperLimit":"7.524"},{"groupId":"OG004","value":"1.31","lowerLimit":"1.129","upperLimit":"1.520"}]}]},{"title":"Day 30:Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.16","lowerLimit":"7.714","upperLimit":"10.884"},{"groupId":"OG001","value":"9.20","lowerLimit":"7.551","upperLimit":"11.215"},{"groupId":"OG002","value":"12.00","lowerLimit":"10.318","upperLimit":"13.957"},{"groupId":"OG003","value":"11.53","lowerLimit":"8.447","upperLimit":"15.729"},{"groupId":"OG004","value":"1.05","lowerLimit":"0.979","upperLimit":"1.116"}]}]},{"title":"Day 30:Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.19","lowerLimit":"4.989","upperLimit":"7.677"},{"groupId":"OG001","value":"4.85","lowerLimit":"4.007","upperLimit":"5.873"},{"groupId":"OG002","value":"8.50","lowerLimit":"6.996","upperLimit":"10.327"},{"groupId":"OG003","value":"1.08","lowerLimit":"1.024","upperLimit":"1.146"},{"groupId":"OG004","value":"1.33","lowerLimit":"1.115","upperLimit":"1.588"}]}]},{"title":"Day 30:Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.21","lowerLimit":"2.745","upperLimit":"3.750"},{"groupId":"OG001","value":"4.08","lowerLimit":"3.355","upperLimit":"4.952"},{"groupId":"OG002","value":"4.67","lowerLimit":"3.988","upperLimit":"5.467"},{"groupId":"OG003","value":"3.93","lowerLimit":"2.991","upperLimit":"5.156"},{"groupId":"OG004","value":"1.01","lowerLimit":"0.938","upperLimit":"1.088"}]}]},{"title":"Day 30:Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.51","lowerLimit":"3.065","upperLimit":"4.013"},{"groupId":"OG001","value":"3.28","lowerLimit":"2.810","upperLimit":"3.836"},{"groupId":"OG002","value":"4.01","lowerLimit":"3.437","upperLimit":"4.673"},{"groupId":"OG003","value":"1.11","lowerLimit":"1.054","upperLimit":"1.174"},{"groupId":"OG004","value":"1.16","lowerLimit":"1.040","upperLimit":"1.288"}]}]},{"title":"Day 30:Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.43","lowerLimit":"4.559","upperLimit":"6.458"},{"groupId":"OG001","value":"4.99","lowerLimit":"4.152","upperLimit":"6.003"},{"groupId":"OG002","value":"5.78","lowerLimit":"4.842","upperLimit":"6.910"},{"groupId":"OG003","value":"1.03","lowerLimit":"0.959","upperLimit":"1.098"},{"groupId":"OG004","value":"1.36","lowerLimit":"1.184","upperLimit":"1.560"}]}]},{"title":"Day 30:Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.05","lowerLimit":"4.318","upperLimit":"5.912"},{"groupId":"OG001","value":"3.98","lowerLimit":"3.292","upperLimit":"4.805"},{"groupId":"OG002","value":"6.60","lowerLimit":"5.577","upperLimit":"7.802"},{"groupId":"OG003","value":"1.08","lowerLimit":"1.016","upperLimit":"1.149"},{"groupId":"OG004","value":"1.14","lowerLimit":"1.059","upperLimit":"1.230"}]}]},{"title":"Day 30:Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.73","lowerLimit":"3.158","upperLimit":"4.395"},{"groupId":"OG001","value":"3.35","lowerLimit":"2.777","upperLimit":"4.038"},{"groupId":"OG002","value":"4.83","lowerLimit":"4.067","upperLimit":"5.737"},{"groupId":"OG003","value":"1.05","lowerLimit":"0.986","upperLimit":"1.116"},{"groupId":"OG004","value":"1.13","lowerLimit":"1.004","upperLimit":"1.275"}]}]},{"title":"Day 30:Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.48","lowerLimit":"4.481","upperLimit":"6.695"},{"groupId":"OG001","value":"8.60","lowerLimit":"6.697","upperLimit":"11.044"},{"groupId":"OG002","value":"7.00","lowerLimit":"5.596","upperLimit":"8.766"},{"groupId":"OG003","value":"8.70","lowerLimit":"6.293","upperLimit":"12.038"},{"groupId":"OG004","value":"1.03","lowerLimit":"0.933","upperLimit":"1.141"}]}]},{"title":"Day 30:Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.20","lowerLimit":"1.915","upperLimit":"2.534"},{"groupId":"OG001","value":"2.04","lowerLimit":"1.749","upperLimit":"2.373"},{"groupId":"OG002","value":"2.75","lowerLimit":"2.344","upperLimit":"3.238"},{"groupId":"OG003","value":"1.06","lowerLimit":"0.949","upperLimit":"1.177"},{"groupId":"OG004","value":"1.03","lowerLimit":"0.915","upperLimit":"1.149"}]}]},{"title":"Day 30:Serotype EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.97","lowerLimit":"7.72","upperLimit":"12.89"},{"groupId":"OG001","value":"10.98","lowerLimit":"8.16","upperLimit":"14.76"},{"groupId":"OG002","value":"10.26","lowerLimit":"7.85","upperLimit":"13.42"},{"groupId":"OG003","value":"10.03","lowerLimit":"6.52","upperLimit":"15.45"},{"groupId":"OG004","value":"0.97","lowerLimit":"0.95","upperLimit":"0.99"}]}]},{"title":"Day 181: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.07","lowerLimit":"2.598","upperLimit":"3.626"},{"groupId":"OG001","value":"4.05","lowerLimit":"3.272","upperLimit":"5.019"},{"groupId":"OG002","value":"4.23","lowerLimit":"3.442","upperLimit":"5.201"},{"groupId":"OG003","value":"4.08","lowerLimit":"3.055","upperLimit":"5.447"},{"groupId":"OG004","value":"1.23","lowerLimit":"1.045","upperLimit":"1.445"}]}]},{"title":"Day 181: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.14","lowerLimit":"5.076","upperLimit":"7.438"},{"groupId":"OG001","value":"6.67","lowerLimit":"5.312","upperLimit":"8.382"},{"groupId":"OG002","value":"9.38","lowerLimit":"7.788","upperLimit":"11.309"},{"groupId":"OG003","value":"9.04","lowerLimit":"6.375","upperLimit":"12.817"},{"groupId":"OG004","value":"1.07","lowerLimit":"0.990","upperLimit":"1.162"}]}]},{"title":"Day 181: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.74","lowerLimit":"2.949","upperLimit":"4.734"},{"groupId":"OG001","value":"2.97","lowerLimit":"2.478","upperLimit":"3.567"},{"groupId":"OG002","value":"4.54","lowerLimit":"3.753","upperLimit":"5.496"},{"groupId":"OG003","value":"1.04","lowerLimit":"0.968","upperLimit":"1.125"},{"groupId":"OG004","value":"1.21","lowerLimit":"1.032","upperLimit":"1.429"}]}]},{"title":"Day 181: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.10","lowerLimit":"1.785","upperLimit":"2.477"},{"groupId":"OG001","value":"2.90","lowerLimit":"2.382","upperLimit":"3.532"},{"groupId":"OG002","value":"3.15","lowerLimit":"2.656","upperLimit":"3.738"},{"groupId":"OG003","value":"2.69","lowerLimit":"2.084","upperLimit":"3.480"},{"groupId":"OG004","value":"0.93","lowerLimit":"0.853","upperLimit":"1.006"}]}]},{"title":"Day 181: Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","lowerLimit":"2.155","upperLimit":"2.841"},{"groupId":"OG001","value":"2.52","lowerLimit":"2.135","upperLimit":"2.974"},{"groupId":"OG002","value":"3.14","lowerLimit":"2.673","upperLimit":"3.698"},{"groupId":"OG003","value":"1.11","lowerLimit":"0.990","upperLimit":"1.242"},{"groupId":"OG004","value":"1.17","lowerLimit":"1.022","upperLimit":"1.341"}]}]},{"title":"Day 181: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.93","lowerLimit":"3.213","upperLimit":"4.812"},{"groupId":"OG001","value":"3.84","lowerLimit":"3.160","upperLimit":"4.671"},{"groupId":"OG002","value":"4.21","lowerLimit":"3.470","upperLimit":"5.107"},{"groupId":"OG003","value":"1.06","lowerLimit":"0.931","upperLimit":"1.203"},{"groupId":"OG004","value":"1.24","lowerLimit":"1.071","upperLimit":"1.426"}]}]},{"title":"Day 181: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.30","lowerLimit":"2.752","upperLimit":"3.955"},{"groupId":"OG001","value":"2.89","lowerLimit":"2.361","upperLimit":"3.530"},{"groupId":"OG002","value":"4.75","lowerLimit":"3.969","upperLimit":"5.685"},{"groupId":"OG003","value":"1.06","lowerLimit":"0.946","upperLimit":"1.182"},{"groupId":"OG004","value":"1.11","lowerLimit":"1.024","upperLimit":"1.195"}]}]},{"title":"Day 181: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","lowerLimit":"2.192","upperLimit":"3.049"},{"groupId":"OG001","value":"2.48","lowerLimit":"2.061","upperLimit":"2.986"},{"groupId":"OG002","value":"2.96","lowerLimit":"2.481","upperLimit":"3.544"},{"groupId":"OG003","value":"0.98","lowerLimit":"0.911","upperLimit":"1.062"},{"groupId":"OG004","value":"1.10","lowerLimit":"1.005","upperLimit":"1.206"}]}]},{"title":"Day 181: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.61","lowerLimit":"2.920","upperLimit":"4.468"},{"groupId":"OG001","value":"5.35","lowerLimit":"4.133","upperLimit":"6.918"},{"groupId":"OG002","value":"3.88","lowerLimit":"3.114","upperLimit":"4.841"},{"groupId":"OG003","value":"4.67","lowerLimit":"3.387","upperLimit":"6.429"},{"groupId":"OG004","value":"0.99","lowerLimit":"0.895","upperLimit":"1.104"}]}]},{"title":"Day 181: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.59","lowerLimit":"1.417","upperLimit":"1.790"},{"groupId":"OG001","value":"1.54","lowerLimit":"1.339","upperLimit":"1.776"},{"groupId":"OG002","value":"2.07","lowerLimit":"1.764","upperLimit":"2.430"},{"groupId":"OG003","value":"0.92","lowerLimit":"0.829","upperLimit":"1.014"},{"groupId":"OG004","value":"0.92","lowerLimit":"0.851","upperLimit":"0.984"}]}]},{"title":"Day 181: Serotype EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.74","lowerLimit":"3.58","upperLimit":"6.28"},{"groupId":"OG001","value":"5.61","lowerLimit":"4.11","upperLimit":"7.66"},{"groupId":"OG002","value":"4.46","lowerLimit":"3.46","upperLimit":"5.75"},{"groupId":"OG003","value":"5.37","lowerLimit":"3.66","upperLimit":"7.89"},{"groupId":"OG004","value":"0.95","lowerLimit":"0.92","upperLimit":"0.98"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase From Baseline in Serotype-specific Serum Antibody Titers as Measured by Multiplex ECL Based Immunoassay on Days 30 and 181","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype (ST)-specific serum antibody titers as measured by multiplex ECL based immunoassay on Days 30 and 181 was reported. The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Days 30 and 181 for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA was calculated as the ratio of titer values of serum antibody on Day 30 and Day 181 and pre-vaccination (on Day 1 that is, Day 30/Day 1 and Day 181/Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint and \"n\" signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 (pre-vaccination) and Days 30 and 181","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"classes":[{"title":"Day 30: Serotype O1A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.8","lowerLimit":"69.42","upperLimit":"86.36"},{"groupId":"OG001","value":"82.8","lowerLimit":"73.57","upperLimit":"89.83"},{"groupId":"OG002","value":"80.8","lowerLimit":"71.66","upperLimit":"88.03"},{"groupId":"OG003","value":"77.1","lowerLimit":"62.69","upperLimit":"87.97"},{"groupId":"OG004","value":"12.5","lowerLimit":"4.73","upperLimit":"25.25"}]}]},{"title":"Day 30: Serotype O1A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","lowerLimit":"43.23","upperLimit":"63.62"},{"groupId":"OG001","value":"62.4","lowerLimit":"51.72","upperLimit":"72.21"},{"groupId":"OG002","value":"63.6","lowerLimit":"53.36","upperLimit":"73.07"},{"groupId":"OG003","value":"64.6","lowerLimit":"49.46","upperLimit":"77.84"},{"groupId":"OG004","value":"4.2","lowerLimit":"0.51","upperLimit":"14.25"}]}]},{"title":"Day 30: Serotype O2: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","lowerLimit":"87.27","upperLimit":"97.74"},{"groupId":"OG001","value":"91.4","lowerLimit":"83.75","upperLimit":"96.21"},{"groupId":"OG002","value":"98.0","lowerLimit":"92.89","upperLimit":"99.75"},{"groupId":"OG003","value":"89.6","lowerLimit":"77.34","upperLimit":"96.53"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"}]}]},{"title":"Day 30: Serotype O2: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.8","lowerLimit":"75.09","upperLimit":"90.47"},{"groupId":"OG001","value":"79.6","lowerLimit":"69.95","upperLimit":"87.23"},{"groupId":"OG002","value":"91.9","lowerLimit":"84.70","upperLimit":"96.45"},{"groupId":"OG003","value":"79.2","lowerLimit":"65.01","upperLimit":"89.53"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"}]}]},{"title":"Day 30: Serotype O4: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"79.8","lowerLimit":"70.54","upperLimit":"87.20"},{"groupId":"OG001","value":"81.7","lowerLimit":"72.35","upperLimit":"88.98"},{"groupId":"OG002","value":"88.9","lowerLimit":"80.9","upperLimit":"94.32"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"12.5","lowerLimit":"4.73","upperLimit":"25.25"}]}]},{"title":"Day 30: Serotype O4: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.6","lowerLimit":"51.30","upperLimit":"71.22"},{"groupId":"OG001","value":"59.1","lowerLimit":"48.46","upperLimit":"69.23"},{"groupId":"OG002","value":"75.8","lowerLimit":"66.11","upperLimit":"83.81"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"4.2","lowerLimit":"0.51","upperLimit":"14.25"}]}]},{"title":"Day 30: Serotype O6A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","lowerLimit":"53.36","upperLimit":"73.07"},{"groupId":"OG001","value":"74.2","lowerLimit":"64.08","upperLimit":"82.71"},{"groupId":"OG002","value":"80.8","lowerLimit":"71.66","upperLimit":"88.03"},{"groupId":"OG003","value":"72.9","lowerLimit":"58.15","upperLimit":"84.72"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"}]}]},{"title":"Day 30: Serotype O6A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.4","lowerLimit":"28.78","upperLimit":"48.70"},{"groupId":"OG001","value":"48.4","lowerLimit":"37.89","upperLimit":"58.99"},{"groupId":"OG002","value":"61.6","lowerLimit":"51.30","upperLimit":"71.22"},{"groupId":"OG003","value":"45.8","lowerLimit":"31.37","upperLimit":"60.83"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"}]}]},{"title":"Day 30: Serotype O8: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","lowerLimit":"68.31","upperLimit":"85.52"},{"groupId":"OG001","value":"68.8","lowerLimit":"58.37","upperLimit":"78.02"},{"groupId":"OG002","value":"73.7","lowerLimit":"63.93","upperLimit":"82.07"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.40"},{"groupId":"OG004","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"}]}]},{"title":"Day 30: Serotype O8: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.4","lowerLimit":"31.60","upperLimit":"51.76"},{"groupId":"OG001","value":"36.6","lowerLimit":"26.81","upperLimit":"47.19"},{"groupId":"OG002","value":"55.6","lowerLimit":"45.22","upperLimit":"65.55"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"}]}]},{"title":"Day 30: Serotype O15: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","lowerLimit":"78.59","upperLimit":"92.82"},{"groupId":"OG001","value":"80.6","lowerLimit":"71.15","upperLimit":"88.11"},{"groupId":"OG002","value":"83.8","lowerLimit":"75.09","upperLimit":"90.47"},{"groupId":"OG003","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"},{"groupId":"OG004","value":"14.6","lowerLimit":"6.07","upperLimit":"27.76"}]}]},{"title":"Day 30: Serotype O15: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","lowerLimit":"44.23","upperLimit":"64.59"},{"groupId":"OG001","value":"63.4","lowerLimit":"52.81","upperLimit":"73.19"},{"groupId":"OG002","value":"64.6","lowerLimit":"54.40","upperLimit":"73.99"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"6.3","lowerLimit":"1.31","upperLimit":"17.20"}]}]},{"title":"Day 30: Serotype O16: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","lowerLimit":"78.59","upperLimit":"92.82"},{"groupId":"OG001","value":"72.0","lowerLimit":"61.78","upperLimit":"80.86"},{"groupId":"OG002","value":"86.9","lowerLimit":"78.59","upperLimit":"92.82"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"}]}]},{"title":"Day 30: Serotype O16: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","lowerLimit":"50.28","upperLimit":"70.28"},{"groupId":"OG001","value":"49.5","lowerLimit":"38.93","upperLimit":"60.03"},{"groupId":"OG002","value":"72.7","lowerLimit":"62.85","upperLimit":"81.20"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"}]}]},{"title":"Day 30: Serotype O18A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.7","lowerLimit":"63.93","upperLimit":"82.07"},{"groupId":"OG001","value":"64.5","lowerLimit":"53.91","upperLimit":"74.17"},{"groupId":"OG002","value":"80.8","lowerLimit":"71.66","upperLimit":"88.03"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"4.2","lowerLimit":"0.51","upperLimit":"14.25"}]}]},{"title":"Day 30: Serotype O18A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","lowerLimit":"37.34","upperLimit":"57.76"},{"groupId":"OG001","value":"37.6","lowerLimit":"27.79","upperLimit":"48.28"},{"groupId":"OG002","value":"60.6","lowerLimit":"50.28","upperLimit":"70.28"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"},{"groupId":"OG004","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"}]}]},{"title":"Day 30: Serotype O25B: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","lowerLimit":"72.80","upperLimit":"88.85"},{"groupId":"OG001","value":"84.9","lowerLimit":"76.03","upperLimit":"91.52"},{"groupId":"OG002","value":"83.8","lowerLimit":"75.09","upperLimit":"90.47"},{"groupId":"OG003","value":"87.5","lowerLimit":"74.75","upperLimit":"95.27"},{"groupId":"OG004","value":"4.2","lowerLimit":"0.51","upperLimit":"14.25"}]}]},{"title":"Day 30: Serotype O25B: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","lowerLimit":"50.28","upperLimit":"70.28"},{"groupId":"OG001","value":"75.3","lowerLimit":"65.24","upperLimit":"83.63"},{"groupId":"OG002","value":"67.7","lowerLimit":"57.53","upperLimit":"76.73"},{"groupId":"OG003","value":"75.0","lowerLimit":"60.40","upperLimit":"86.36"},{"groupId":"OG004","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"}]}]},{"title":"Day 30: Serotype O75: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.5","lowerLimit":"38.32","upperLimit":"58.75"},{"groupId":"OG001","value":"43.0","lowerLimit":"32.78","upperLimit":"53.69"},{"groupId":"OG002","value":"59.6","lowerLimit":"49.26","upperLimit":"69.34"},{"groupId":"OG003","value":"4.2","lowerLimit":"0.51","upperLimit":"14.25"},{"groupId":"OG004","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"}]}]},{"title":"Day 30: Serotype O75: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","lowerLimit":"11.9","upperLimit":"28.34"},{"groupId":"OG001","value":"22.6","lowerLimit":"14.55","upperLimit":"32.42"},{"groupId":"OG002","value":"28.3","lowerLimit":"19.69","upperLimit":"38.22"},{"groupId":"OG003","value":"4.2","lowerLimit":"0.51","upperLimit":"14.25"},{"groupId":"OG004","value":"2.1","lowerLimit":"0.05","upperLimit":"11.07"}]}]},{"title":"Day 30: Serotype EPA: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","lowerLimit":"78.59","upperLimit":"92.82"},{"groupId":"OG001","value":"80.6","lowerLimit":"71.15","upperLimit":"88.11"},{"groupId":"OG002","value":"85.9","lowerLimit":"77.41","upperLimit":"92.05"},{"groupId":"OG003","value":"77.1","lowerLimit":"62.69","upperLimit":"87.97"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"}]}]},{"title":"Day 30: Serotype EPA: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.7","lowerLimit":"63.93","upperLimit":"82.07"},{"groupId":"OG001","value":"74.2","lowerLimit":"64.08","upperLimit":"82.71"},{"groupId":"OG002","value":"75.8","lowerLimit":"66.11","upperLimit":"83.81"},{"groupId":"OG003","value":"72.9","lowerLimit":"58.15","upperLimit":"84.72"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"7.40"}]}]},{"title":"Day 181: : Serotype O1A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","lowerLimit":"52.66","upperLimit":"75.12"},{"groupId":"OG001","value":"73.3","lowerLimit":"61.86","upperLimit":"82.89"},{"groupId":"OG002","value":"72.5","lowerLimit":"61.38","upperLimit":"81.90"},{"groupId":"OG003","value":"67.4","lowerLimit":"51.46","upperLimit":"80.92"},{"groupId":"OG004","value":"10.8","lowerLimit":"3.03","upperLimit":"25.42"}]}]},{"title":"Day 181: Serotype O1A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","lowerLimit":"24.88","upperLimit":"47.34"},{"groupId":"OG001","value":"49.3","lowerLimit":"37.58","upperLimit":"61.14"},{"groupId":"OG002","value":"51.3","lowerLimit":"39.81","upperLimit":"62.59"},{"groupId":"OG003","value":"51.2","lowerLimit":"35.46","upperLimit":"66.69"},{"groupId":"OG004","value":"5.4","lowerLimit":"0.66","upperLimit":"18.19"}]}]},{"title":"Day 181: Serotype O2: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","lowerLimit":"80.31","upperLimit":"95.34"},{"groupId":"OG001","value":"86.7","lowerLimit":"76.84","upperLimit":"93.42"},{"groupId":"OG002","value":"92.5","lowerLimit":"84.39","upperLimit":"97.20"},{"groupId":"OG003","value":"83.7","lowerLimit":"69.30","upperLimit":"93.19"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"9.49"}]}]},{"title":"Day 181: Serotype O2: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","lowerLimit":"58.13","upperLimit":"79.75"},{"groupId":"OG001","value":"70.7","lowerLimit":"59.02","upperLimit":"80.62"},{"groupId":"OG002","value":"83.8","lowerLimit":"73.82","upperLimit":"91.05"},{"groupId":"OG003","value":"74.4","lowerLimit":"58.83","upperLimit":"86.48"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"9.49"}]}]},{"title":"Day 181: Serotype O4: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","lowerLimit":"56.75","upperLimit":"78.61"},{"groupId":"OG001","value":"65.3","lowerLimit":"53.46","upperLimit":"75.96"},{"groupId":"OG002","value":"81.3","lowerLimit":"70.97","upperLimit":"89.11"},{"groupId":"OG003","value":"2.3","lowerLimit":"0.06","upperLimit":"12.29"},{"groupId":"OG004","value":"5.4","lowerLimit":"0.66","upperLimit":"18.19"}]}]},{"title":"Day 181: Serotype O4: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","lowerLimit":"32.08","upperLimit":"55.29"},{"groupId":"OG001","value":"33.3","lowerLimit":"22.86","upperLimit":"45.17"},{"groupId":"OG002","value":"55.0","lowerLimit":"43.47","upperLimit":"66.15"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"8.22"},{"groupId":"OG004","value":"5.4","lowerLimit":"0.66","upperLimit":"18.19"}]}]},{"title":"Day 181: Serotype O6A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.1","lowerLimit":"34.55","upperLimit":"57.87"},{"groupId":"OG001","value":"60.0","lowerLimit":"48.04","upperLimit":"71.15"},{"groupId":"OG002","value":"67.5","lowerLimit":"56.11","upperLimit":"77.55"},{"groupId":"OG003","value":"55.8","lowerLimit":"39.88","upperLimit":"70.9"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"9.49"}]}]},{"title":"Day 181: Serotype O6A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","lowerLimit":"10.45","upperLimit":"28.97"},{"groupId":"OG001","value":"33.3","lowerLimit":"22.86","upperLimit":"45.17"},{"groupId":"OG002","value":"33.8","lowerLimit":"23.55","upperLimit":"45.19"},{"groupId":"OG003","value":"32.6","lowerLimit":"19.08","upperLimit":"48.54"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"9.49"}]}]},{"title":"Day 181: Serotype O8: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","lowerLimit":"48.65","upperLimit":"71.56"},{"groupId":"OG001","value":"56.0","lowerLimit":"44.06","upperLimit":"67.45"},{"groupId":"OG002","value":"65.0","lowerLimit":"53.52","upperLimit":"75.33"},{"groupId":"OG003","value":"9.3","lowerLimit":"2.59","upperLimit":"22.14"},{"groupId":"OG004","value":"5.4","lowerLimit":"0.66","upperLimit":"18.19"}]}]},{"title":"Day 181: Serotype O8: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","lowerLimit":"9.43","upperLimit":"27.47"},{"groupId":"OG001","value":"24.0","lowerLimit":"14.89","upperLimit":"35.25"},{"groupId":"OG002","value":"37.5","lowerLimit":"26.92","upperLimit":"49.04"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"8.22"},{"groupId":"OG004","value":"2.7","lowerLimit":"0.07","upperLimit":"14.16"}]}]},{"title":"Day 181: Serotype O15: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.7","lowerLimit":"62.32","upperLimit":"83.13"},{"groupId":"OG001","value":"76.0","lowerLimit":"64.75","upperLimit":"85.11"},{"groupId":"OG002","value":"81.3","lowerLimit":"70.97","upperLimit":"89.11"},{"groupId":"OG003","value":"4.7","lowerLimit":"0.57","upperLimit":"15.81"},{"groupId":"OG004","value":"8.1","lowerLimit":"1.70","upperLimit":"21.91"}]}]},{"title":"Day 181: Serotype O15: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","lowerLimit":"33.31","upperLimit":"56.59"},{"groupId":"OG001","value":"49.3","lowerLimit":"37.58","upperLimit":"61.14"},{"groupId":"OG002","value":"45.0","lowerLimit":"33.85","upperLimit":"56.53"},{"groupId":"OG003","value":"2.3","lowerLimit":"0.06","upperLimit":"12.29"},{"groupId":"OG004","value":"2.7","lowerLimit":"0.07","upperLimit":"14.16"}]}]},{"title":"Day 181: Serotype O16: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","lowerLimit":"60.91","upperLimit":"82.01"},{"groupId":"OG001","value":"60.0","lowerLimit":"48.04","upperLimit":"71.15"},{"groupId":"OG002","value":"87.5","lowerLimit":"78.21","upperLimit":"93.84"},{"groupId":"OG003","value":"4.7","lowerLimit":"0.57","upperLimit":"15.81"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"9.49"}]}]},{"title":"Day 181: Serotype O16: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","lowerLimit":"26.06","upperLimit":"48.69"},{"groupId":"OG001","value":"36.0","lowerLimit":"25.23","upperLimit":"47.91"},{"groupId":"OG002","value":"56.3","lowerLimit":"44.70","upperLimit":"67.32"},{"groupId":"OG003","value":"2.3","lowerLimit":"0.06","upperLimit":"12.29"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"9.49"}]}]},{"title":"Day 181: Serotype O18A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","lowerLimit":"51.3","upperLimit":"73.9"},{"groupId":"OG001","value":"52.0","lowerLimit":"40.15","upperLimit":"63.69"},{"groupId":"OG002","value":"60.0","lowerLimit":"48.44","upperLimit":"70.80"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"8.22"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"9.49"}]}]},{"title":"Day 181: Serotype O18A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","lowerLimit":"14.68","upperLimit":"34.82"},{"groupId":"OG001","value":"25.3","lowerLimit":"15.99","upperLimit":"36.70"},{"groupId":"OG002","value":"33.8","lowerLimit":"23.55","upperLimit":"45.19"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"8.22"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"9.49"}]}]},{"title":"Day 181: Serotype O25B: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","lowerLimit":"55.37","upperLimit":"77.46"},{"groupId":"OG001","value":"74.7","lowerLimit":"63.30","upperLimit":"84.01"},{"groupId":"OG002","value":"72.5","lowerLimit":"61.38","upperLimit":"81.90"},{"groupId":"OG003","value":"76.7","lowerLimit":"61.37","upperLimit":"88.24"},{"groupId":"OG004","value":"2.7","lowerLimit":"0.07","upperLimit":"14.16"}]}]},{"title":"Day 181: Serotype O25B: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","lowerLimit":"33.31","upperLimit":"56.59"},{"groupId":"OG001","value":"56.0","lowerLimit":"44.06","upperLimit":"67.45"},{"groupId":"OG002","value":"42.5","lowerLimit":"31.51","upperLimit":"54.06"},{"groupId":"OG003","value":"51.2","lowerLimit":"35.46","upperLimit":"66.69"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"9.49"}]}]},{"title":"Day 181: Serotype O75: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","lowerLimit":"16.87","upperLimit":"37.68"},{"groupId":"OG001","value":"26.7","lowerLimit":"17.11","upperLimit":"38.14"},{"groupId":"OG002","value":"45.0","lowerLimit":"33.85","upperLimit":"56.53"},{"groupId":"OG003","value":"2.3","lowerLimit":"0.06","upperLimit":"12.29"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"9.49"}]}]},{"title":"Day 181: Serotype O75: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"1.45","upperLimit":"12.93"},{"groupId":"OG001","value":"10.7","lowerLimit":"4.72","upperLimit":"19.9"},{"groupId":"OG002","value":"13.8","lowerLimit":"7.07","upperLimit":"23.27"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.00","upperLimit":"8.22"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.0","upperLimit":"9.49"}]}]},{"title":"Day 181: Serotype EPA: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","lowerLimit":"60.91","upperLimit":"82.01"},{"groupId":"OG001","value":"70.7","lowerLimit":"59.02","upperLimit":"80.62"},{"groupId":"OG002","value":"71.3","lowerLimit":"60.05","upperLimit":"80.82"},{"groupId":"OG003","value":"76.7","lowerLimit":"61.37","upperLimit":"88.24"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"9.49"}]}]},{"title":"Day 181: Serotype EPA: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.3","lowerLimit":"39.57","upperLimit":"62.96"},{"groupId":"OG001","value":"57.3","lowerLimit":"45.38","upperLimit":"68.69"},{"groupId":"OG002","value":"47.5","lowerLimit":"36.21","upperLimit":"58.98"},{"groupId":"OG003","value":"55.8","lowerLimit":"39.88","upperLimit":"70.92"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.00","upperLimit":"9.49"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype Specific Antibodies as Measured by MOPA on Days 30 and 181","description":"GMRs for each O-antigen (serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75) were determined using a validated MOPA. For sample pairs with available validated MOPA results from both Day 1 and Day 30, or Day 1 and 181, GMR from baseline for serotype specific antibodies was calculated as the ratio of GMTs on Days 30 or 181 and pre-vaccination (on Day 1). For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set used. \"N\" = number of participants evaluable for the endpoint. High dose ExPEC10V and Prevnar 13: validated MOPA at all timepoints. Low and medium ExPEC10V and ExPEC4V: Day 1 tested with qualified MOPA; Days 30 and 181 with validated MOPA. GMRs require data from the same assay at both timepoints. Because validated MOPA data are missing at Day 1 for low and medium ExPEC10V and ExPEC4V, GMRs could not be calculated.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline (Day 1, pre-vaccination) and Days 30 and 181","groups":[{"id":"OG000","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"51"}]}],"classes":[{"title":"Day 30:Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"1.58","lowerLimit":"1.166","upperLimit":"2.153"},{"groupId":"OG001","value":"0.65","lowerLimit":"0.338","upperLimit":"1.238"}]}]},{"title":"Day 30:Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"11.86","lowerLimit":"8.298","upperLimit":"16.940"},{"groupId":"OG001","value":"0.67","lowerLimit":"0.408","upperLimit":"1.107"}]}]},{"title":"Day 30:Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"3.62","lowerLimit":"2.823","upperLimit":"4.642"},{"groupId":"OG001","value":"1.59","lowerLimit":"0.727","upperLimit":"3.493"}]}]},{"title":"Day 30:Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"1.72","lowerLimit":"1.319","upperLimit":"2.249"},{"groupId":"OG001","value":"0.97","lowerLimit":"0.391","upperLimit":"2.394"}]}]},{"title":"Day 30:Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"6.51","lowerLimit":"4.645","upperLimit":"9.134"},{"groupId":"OG001","value":"1.70","lowerLimit":"0.565","upperLimit":"5.140"}]}]},{"title":"Day 30:Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"10.50","lowerLimit":"7.958","upperLimit":"13.848"},{"groupId":"OG001","value":"1.11","lowerLimit":"0.676","upperLimit":"1.825"}]}]},{"title":"Day 30:Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"2.35","lowerLimit":"1.758","upperLimit":"3.146"},{"groupId":"OG001","value":"1.04","lowerLimit":"0.400","upperLimit":"2.715"}]}]},{"title":"Day 30:Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"2.16","lowerLimit":"1.771","upperLimit":"2.627"},{"groupId":"OG001","value":"1.02","lowerLimit":"0.972","upperLimit":"1.074"}]}]},{"title":"Day 30:Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"4.02","lowerLimit":"2.993","upperLimit":"5.405"},{"groupId":"OG001","value":"1.38","lowerLimit":"0.515","upperLimit":"3.689"}]}]},{"title":"Day 181: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"0.93","lowerLimit":"0.732","upperLimit":"1.189"},{"groupId":"OG001","value":"0.99","lowerLimit":"0.530","upperLimit":"1.833"}]}]},{"title":"Day 181: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"4.79","lowerLimit":"3.457","upperLimit":"6.649"},{"groupId":"OG001","value":"0.96","lowerLimit":"0.432","upperLimit":"2.120"}]}]},{"title":"Day 181: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"1.94","lowerLimit":"1.575","upperLimit":"2.381"},{"groupId":"OG001","value":"1.13","lowerLimit":"0.447","upperLimit":"2.857"}]}]},{"title":"Day 181: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"0.791","upperLimit":"1.257"},{"groupId":"OG001","value":"0.59","lowerLimit":"0.268","upperLimit":"1.304"}]}]},{"title":"Day 181: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"2.75","lowerLimit":"2.034","upperLimit":"3.731"},{"groupId":"OG001","value":"1.22","lowerLimit":"0.616","upperLimit":"2.415"}]}]},{"title":"Day 181: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"4.86","lowerLimit":"3.612","upperLimit":"6.550"},{"groupId":"OG001","value":"1.66","lowerLimit":"1.086","upperLimit":"2.551"}]}]},{"title":"Day 181: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"1.18","lowerLimit":"0.920","upperLimit":"1.508"},{"groupId":"OG001","value":"1.82","lowerLimit":"0.584","upperLimit":"5.684"}]}]},{"title":"Day 181: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"1.37","lowerLimit":"1.196","upperLimit":"1.572"},{"groupId":"OG001","value":"0.96","lowerLimit":"0.858","upperLimit":"1.070"}]}]},{"title":"Day 181: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"1.78","lowerLimit":"1.402","upperLimit":"2.269"},{"groupId":"OG001","value":"0.89","lowerLimit":"0.406","upperLimit":"1.962"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Geometric Mean Titers (GMTs) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by MOPA on Days 30 and 181","description":"GMTs of serotype-specific total IgG serum antibodies as measured by MOPA on Days 30 and 181 were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A,O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. LLOQ values were O1A: 33, O2: 42, O4: 12, O6A: 62, O15: 75, O16: 17, O18A: 44, O25B: 58, O75: 14. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this outcome measure. High dose ExPEC10V and Prevnar 13: validated MOPA at all timepoints. Low and medium ExPEC10V and ExPEC4V: Day 1 tested with qualified MOPA; Days 30 and 181 with validated MOPA.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Days 30 and 181","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"51"}]}],"classes":[{"title":"Day 30: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"485.7","lowerLimit":"383.6","upperLimit":"615.0"},{"groupId":"OG001","value":"452.6","lowerLimit":"343.0","upperLimit":"597.3"},{"groupId":"OG002","value":"517.3","lowerLimit":"383.9","upperLimit":"697.0"},{"groupId":"OG003","value":"815.3","lowerLimit":"545.7","upperLimit":"1217.9"},{"groupId":"OG004","value":"300.8","lowerLimit":"215.4","upperLimit":"420.1"}]}]},{"title":"Day 30: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"2189.0","lowerLimit":"1618.1","upperLimit":"2961.3"},{"groupId":"OG001","value":"2533.1","lowerLimit":"1768.1","upperLimit":"3629.1"},{"groupId":"OG002","value":"4431.3","lowerLimit":"3143.2","upperLimit":"6247.3"},{"groupId":"OG003","value":"3748.8","lowerLimit":"2391.6","upperLimit":"5876.4"},{"groupId":"OG004","value":"270.4","lowerLimit":"201.1","upperLimit":"363.6"}]}]},{"title":"Day 30: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"609.5","lowerLimit":"470.2","upperLimit":"790.2"},{"groupId":"OG001","value":"562.1","lowerLimit":"431.7","upperLimit":"731.9"},{"groupId":"OG002","value":"667.1","lowerLimit":"518.0","upperLimit":"859.1"},{"groupId":"OG003","value":"236.2","lowerLimit":"177.7","upperLimit":"313.9"},{"groupId":"OG004","value":"193.3","lowerLimit":"152.8","upperLimit":"244.7"}]}]},{"title":"Day 30: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"740.5","lowerLimit":"574.6","upperLimit":"954.4"},{"groupId":"OG001","value":"1123.7","lowerLimit":"864.6","upperLimit":"1460.4"},{"groupId":"OG002","value":"994.7","lowerLimit":"763.8","upperLimit":"1295.3"},{"groupId":"OG003","value":"1067.7","lowerLimit":"718.9","upperLimit":"1585.6"},{"groupId":"OG004","value":"519.9","lowerLimit":"339.3","upperLimit":"796.5"}]}]},{"title":"Day 30: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"2423.3","lowerLimit":"1767.9","upperLimit":"3321.7"},{"groupId":"OG001","value":"2403.7","lowerLimit":"1744.4","upperLimit":"3312.2"},{"groupId":"OG002","value":"2658.9","lowerLimit":"1931.1","upperLimit":"3660.8"},{"groupId":"OG003","value":"477.8","lowerLimit":"341.5","upperLimit":"668.4"},{"groupId":"OG004","value":"527.5","lowerLimit":"345.5","upperLimit":"805.4"}]}]},{"title":"Day 30: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"987.0","lowerLimit":"727.8","upperLimit":"1338.5"},{"groupId":"OG001","value":"1005.1","lowerLimit":"701.4","upperLimit":"1440.3"},{"groupId":"OG002","value":"1465.5","lowerLimit":"1085.3","upperLimit":"1978.8"},{"groupId":"OG003","value":"107.5","lowerLimit":"74.6","upperLimit":"155.0"},{"groupId":"OG004","value":"110.4","lowerLimit":"78.1","upperLimit":"156.1"}]}]},{"title":"Day 30: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"523.5","lowerLimit":"412.6","upperLimit":"664.2"},{"groupId":"OG001","value":"538.3","lowerLimit":"402.8","upperLimit":"719.3"},{"groupId":"OG002","value":"592.9","lowerLimit":"451.5","upperLimit":"778.7"},{"groupId":"OG003","value":"226.5","lowerLimit":"155.7","upperLimit":"329.5"},{"groupId":"OG004","value":"195.1","lowerLimit":"141.5","upperLimit":"269.1"}]}]},{"title":"Day 30: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"118.2","lowerLimit":"91.1","upperLimit":"153.4"},{"groupId":"OG001","value":"168.8","lowerLimit":"122.2","upperLimit":"233.1"},{"groupId":"OG002","value":"134.0","lowerLimit":"103.5","upperLimit":"173.4"},{"groupId":"OG003","value":"140.2","lowerLimit":"97.0","upperLimit":"202.6"},{"groupId":"OG004","value":"63.3","lowerLimit":"NA","upperLimit":"96.5","comment":"Lower limit of 95% CI could not be estimated as the value was below the LLOQ (58)."}]}]},{"title":"Day 30: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"221.2","lowerLimit":"176.2","upperLimit":"277.7"},{"groupId":"OG001","value":"148.5","lowerLimit":"111.8","upperLimit":"197.2"},{"groupId":"OG002","value":"246.4","lowerLimit":"177.5","upperLimit":"342.1"},{"groupId":"OG003","value":"71.9","lowerLimit":"50.4","upperLimit":"102.7"},{"groupId":"OG004","value":"97.6","lowerLimit":"69.8","upperLimit":"136.5"}]}]},{"title":"Day 181: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"369.0","lowerLimit":"290.7","upperLimit":"468.3"},{"groupId":"OG001","value":"249.1","lowerLimit":"194.9","upperLimit":"318.4"},{"groupId":"OG002","value":"291.5","lowerLimit":"215.3","upperLimit":"394.7"},{"groupId":"OG003","value":"466.6","lowerLimit":"311.9","upperLimit":"698.0"},{"groupId":"OG004","value":"254.3","lowerLimit":"162.3","upperLimit":"398.4"}]}]},{"title":"Day 181: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"1196.5","lowerLimit":"869.4","upperLimit":"1646.7"},{"groupId":"OG001","value":"1076.4","lowerLimit":"777.7","upperLimit":"1489.8"},{"groupId":"OG002","value":"1887.2","lowerLimit":"1313.0","upperLimit":"2712.4"},{"groupId":"OG003","value":"1687.3","lowerLimit":"1057.5","upperLimit":"2692.1"},{"groupId":"OG004","value":"246.7","lowerLimit":"173.3","upperLimit":"351.3"}]}]},{"title":"Day 181: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"340.9","lowerLimit":"259.8","upperLimit":"447.3"},{"groupId":"OG001","value":"298.9","lowerLimit":"231.5","upperLimit":"385.9"},{"groupId":"OG002","value":"330.5","lowerLimit":"263.7","upperLimit":"414.2"},{"groupId":"OG003","value":"190.5","lowerLimit":"140.6","upperLimit":"258.2"},{"groupId":"OG004","value":"171.5","lowerLimit":"124.8","upperLimit":"235.6"}]}]},{"title":"Day 181: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"616.9","lowerLimit":"469.9","upperLimit":"809.8"},{"groupId":"OG001","value":"773.5","lowerLimit":"580.5","upperLimit":"1030.7"},{"groupId":"OG002","value":"599.4","lowerLimit":"454.6","upperLimit":"790.3"},{"groupId":"OG003","value":"623.3","lowerLimit":"383.9","upperLimit":"1012.0"},{"groupId":"OG004","value":"506.5","lowerLimit":"280.3","upperLimit":"915.3"}]}]},{"title":"Day 181: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"1053.1","lowerLimit":"724.1","upperLimit":"1531.6"},{"groupId":"OG001","value":"1431.8","lowerLimit":"1014.1","upperLimit":"2021.6"},{"groupId":"OG002","value":"1110.1","lowerLimit":"832.6","upperLimit":"1480.0"},{"groupId":"OG003","value":"347.7","lowerLimit":"240.4","upperLimit":"503.0"},{"groupId":"OG004","value":"438.2","lowerLimit":"282.6","upperLimit":"679.5"}]}]},{"title":"Day 181: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"546.7","lowerLimit":"386.5","upperLimit":"773.2"},{"groupId":"OG001","value":"426.9","lowerLimit":"298.6","upperLimit":"610.3"},{"groupId":"OG002","value":"656.3","lowerLimit":"474.2","upperLimit":"908.5"},{"groupId":"OG003","value":"102.5","lowerLimit":"73.3","upperLimit":"143.3"},{"groupId":"OG004","value":"77.9","lowerLimit":"51.6","upperLimit":"117.6"}]}]},{"title":"Day 181: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"309.4","lowerLimit":"242.6","upperLimit":"394.7"},{"groupId":"OG001","value":"341.3","lowerLimit":"255.5","upperLimit":"455.9"},{"groupId":"OG002","value":"291.6","lowerLimit":"221.1","upperLimit":"384.5"},{"groupId":"OG003","value":"176.9","lowerLimit":"123.3","upperLimit":"253.7"},{"groupId":"OG004","value":"203.7","lowerLimit":"142.8","upperLimit":"290.6"}]}]},{"title":"Day 181: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"75.4","lowerLimit":"60.1","upperLimit":"94.6"},{"groupId":"OG001","value":"84.3","lowerLimit":"65.6","upperLimit":"108.3"},{"groupId":"OG002","value":"74.1","lowerLimit":"58.4","upperLimit":"94.0"},{"groupId":"OG003","value":"67.8","lowerLimit":"NA","upperLimit":"93.0","comment":"Lower limit of 95% CI could not be estimated as the value was below the LLOQ (58)."},{"groupId":"OG004","value":"NA","lowerLimit":"NA","upperLimit":"69.1","comment":"Geometric mean and lower limit of 95% CI could not be estimated as the value was below the LLOQ (58)."}]}]},{"title":"Day 181: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"121.7","lowerLimit":"95.8","upperLimit":"154.8"},{"groupId":"OG001","value":"72.4","lowerLimit":"55.6","upperLimit":"94.1"},{"groupId":"OG002","value":"103.1","lowerLimit":"79.1","upperLimit":"134.5"},{"groupId":"OG003","value":"40.3","lowerLimit":"28.6","upperLimit":"56.9"},{"groupId":"OG004","value":"55.1","lowerLimit":"38.0","upperLimit":"80.1"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by MOPA on Days 30 and 181","description":"For sample pairs with available validated MOPA results, for each O-antigen (serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75), the fold increase was calculated as the ratio of validated MOPA results on Days 30 or 181 and pre-vaccination (Day 30/Day 1 and 181/Day 1). The percentage of participants with \\>=2-fold and \\>=4-fold increase in serotype-specific serum antibody titers was calculated. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set used. \"N\" = number of participants evaluable for the endpoint. High dose ExPEC10V and Prevnar 13: validated MOPA at all timepoints. Low and medium ExPEC10V and ExPEC4V: Day 1 tested with qualified MOPA; Days 30 and 181 with validated MOPA. Percentage of participants with a \\>= 2-fold and \\>=4-fold require data from the same assay at both timepoints. Because validated MOPA data are missing at Day 1 for low and medium ExPEC10V and ExPEC4V, fold change could not be calculated.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 (pre-vaccination) and Days 30 and 181","groups":[{"id":"OG000","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"51"}]}],"classes":[{"title":"Day 30: Serotype O1A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"33.7","lowerLimit":"24.31","upperLimit":"44.11"},{"groupId":"OG001","value":"11.1","lowerLimit":"0.28","upperLimit":"48.25"}]}]},{"title":"Day 30: Serotype O1A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"24.2","lowerLimit":"16.01","upperLimit":"34.08"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"33.63"}]}]},{"title":"Day 30: Serotype O2: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"80.0","lowerLimit":"70.54","upperLimit":"87.51"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"33.63"}]}]},{"title":"Day 30: Serotype O2: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"73.7","lowerLimit":"63.65","upperLimit":"82.19"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"33.63"}]}]},{"title":"Day 30: Serotype O4: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"63.2","lowerLimit":"52.64","upperLimit":"72.83"},{"groupId":"OG001","value":"33.3","lowerLimit":"7.49","upperLimit":"70.07"}]}]},{"title":"Day 30: Serotype O4: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"43.2","lowerLimit":"33.03","upperLimit":"53.72"},{"groupId":"OG001","value":"33.3","lowerLimit":"7.49","upperLimit":"70.07"}]}]},{"title":"Day 30: Serotype O6A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"35.8","lowerLimit":"26.21","upperLimit":"46.28"},{"groupId":"OG001","value":"22.2","lowerLimit":"2.81","upperLimit":"60.01"}]}]},{"title":"Day 30: Serotype O6A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"23.2","lowerLimit":"15.12","upperLimit":"32.94"},{"groupId":"OG001","value":"11.1","lowerLimit":"0.28","upperLimit":"48.25"}]}]},{"title":"Day 30: Serotype O15: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"67.4","lowerLimit":"56.98","upperLimit":"76.64"},{"groupId":"OG001","value":"33.3","lowerLimit":"7.49","upperLimit":"70.07"}]}]},{"title":"Day 30: Serotype O15: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"53.7","lowerLimit":"43.15","upperLimit":"63.98"},{"groupId":"OG001","value":"22.2","lowerLimit":"2.81","upperLimit":"60.01"}]}]},{"title":"Day 30: Serotype O16: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"89.4","lowerLimit":"81.30","upperLimit":"94.78"},{"groupId":"OG001","value":"22.2","lowerLimit":"2.81","upperLimit":"60.01"}]}]},{"title":"Day 30: Serotype O16: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"73.4","lowerLimit":"63.29","upperLimit":"81.99"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"33.63"}]}]},{"title":"Day 30: Serotype O18A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"50.5","lowerLimit":"40.07","upperLimit":"60.95"},{"groupId":"OG001","value":"22.2","lowerLimit":"2.81","upperLimit":"60.01"}]}]},{"title":"Day 30: Serotype O18A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"33.7","lowerLimit":"24.31","upperLimit":"44.11"},{"groupId":"OG001","value":"11.1","lowerLimit":"0.28","upperLimit":"48.25"}]}]},{"title":"Day 30: Serotype O25B: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"41.5","lowerLimit":"31.41","upperLimit":"52.12"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"33.63"}]}]},{"title":"Day 30: Serotype O25B: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"22.3","lowerLimit":"14.39","upperLimit":"32.10"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"33.63"}]}]},{"title":"Day 30: Serotype O75: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"65.3","lowerLimit":"54.80","upperLimit":"74.74"},{"groupId":"OG001","value":"33.3","lowerLimit":"7.49","upperLimit":"70.07"}]}]},{"title":"Day 30: Serotype O75: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"44.2","lowerLimit":"34.02","upperLimit":"54.77"},{"groupId":"OG001","value":"22.2","lowerLimit":"2.81","upperLimit":"60.01"}]}]},{"title":"Day 181: Serotype O1A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"15.4","lowerLimit":"8.21","upperLimit":"25.33"},{"groupId":"OG001","value":"16.7","lowerLimit":"0.42","upperLimit":"64.12"}]}]},{"title":"Day 181: Serotype O1A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"4.53","upperLimit":"19.21"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 181: Serotype O2: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"67.9","lowerLimit":"56.42","upperLimit":"78.07"},{"groupId":"OG001","value":"16.7","lowerLimit":"0.42","upperLimit":"64.12"}]}]},{"title":"Day 181: Serotype O2: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"51.3","lowerLimit":"39.69","upperLimit":"62.77"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 181: Serotype O4: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"51.3","lowerLimit":"39.69","upperLimit":"62.77"},{"groupId":"OG001","value":"33.3","lowerLimit":"4.33","upperLimit":"77.72"}]}]},{"title":"Day 181: Serotype O4: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"23.1","lowerLimit":"14.29","upperLimit":"34.00"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 181: Serotype O6A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"23.1","lowerLimit":"14.29","upperLimit":"34.00"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 181: Serotype O6A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"4.53","upperLimit":"19.21"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 181: Serotype O15: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"56.4","lowerLimit":"44.70","upperLimit":"67.61"},{"groupId":"OG001","value":"33.3","lowerLimit":"4.33","upperLimit":"77.72"}]}]},{"title":"Day 181: Serotype O15: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"23.06","upperLimit":"44.92"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 181: Serotype O16: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"75.3","lowerLimit":"64.18","upperLimit":"84.44"},{"groupId":"OG001","value":"33.3","lowerLimit":"4.33","upperLimit":"77.72"}]}]},{"title":"Day 181: Serotype O16: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"51.9","lowerLimit":"40.26","upperLimit":"63.48"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 181: Serotype O18A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"30.8","lowerLimit":"20.81","upperLimit":"42.24"},{"groupId":"OG001","value":"66.7","lowerLimit":"22.28","upperLimit":"95.67"}]}]},{"title":"Day 181: Serotype O18A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"4.53","upperLimit":"19.21"},{"groupId":"OG001","value":"33.3","lowerLimit":"4.33","upperLimit":"77.72"}]}]},{"title":"Day 181: Serotype O25B: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"22.1","lowerLimit":"13.42","upperLimit":"32.98"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 181: Serotype O25B: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"1.43","upperLimit":"12.77"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 181: Serotype O75: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"47.4","lowerLimit":"36.01","upperLimit":"59.07"},{"groupId":"OG001","value":"16.7","lowerLimit":"0.42","upperLimit":"64.12"}]}]},{"title":"Day 181: Serotype O75: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"23.1","lowerLimit":"14.29","upperLimit":"34.00"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Number of Participants With Serious Adverse Events (SAEs) Related to Study Vaccine or Study Procedure From Day 182 up to End of Study (Day 1826)","description":"Number of participants with SAEs related to study vaccine or study procedure was reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent understudy. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","populationDescription":"The FAS included all randomized participants with a vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 182 up to end of study (Day 1826)","groups":[{"id":"OG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection ofExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1."},{"id":"OG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1."},{"id":"OG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1."},{"id":"OG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"104"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Geometric Mean Titers (GMTs) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex ECL Based Immunoassay on Days 366, 731, 1096, 1461 and 1826","description":"GMTs of serotype-specific total IgG serum antibodies as measured by ECL based immunoassay were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples. LLOQ values for O1A: 69149, O2: 65287, O4: 67356, O6A: 150748, O8: 72196, O15: 66910, O16: 71586, O18A: 70519, O25B: 61990, O75: 133019, and EPA: 66165. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"PPI analysis set used. \"N\" (number of participants analyzed): participants evaluable for this endpoint and \"n\" (number analyzed): participants evaluable at specified categories. Data for this endpoint was planned to be collected and analyzed only on the ExPEC10V dose selected for further clinical development based on Day 30 primary analysis. Since high-dose ExPEC10V was selected and Prevnar 13 was continued as comparator, only data from these groups is available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Days 366, 731, 1096, 1461 and 1826","groups":[{"id":"OG000","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"classes":[{"title":"Day 366: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3934158.7","lowerLimit":"3201033.1","upperLimit":"4835190.3"},{"groupId":"OG001","value":"1605160.3","lowerLimit":"1139469.6","upperLimit":"2261174.4"}]}]},{"title":"Day 731: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3045758.4","lowerLimit":"2382153.2","upperLimit":"3894226.5"},{"groupId":"OG001","value":"1143355.0","lowerLimit":"756785.2","upperLimit":"1727386.8"}]}]},{"title":"Day 1096: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2796702.3","lowerLimit":"2156387.6","upperLimit":"3627151.2"},{"groupId":"OG001","value":"1226079.9","lowerLimit":"796412.6","upperLimit":"1887554.1"}]}]},{"title":"Day 1461: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3061251.0","lowerLimit":"2233370.1","upperLimit":"4196016.6"},{"groupId":"OG001","value":"2051609.9","lowerLimit":"1151725.0","upperLimit":"3654607.7"}]}]},{"title":"Day 1826: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2510326.1","lowerLimit":"1749766.6","upperLimit":"3601472.9"},{"groupId":"OG001","value":"1415585.1","lowerLimit":"729252.3","upperLimit":"2747857.2"}]}]},{"title":"Day 366: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3550164.5","lowerLimit":"2808076.4","upperLimit":"4488363.6"},{"groupId":"OG001","value":"558977.9","lowerLimit":"422941.4","upperLimit":"738769.7"}]}]},{"title":"Day 731: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3625183.6","lowerLimit":"2836267.9","upperLimit":"4633538.3"},{"groupId":"OG001","value":"694262.8","lowerLimit":"464778.4","upperLimit":"1037055.1"}]}]},{"title":"Day 1096: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3629211.5","lowerLimit":"2829177.2","upperLimit":"4655479.5"},{"groupId":"OG001","value":"686457.3","lowerLimit":"441411.8","upperLimit":"1067537.5"}]}]},{"title":"Day 1461: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3659457.8","lowerLimit":"2685565.0","upperLimit":"4986523.1"},{"groupId":"OG001","value":"833384.9","lowerLimit":"446849.3","upperLimit":"1554283.2"}]}]},{"title":"Day 1826: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3252095.8","lowerLimit":"2248988.6","upperLimit":"4702614.7"},{"groupId":"OG001","value":"609740.1","lowerLimit":"280074.9","upperLimit":"1327441.3"}]}]},{"title":"Day 366: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1429668.5","lowerLimit":"1165397.8","upperLimit":"1753866.4"},{"groupId":"OG001","value":"555656.1","lowerLimit":"427063.9","upperLimit":"722968.3"}]}]},{"title":"Day 731: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1363392.1","lowerLimit":"1095361.6","upperLimit":"1697008.7"},{"groupId":"OG001","value":"475609.0","lowerLimit":"338935.6","upperLimit":"667394.8"}]}]},{"title":"Day 1096: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1468864.1","lowerLimit":"1183756.4","upperLimit":"1822639.9"},{"groupId":"OG001","value":"548486.3","lowerLimit":"379268.3","upperLimit":"793204.1"}]}]},{"title":"Day 1461: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1636156.0","lowerLimit":"1240514.2","upperLimit":"2157981.2"},{"groupId":"OG001","value":"698085.2","lowerLimit":"433044.7","upperLimit":"1125341.0"}]}]},{"title":"Day 1826: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1046670.4","lowerLimit":"778237.4","upperLimit":"1407692.4"},{"groupId":"OG001","value":"474799.1","lowerLimit":"277284.3","upperLimit":"813007.2"}]}]},{"title":"Day 366: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2720316.5","lowerLimit":"2256764.3","upperLimit":"3279084.9"},{"groupId":"OG001","value":"1140758.7","lowerLimit":"870845.9","upperLimit":"1494329.1"}]}]},{"title":"Day 731: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1938035.7","lowerLimit":"1550939.3","upperLimit":"2421747.0"},{"groupId":"OG001","value":"656929.5","lowerLimit":"476890.5","upperLimit":"904938.0"}]}]},{"title":"Day 1096: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1908743.4","lowerLimit":"1507339.8","upperLimit":"2417040.6"},{"groupId":"OG001","value":"763111.9","lowerLimit":"558645.1","upperLimit":"1042414.4"}]}]},{"title":"Day 1461: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1648828.8","lowerLimit":"1197245.3","upperLimit":"2270743.1"},{"groupId":"OG001","value":"901423.2","lowerLimit":"580706.7","upperLimit":"1399267.1"}]}]},{"title":"Day 1826: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1468233.5","lowerLimit":"1065011.1","upperLimit":"2024119.5"},{"groupId":"OG001","value":"701895.9","lowerLimit":"468747.4","upperLimit":"1051009.2"}]}]},{"title":"Day 366: Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3623746.8","lowerLimit":"3024857.5","upperLimit":"4341209.8"},{"groupId":"OG001","value":"1430653.9","lowerLimit":"1072253.4","upperLimit":"1908849.6"}]}]},{"title":"Day 731: Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4270645.7","lowerLimit":"3499266.5","upperLimit":"5212068.0"},{"groupId":"OG001","value":"2059650.9","lowerLimit":"1475833.6","upperLimit":"2874417.4"}]}]},{"title":"Day 1096: Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4008813.4","lowerLimit":"3266716.4","upperLimit":"4919491.9"},{"groupId":"OG001","value":"1899779.1","lowerLimit":"1312135.7","upperLimit":"2750600.2"}]}]},{"title":"Day 1461: Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3942469.5","lowerLimit":"3029442.8","upperLimit":"5130668.3"},{"groupId":"OG001","value":"2118665.0","lowerLimit":"1293637.1","upperLimit":"3469861.5"}]}]},{"title":"Day 1826: Serotype O8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3271322.5","lowerLimit":"2489462.5","upperLimit":"4298739.4"},{"groupId":"OG001","value":"1985249.0","lowerLimit":"1280656.7","upperLimit":"3077494.0"}]}]},{"title":"Day 366: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2758990.7","lowerLimit":"2227724.4","upperLimit":"3416952.9"},{"groupId":"OG001","value":"1026707.7","lowerLimit":"748937.3","upperLimit":"1407499.4"}]}]},{"title":"Day 731: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2733971.3","lowerLimit":"2215513.4","upperLimit":"3373754.8"},{"groupId":"OG001","value":"1282357.8","lowerLimit":"894038.1","upperLimit":"1839341.6"}]}]},{"title":"Day 1096: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2605816.2","lowerLimit":"2048432.4","upperLimit":"3314865.4"},{"groupId":"OG001","value":"1164007.7","lowerLimit":"792330.9","upperLimit":"1710035.4"}]}]},{"title":"Day 1461: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2675476.7","lowerLimit":"2035772.1","upperLimit":"3516196.9"},{"groupId":"OG001","value":"1318256.0","lowerLimit":"878009.0","upperLimit":"1979249.6"}]}]},{"title":"Day 1826: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2452726.4","lowerLimit":"1794091.2","upperLimit":"3353155.4"},{"groupId":"OG001","value":"1339915.0","lowerLimit":"858920.2","upperLimit":"2090266.8"}]}]},{"title":"Day 366: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2784393.1","lowerLimit":"2248058.4","upperLimit":"3448684.8"},{"groupId":"OG001","value":"766620.1","lowerLimit":"570562.4","upperLimit":"1030047.4"}]}]},{"title":"Day 731: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2191014.4","lowerLimit":"1676843.6","upperLimit":"2862845.6"},{"groupId":"OG001","value":"432088.3","lowerLimit":"280872.9","upperLimit":"664714.5"}]}]},{"title":"Day 1096: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1953749.9","lowerLimit":"1467640.7","upperLimit":"2600867.1"},{"groupId":"OG001","value":"408528.9","lowerLimit":"257897.7","upperLimit":"647139.9"}]}]},{"title":"Day 1461: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1808141.1","lowerLimit":"1314903.6","upperLimit":"2486398.5"},{"groupId":"OG001","value":"588532.7","lowerLimit":"315738.3","upperLimit":"1097018.3"}]}]},{"title":"Day 1826: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1418665.2","lowerLimit":"1021423.3","upperLimit":"1970398.5"},{"groupId":"OG001","value":"441156.2","lowerLimit":"228168.2","upperLimit":"852961.9"}]}]},{"title":"Day 366: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2180993.4","lowerLimit":"1813783.2","upperLimit":"2622547.1"},{"groupId":"OG001","value":"1011099.1","lowerLimit":"803648.4","upperLimit":"1272100.4"}]}]},{"title":"Day 731: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2120844.7","lowerLimit":"1737493.1","upperLimit":"2588776.9"},{"groupId":"OG001","value":"1011635.3","lowerLimit":"770544.8","upperLimit":"1328158.9"}]}]},{"title":"Day 1096: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2139682.8","lowerLimit":"1721939.0","upperLimit":"2658771.7"},{"groupId":"OG001","value":"1069851.1","lowerLimit":"812183.5","upperLimit":"1409264.4"}]}]},{"title":"Day 1461: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1799444.8","lowerLimit":"1411938.5","upperLimit":"2293302.1"},{"groupId":"OG001","value":"1155976.5","lowerLimit":"798832.2","upperLimit":"1672794.0"}]}]},{"title":"Day 1826: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1634243.4","lowerLimit":"1224433.2","upperLimit":"2181214.6"},{"groupId":"OG001","value":"938306.2","lowerLimit":"615022.6","upperLimit":"1431522.1"}]}]},{"title":"Day 366: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"744315.5","lowerLimit":"587104.6","upperLimit":"943623.5"},{"groupId":"OG001","value":"278650.7","lowerLimit":"211316.5","upperLimit":"367440.3"}]}]},{"title":"Day 731: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"469677.8","lowerLimit":"345884.4","upperLimit":"637777.3"},{"groupId":"OG001","value":"159425.2","lowerLimit":"108167.9","upperLimit":"234971.5"}]}]},{"title":"Day 1096: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"457385.0","lowerLimit":"342281.3","upperLimit":"611196.1"},{"groupId":"OG001","value":"180091.3","lowerLimit":"120576.0","upperLimit":"268982.7"}]}]},{"title":"Day 1461: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"527143.7","lowerLimit":"369078.7","upperLimit":"752903.0"},{"groupId":"OG001","value":"292822.0","lowerLimit":"178948.4","upperLimit":"479158.8"}]}]},{"title":"Day 1826: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"376505.3","lowerLimit":"247784.9","upperLimit":"572093.9"},{"groupId":"OG001","value":"173640.5","lowerLimit":"98267.2","upperLimit":"306826.7"}]}]},{"title":"Day 366: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1960676.9","lowerLimit":"1639629.8","upperLimit":"2344586.6"},{"groupId":"OG001","value":"1519723.2","lowerLimit":"1099805.5","upperLimit":"2099970.1"}]}]},{"title":"Day 731: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1991539.0","lowerLimit":"1598606.6","upperLimit":"2481053.0"},{"groupId":"OG001","value":"1689340.2","lowerLimit":"1218863.3","upperLimit":"2341419.5"}]}]},{"title":"Day 1096: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2152383.1","lowerLimit":"1720798.5","upperLimit":"2692211.4"},{"groupId":"OG001","value":"1732413.2","lowerLimit":"1200043.3","upperLimit":"2500956.0"}]}]},{"title":"Day 1461: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1811492.3","lowerLimit":"1376465.0","upperLimit":"2384008.6"},{"groupId":"OG001","value":"1821419.2","lowerLimit":"1047856.4","upperLimit":"3166052.1"}]}]},{"title":"Day 1826: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1912235.2","lowerLimit":"1470493.6","upperLimit":"2486677.5"},{"groupId":"OG001","value":"1848589.6","lowerLimit":"1050960.1","upperLimit":"3251582.6"}]}]},{"title":"Day 366: Serotype EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"395660.6","lowerLimit":"278689.7","upperLimit":"561726.1"},{"groupId":"OG001","value":"66438.6","lowerLimit":"NA","upperLimit":"93488.9","comment":"Lower limit of 95% CI could not be estimated as it was below LLOQ (66165)."}]}]},{"title":"Day 731: Serotype EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"255548.1","lowerLimit":"174717.6","upperLimit":"373773.7"},{"groupId":"OG001","value":"74302.9","lowerLimit":"NA","upperLimit":"115058.4","comment":"Lower limit of 95% CI could not be estimated as it was below LLOQ (66165)."}]}]},{"title":"Day 1096: Serotype EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"284265.5","lowerLimit":"191542.8","upperLimit":"421873.6"},{"groupId":"OG001","value":"81384.5","lowerLimit":"NA","upperLimit":"128120.5","comment":"Lower limit of 95% CI could not be estimated as it was below LLOQ (66165)."}]}]},{"title":"Day 1461: Serotype EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"285201.1","lowerLimit":"175060.8","upperLimit":"464636.9"},{"groupId":"OG001","value":"104825.0","lowerLimit":"NA","upperLimit":"213630.5","comment":"Lower limit of 95% CI could not be estimated as it was below LLOQ (66165)."}]}]},{"title":"Day 1826: Serotype EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"236408.3","lowerLimit":"142449.3","upperLimit":"392342.4"},{"groupId":"OG001","value":"95540.4","lowerLimit":"NA","upperLimit":"201601.6","comment":"Lower limit of 95% CI could not be estimated as it was below LLOQ (66165)."}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With a >=2-Fold and >=4-Fold Increase From Baseline in Serotype Specific Serum Antibody Titers as Measured by Multiplex ECL Based Immunoassay on Days 366, 731, 1096, 1461 and 1826","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by multiplex ECL based immunoassay on Days 366, 731, 1096, 1461, and 1826 was reported. The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Days 366, 731, 1096, 1461, and 1826 for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA was calculated as the ratio of titer values of serum antibody on Days 366, 731, 1096, 1461 and 1826 and pre-vaccination (on day 1) that is, Day 366/Day 1, 731/Day 1, 1096/Day 1, 1461/Day 1 and 1826/Day 1. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set used. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this outcome measure. Data for this endpoint was planned to be collected and analyzed only on the ExPEC10V dose selected for further clinical development based on Day 30 primary analysis. Since high-dose ExPEC10V was selected and Prevnar 13 was continued as comparator, only data from these groups is available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline (Day 1, pre-vaccination) and Days 366, 731, 1096, 1461, 1826","groups":[{"id":"OG000","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"51"}]}],"classes":[{"title":"Day 366: Serotype O1A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"70.4","lowerLimit":"58.41","upperLimit":"80.67"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.64","upperLimit":"17.75"}]}]},{"title":"Day 731: Serotype O1A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"58.1","lowerLimit":"44.85","upperLimit":"70.49"},{"groupId":"OG001","value":"8.6","lowerLimit":"1.80","upperLimit":"23.06"}]}]},{"title":"Day 1096: Serotype O1A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"56.1","lowerLimit":"42.36","upperLimit":"69.26"},{"groupId":"OG001","value":"9.4","lowerLimit":"1.98","upperLimit":"25.02"}]}]},{"title":"Day 1461: Serotype O1A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"61.1","lowerLimit":"43.46","upperLimit":"76.86"},{"groupId":"OG001","value":"17.6","lowerLimit":"3.80","upperLimit":"43.43"}]}]},{"title":"Day 1826: Serotype O1A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"51.4","lowerLimit":"33.99","upperLimit":"68.62"},{"groupId":"OG001","value":"5.9","lowerLimit":"0.15","upperLimit":"28.69"}]}]},{"title":"Day 366: Serotype O1A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"45.1","lowerLimit":"33.23","upperLimit":"57.34"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.07","upperLimit":"13.81"}]}]},{"title":"Day 731: Serotype O1A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"38.7","lowerLimit":"26.60","upperLimit":"51.93"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.00"}]}]},{"title":"Day 1096: Serotype O1A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"35.1","lowerLimit":"22.91","upperLimit":"48.87"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.89"}]}]},{"title":"Day 1461: Serotype O1A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"36.1","lowerLimit":"20.82","upperLimit":"53.78"},{"groupId":"OG001","value":"11.8","lowerLimit":"1.46","upperLimit":"36.44"}]}]},{"title":"Day 1826: Serotype O1A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"31.4","lowerLimit":"16.85","upperLimit":"49.29"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 366: Serotype O2: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"91.5","lowerLimit":"82.51","upperLimit":"96.84"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.64","upperLimit":"17.75"}]}]},{"title":"Day 731: Serotype O2: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"95.2","lowerLimit":"86.50","upperLimit":"98.99"},{"groupId":"OG001","value":"20.0","lowerLimit":"8.44","upperLimit":"36.94"}]}]},{"title":"Day 1096: Serotype O2: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"98.2","lowerLimit":"90.61","upperLimit":"99.96"},{"groupId":"OG001","value":"15.6","lowerLimit":"5.28","upperLimit":"32.79"}]}]},{"title":"Day 1461: Serotype O2: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"97.2","lowerLimit":"85.47","upperLimit":"99.93"},{"groupId":"OG001","value":"11.8","lowerLimit":"1.46","upperLimit":"36.44"}]}]},{"title":"Day 1826: Serotype O2: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"85.7","lowerLimit":"69.74","upperLimit":"95.19"},{"groupId":"OG001","value":"17.6","lowerLimit":"3.80","upperLimit":"43.43"}]}]},{"title":"Day 366: Serotype O2: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"77.5","lowerLimit":"66.00","upperLimit":"86.54"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"9.25"}]}]},{"title":"Day 731: Serotype O2: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"75.8","lowerLimit":"63.26","upperLimit":"85.78"},{"groupId":"OG001","value":"2.9","lowerLimit":"0.07","upperLimit":"14.92"}]}]},{"title":"Day 1096: Serotype O2: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"73.7","lowerLimit":"60.34","upperLimit":"84.46"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.89"}]}]},{"title":"Day 1461: Serotype O2: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"72.2","lowerLimit":"54.81","upperLimit":"85.80"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 1826: Serotype O2: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"68.6","lowerLimit":"50.71","upperLimit":"83.15"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 366: Serotype O4: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"70.4","lowerLimit":"58.41","upperLimit":"80.67"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.07","upperLimit":"13.81"}]}]},{"title":"Day 731: Serotype O4: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"71.0","lowerLimit":"58.05","upperLimit":"81.80"},{"groupId":"OG001","value":"8.6","lowerLimit":"1.80","upperLimit":"23.06"}]}]},{"title":"Day 1096: Serotype O4: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"77.2","lowerLimit":"64.16","upperLimit":"87.26"},{"groupId":"OG001","value":"15.6","lowerLimit":"5.28","upperLimit":"32.79"}]}]},{"title":"Day 1461: Serotype O4: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"94.4","lowerLimit":"81.34","upperLimit":"99.32"},{"groupId":"OG001","value":"23.5","lowerLimit":"6.81","upperLimit":"49.90"}]}]},{"title":"Day 1826: Serotype O4: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"65.7","lowerLimit":"47.79","upperLimit":"80.87"},{"groupId":"OG001","value":"11.8","lowerLimit":"1.46","upperLimit":"36.44"}]}]},{"title":"Day 366: Serotype O4: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"35.2","lowerLimit":"24.24","upperLimit":"47.46"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.07","upperLimit":"13.81"}]}]},{"title":"Day 731: Serotype O4: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"41.9","lowerLimit":"29.51","upperLimit":"55.15"},{"groupId":"OG001","value":"2.9","lowerLimit":"0.07","upperLimit":"14.92"}]}]},{"title":"Day 1096: Serotype O4: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"38.6","lowerLimit":"26.00","upperLimit":"52.43"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.08","upperLimit":"16.22"}]}]},{"title":"Day 1461: Serotype O4: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"32.92","upperLimit":"67.08"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 1826: Serotype O4: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"22.9","lowerLimit":"10.42","upperLimit":"40.14"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 366: Serotype O6A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"56.3","lowerLimit":"44.05","upperLimit":"68.09"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"9.25"}]}]},{"title":"Day 731: Serotype O6A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"30.6","lowerLimit":"19.56","upperLimit":"43.65"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.00"}]}]},{"title":"Day 1096: Serotype O6A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"28.1","lowerLimit":"16.97","upperLimit":"41.54"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.77","upperLimit":"20.81"}]}]},{"title":"Day 1461: Serotype O6A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"19.4","lowerLimit":"8.19","upperLimit":"36.02"},{"groupId":"OG001","value":"5.9","lowerLimit":"0.15","upperLimit":"28.69"}]}]},{"title":"Day 1826: Serotype O6A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"8.44","upperLimit":"36.94"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 366: Serotype O6A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"23.9","lowerLimit":"14.61","upperLimit":"35.54"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"9.25"}]}]},{"title":"Day 731: Serotype O6A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"12.9","lowerLimit":"5.74","upperLimit":"23.85"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.00"}]}]},{"title":"Day 1096: Serotype O6A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"14.0","lowerLimit":"6.26","upperLimit":"25.79"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.89"}]}]},{"title":"Day 1461: Serotype O6A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"3.11","upperLimit":"26.06"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 1826: Serotype O6A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"1.80","upperLimit":"23.06"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 366: Serotype O8: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"59.2","lowerLimit":"46.84","upperLimit":"70.68"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.07","upperLimit":"13.81"}]}]},{"title":"Day 731: Serotype O8: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"66.1","lowerLimit":"52.99","upperLimit":"77.67"},{"groupId":"OG001","value":"28.6","lowerLimit":"14.64","upperLimit":"46.30"}]}]},{"title":"Day 1096: Serotype O8: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"59.6","lowerLimit":"45.82","upperLimit":"72.44"},{"groupId":"OG001","value":"28.1","lowerLimit":"13.75","upperLimit":"46.75"}]}]},{"title":"Day 1461: Serotype O8: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"69.4","lowerLimit":"51.89","upperLimit":"83.65"},{"groupId":"OG001","value":"29.4","lowerLimit":"10.31","upperLimit":"55.96"}]}]},{"title":"Day 1826: Serotype O8: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"51.4","lowerLimit":"33.99","upperLimit":"68.62"},{"groupId":"OG001","value":"17.6","lowerLimit":"3.80","upperLimit":"43.43"}]}]},{"title":"Day 366: Serotype O8: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"22.5","lowerLimit":"13.46","upperLimit":"34.00"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"9.25"}]}]},{"title":"Day 731: Serotype O8: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"38.7","lowerLimit":"26.60","upperLimit":"51.93"},{"groupId":"OG001","value":"8.6","lowerLimit":"1.80","upperLimit":"23.06"}]}]},{"title":"Day 1096: Serotype O8: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"24.6","lowerLimit":"14.13","upperLimit":"37.76"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.08","upperLimit":"16.22"}]}]},{"title":"Day 1461: Serotype O8: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"30.6","lowerLimit":"16.35","upperLimit":"48.11"},{"groupId":"OG001","value":"17.6","lowerLimit":"3.80","upperLimit":"43.43"}]}]},{"title":"Day 1826: Serotype O8: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"25.7","lowerLimit":"12.49","upperLimit":"43.26"},{"groupId":"OG001","value":"5.9","lowerLimit":"0.15","upperLimit":"28.69"}]}]},{"title":"Day 366: Serotype O15: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"67.6","lowerLimit":"55.45","upperLimit":"78.24"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.64","upperLimit":"17.75"}]}]},{"title":"Day 731: Serotype O15: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"71.0","lowerLimit":"58.05","upperLimit":"81.80"},{"groupId":"OG001","value":"28.6","lowerLimit":"14.64","upperLimit":"46.30"}]}]},{"title":"Day 1096: Serotype O15: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"63.2","lowerLimit":"49.34","upperLimit":"75.55"},{"groupId":"OG001","value":"21.9","lowerLimit":"9.28","upperLimit":"39.97"}]}]},{"title":"Day 1461: Serotype O15: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"58.3","lowerLimit":"40.76","upperLimit":"74.49"},{"groupId":"OG001","value":"23.5","lowerLimit":"6.81","upperLimit":"49.90"}]}]},{"title":"Day 1826: Serotype O15: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"54.3","lowerLimit":"36.65","upperLimit":"71.17"},{"groupId":"OG001","value":"29.4","lowerLimit":"10.31","upperLimit":"55.96"}]}]},{"title":"Day 366: Serotype O15: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"32.4","lowerLimit":"21.76","upperLimit":"44.55"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.07","upperLimit":"13.81"}]}]},{"title":"Day 731: Serotype O15: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"32.3","lowerLimit":"20.94","upperLimit":"45.34"},{"groupId":"OG001","value":"8.6","lowerLimit":"1.80","upperLimit":"23.06"}]}]},{"title":"Day 1096: Serotype O15: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"28.1","lowerLimit":"16.97","upperLimit":"41.54"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.77","upperLimit":"20.81"}]}]},{"title":"Day 1461: Serotype O15: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"27.8","lowerLimit":"14.20","upperLimit":"45.19"},{"groupId":"OG001","value":"5.9","lowerLimit":"0.15","upperLimit":"28.69"}]}]},{"title":"Day 1826: Serotype O15: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"25.7","lowerLimit":"12.49","upperLimit":"43.26"},{"groupId":"OG001","value":"11.8","lowerLimit":"1.46","upperLimit":"36.44"}]}]},{"title":"Day 366: Serotype O16: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"76.1","lowerLimit":"64.46","upperLimit":"85.39"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.07","upperLimit":"13.81"}]}]},{"title":"Day 731: Serotype O16: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"66.1","lowerLimit":"52.99","upperLimit":"77.67"},{"groupId":"OG001","value":"2.9","lowerLimit":"0.07","upperLimit":"14.92"}]}]},{"title":"Day 1096: Serotype O16: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"54.4","lowerLimit":"40.66","upperLimit":"67.64"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.08","upperLimit":"16.22"}]}]},{"title":"Day 1461: Serotype O16: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"61.1","lowerLimit":"43.46","upperLimit":"76.86"},{"groupId":"OG001","value":"11.8","lowerLimit":"1.46","upperLimit":"36.44"}]}]},{"title":"Day 1826: Serotype O16: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"54.3","lowerLimit":"36.65","upperLimit":"71.17"},{"groupId":"OG001","value":"5.9","lowerLimit":"0.15","upperLimit":"28.69"}]}]},{"title":"Day 366: Serotype O16: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"40.8","lowerLimit":"29.32","upperLimit":"53.16"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.07","upperLimit":"13.81"}]}]},{"title":"Day 731: Serotype O16: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"32.3","lowerLimit":"20.94","upperLimit":"45.34"},{"groupId":"OG001","value":"2.9","lowerLimit":"0.07","upperLimit":"14.92"}]}]},{"title":"Day 1096: Serotype O16: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"28.1","lowerLimit":"16.97","upperLimit":"41.54"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.89"}]}]},{"title":"Day 1461: Serotype O16: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"12.12","upperLimit":"42.20"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 1826: Serotype O16: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"17.1","lowerLimit":"6.56","upperLimit":"33.65"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 366: Serotype O18A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"60.6","lowerLimit":"48.25","upperLimit":"71.97"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.07","upperLimit":"13.81"}]}]},{"title":"Day 731: Serotype O18A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"54.8","lowerLimit":"41.68","upperLimit":"67.52"},{"groupId":"OG001","value":"25.7","lowerLimit":"12.49","upperLimit":"43.26"}]}]},{"title":"Day 1096: Serotype O18A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"50.9","lowerLimit":"37.29","upperLimit":"64.37"},{"groupId":"OG001","value":"18.8","lowerLimit":"7.21","upperLimit":"36.44"}]}]},{"title":"Day 1461: Serotype O18A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"36.1","lowerLimit":"20.82","upperLimit":"53.78"},{"groupId":"OG001","value":"17.6","lowerLimit":"3.80","upperLimit":"43.43"}]}]},{"title":"Day 1826: Serotype O18A: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"28.6","lowerLimit":"14.64","upperLimit":"46.30"},{"groupId":"OG001","value":"11.8","lowerLimit":"1.46","upperLimit":"36.44"}]}]},{"title":"Day 366: Serotype O18A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"12.7","lowerLimit":"5.96","upperLimit":"22.70"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"9.25"}]}]},{"title":"Day 731: Serotype O18A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"21.0","lowerLimit":"11.66","upperLimit":"33.18"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.00"}]}]},{"title":"Day 1096: Serotype O18A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"17.5","lowerLimit":"8.75","upperLimit":"29.91"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.89"}]}]},{"title":"Day 1461: Serotype O18A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"1.75","upperLimit":"22.47"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 1826: Serotype O18A: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"1.80","upperLimit":"23.06"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 366: Serotype O25B: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"64.8","lowerLimit":"52.54","upperLimit":"75.76"},{"groupId":"OG001","value":"5.3","lowerLimit":"0.64","upperLimit":"17.75"}]}]},{"title":"Day 731: Serotype O25B: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"37.02","upperLimit":"62.98"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.00"}]}]},{"title":"Day 1096: Serotype O25B: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"52.6","lowerLimit":"38.97","upperLimit":"66.02"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.89"}]}]},{"title":"Day 1461: Serotype O25B: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"52.8","lowerLimit":"35.49","upperLimit":"69.59"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 1826: Serotype O25B: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"28.6","lowerLimit":"14.64","upperLimit":"46.30"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 366: Serotype O25B: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"33.8","lowerLimit":"23.00","upperLimit":"46.01"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"9.25"}]}]},{"title":"Day 731: Serotype O25B: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"25.8","lowerLimit":"15.53","upperLimit":"38.50"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.00"}]}]},{"title":"Day 1096: Serotype O25B: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"21.1","lowerLimit":"11.38","upperLimit":"33.89"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"10.89"}]}]},{"title":"Day 1461: Serotype O25B: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"16.7","lowerLimit":"6.37","upperLimit":"32.81"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 1826: Serotype O25B: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"1.80","upperLimit":"23.06"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.51"}]}]},{"title":"Day 366: Serotype O75: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"33.8","lowerLimit":"23.00","upperLimit":"46.01"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.07","upperLimit":"13.81"}]}]},{"title":"Day 731: Serotype O75: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"32.3","lowerLimit":"20.94","upperLimit":"45.34"},{"groupId":"OG001","value":"8.6","lowerLimit":"1.80","upperLimit":"23.06"}]}]},{"title":"Day 1096: Serotype O75: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"40.4","lowerLimit":"27.56","upperLimit":"54.18"},{"groupId":"OG001","value":"15.6","lowerLimit":"5.28","upperLimit":"32.79"}]}]},{"title":"Day 1461: Serotype O75: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"18.56","upperLimit":"50.97"},{"groupId":"OG001","value":"5.9","lowerLimit":"0.15","upperLimit":"28.69"}]}]},{"title":"Day 1826: Serotype O75: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"31.4","lowerLimit":"16.85","upperLimit":"49.29"},{"groupId":"OG001","value":"17.6","lowerLimit":"3.80","upperLimit":"43.43"}]}]},{"title":"Day 366: Serotype O75: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"3.16","upperLimit":"17.49"},{"groupId":"OG001","value":"2.6","lowerLimit":"0.07","upperLimit":"13.81"}]}]},{"title":"Day 731: Serotype O75: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"11.3","lowerLimit":"4.66","upperLimit":"21.89"},{"groupId":"OG001","value":"2.9","lowerLimit":"0.07","upperLimit":"14.92"}]}]},{"title":"Day 1096: Serotype O75: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"12.3","lowerLimit":"5.08","upperLimit":"23.68"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.08","upperLimit":"16.22"}]}]},{"title":"Day 1461: Serotype O75: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"16.7","lowerLimit":"6.37","upperLimit":"32.81"},{"groupId":"OG001","value":"5.9","lowerLimit":"0.15","upperLimit":"28.69"}]}]},{"title":"Day 1826: Serotype O75: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"4.81","upperLimit":"30.26"},{"groupId":"OG001","value":"11.8","lowerLimit":"1.46","upperLimit":"36.44"}]}]},{"title":"Day 366: Serotype EPA: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"60.6","lowerLimit":"48.25","upperLimit":"71.97"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"9.25"}]}]},{"title":"Day 731: Serotype EPA: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"45.2","lowerLimit":"32.48","upperLimit":"58.32"},{"groupId":"OG001","value":"5.7","lowerLimit":"0.70","upperLimit":"19.16"}]}]},{"title":"Day 1096: Serotype EPA: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"42.1","lowerLimit":"29.14","upperLimit":"55.92"},{"groupId":"OG001","value":"9.4","lowerLimit":"1.98","upperLimit":"25.02"}]}]},{"title":"Day 1461: Serotype EPA: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"47.2","lowerLimit":"30.41","upperLimit":"64.51"},{"groupId":"OG001","value":"11.8","lowerLimit":"1.46","upperLimit":"36.44"}]}]},{"title":"Day 1826: Serotype EPA: >= 2 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"40.0","lowerLimit":"23.87","upperLimit":"57.89"},{"groupId":"OG001","value":"17.6","lowerLimit":"3.80","upperLimit":"43.43"}]}]},{"title":"Day 366: Serotype EPA: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"38.0","lowerLimit":"26.76","upperLimit":"50.33"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"9.25"}]}]},{"title":"Day 731: Serotype EPA: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"29.0","lowerLimit":"18.20","upperLimit":"41.95"},{"groupId":"OG001","value":"5.7","lowerLimit":"0.70","upperLimit":"19.16"}]}]},{"title":"Day 1096: Serotype EPA: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"28.1","lowerLimit":"16.97","upperLimit":"41.54"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.77","upperLimit":"20.81"}]}]},{"title":"Day 1461: Serotype EPA: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"27.8","lowerLimit":"14.20","upperLimit":"45.19"},{"groupId":"OG001","value":"5.9","lowerLimit":"0.15","upperLimit":"28.69"}]}]},{"title":"Day 1826: Serotype EPA: >= 4 Fold Increase","categories":[{"measurements":[{"groupId":"OG000","value":"22.9","lowerLimit":"10.42","upperLimit":"40.14"},{"groupId":"OG001","value":"11.8","lowerLimit":"1.46","upperLimit":"36.44"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype-specific Antibodies Measured by Multiplex ECL Based Immunoassay on Days 366, 731, 1096, 1461 and 1826","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by multiplex ECL based immunoassay on Days 366, 731, 1096, 1461 and 1826 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples by ECL based immunoassay. GMR of fold change from baseline was calculated as the ratio of GMTs on Days 366, 731, 1096, 1461 and 1826 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set used. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this endpoint. Data for this endpoint was planned to be collected and analyzed only on the ExPEC10V dose selected for further clinical development based on Day 30 primary analysis. Since high-dose ExPEC10V was selected and Prevnar 13 was continued as comparator, only data from these groups is available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline (Day 1, pre-vaccination) and Days 366, 731, 1096, 1461, 1826","groups":[{"id":"OG000","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"classes":[{"title":"Day 366: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"3.57","lowerLimit":"2.893","upperLimit":"4.402"},{"groupId":"OG001","value":"1.10","lowerLimit":"0.969","upperLimit":"1.248"}]}]},{"title":"Day 731: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"2.74","lowerLimit":"2.159","upperLimit":"3.466"},{"groupId":"OG001","value":"0.82","lowerLimit":"0.674","upperLimit":"1.009"}]}]},{"title":"Day 1096: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"2.52","lowerLimit":"1.932","upperLimit":"3.293"},{"groupId":"OG001","value":"0.82","lowerLimit":"0.640","upperLimit":"1.047"}]}]},{"title":"Day 1461: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"2.75","lowerLimit":"2.076","upperLimit":"3.635"},{"groupId":"OG001","value":"1.01","lowerLimit":"0.678","upperLimit":"1.498"}]}]},{"title":"Day 1826: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"2.23","lowerLimit":"1.701","upperLimit":"2.928"},{"groupId":"OG001","value":"0.72","lowerLimit":"0.518","upperLimit":"1.009"}]}]},{"title":"Day 366: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"7.71","lowerLimit":"6.279","upperLimit":"9.457"},{"groupId":"OG001","value":"1.22","lowerLimit":"1.098","upperLimit":"1.348"}]}]},{"title":"Day 731: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"7.62","lowerLimit":"5.994","upperLimit":"9.694"},{"groupId":"OG001","value":"1.34","lowerLimit":"1.103","upperLimit":"1.637"}]}]},{"title":"Day 1096: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"7.78","lowerLimit":"6.202","upperLimit":"9.761"},{"groupId":"OG001","value":"1.31","lowerLimit":"1.101","upperLimit":"1.558"}]}]},{"title":"Day 1461: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"7.13","lowerLimit":"5.471","upperLimit":"9.294"},{"groupId":"OG001","value":"1.32","lowerLimit":"1.062","upperLimit":"1.651"}]}]},{"title":"Day 1826: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"6.29","lowerLimit":"4.594","upperLimit":"8.616"},{"groupId":"OG001","value":"1.05","lowerLimit":"0.800","upperLimit":"1.385"}]}]},{"title":"Day 366: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"3.29","lowerLimit":"2.762","upperLimit":"3.907"},{"groupId":"OG001","value":"1.20","lowerLimit":"1.053","upperLimit":"1.356"}]}]},{"title":"Day 731: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"3.16","lowerLimit":"2.630","upperLimit":"3.808"},{"groupId":"OG001","value":"1.06","lowerLimit":"0.881","upperLimit":"1.280"}]}]},{"title":"Day 1096: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"3.35","lowerLimit":"2.792","upperLimit":"4.029"},{"groupId":"OG001","value":"1.16","lowerLimit":"0.942","upperLimit":"1.439"}]}]},{"title":"Day 1461: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"4.02","lowerLimit":"3.302","upperLimit":"4.890"},{"groupId":"OG001","value":"1.43","lowerLimit":"1.097","upperLimit":"1.865"}]}]},{"title":"Day 1826: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"2.58","lowerLimit":"2.057","upperLimit":"3.233"},{"groupId":"OG001","value":"1.06","lowerLimit":"0.767","upperLimit":"1.461"}]}]},{"title":"Day 366: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"2.54","lowerLimit":"2.178","upperLimit":"2.958"},{"groupId":"OG001","value":"1.09","lowerLimit":"0.988","upperLimit":"1.205"}]}]},{"title":"Day 731: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"1.63","lowerLimit":"1.323","upperLimit":"1.999"},{"groupId":"OG001","value":"0.67","lowerLimit":"0.547","upperLimit":"0.811"}]}]},{"title":"Day 1096: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"1.64","lowerLimit":"1.345","upperLimit":"1.993"},{"groupId":"OG001","value":"0.71","lowerLimit":"0.559","upperLimit":"0.896"}]}]},{"title":"Day 1461: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"1.37","lowerLimit":"1.089","upperLimit":"1.726"},{"groupId":"OG001","value":"0.69","lowerLimit":"0.548","upperLimit":"0.867"}]}]},{"title":"Day 1826: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"1.27","lowerLimit":"0.999","upperLimit":"1.615"},{"groupId":"OG001","value":"0.51","lowerLimit":"0.395","upperLimit":"0.655"}]}]},{"title":"Day 366: Serotype O8","categories":[{"measurements":[{"groupId":"OG000","value":"2.46","lowerLimit":"2.110","upperLimit":"2.868"},{"groupId":"OG001","value":"1.01","lowerLimit":"0.892","upperLimit":"1.143"}]}]},{"title":"Day 731: Serotype O8","categories":[{"measurements":[{"groupId":"OG000","value":"2.93","lowerLimit":"2.396","upperLimit":"3.595"},{"groupId":"OG001","value":"1.52","lowerLimit":"1.221","upperLimit":"1.886"}]}]},{"title":"Day 1096: Serotype O8","categories":[{"measurements":[{"groupId":"OG000","value":"2.61","lowerLimit":"2.120","upperLimit":"3.207"},{"groupId":"OG001","value":"1.29","lowerLimit":"1.028","upperLimit":"1.625"}]}]},{"title":"Day 1461: Serotype O8","categories":[{"measurements":[{"groupId":"OG000","value":"2.99","lowerLimit":"2.275","upperLimit":"3.923"},{"groupId":"OG001","value":"1.44","lowerLimit":"0.981","upperLimit":"2.106"}]}]},{"title":"Day 1826: Serotype O8","categories":[{"measurements":[{"groupId":"OG000","value":"2.54","lowerLimit":"1.930","upperLimit":"3.330"},{"groupId":"OG001","value":"1.42","lowerLimit":"1.070","upperLimit":"1.897"}]}]},{"title":"Day 366: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"3.16","lowerLimit":"2.615","upperLimit":"3.810"},{"groupId":"OG001","value":"1.24","lowerLimit":"1.082","upperLimit":"1.423"}]}]},{"title":"Day 731: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"2.99","lowerLimit":"2.477","upperLimit":"3.609"},{"groupId":"OG001","value":"1.52","lowerLimit":"1.201","upperLimit":"1.912"}]}]},{"title":"Day 1096: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"2.90","lowerLimit":"2.352","upperLimit":"3.569"},{"groupId":"OG001","value":"1.29","lowerLimit":"0.984","upperLimit":"1.681"}]}]},{"title":"Day 1461: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"2.76","lowerLimit":"2.120","upperLimit":"3.586"},{"groupId":"OG001","value":"1.30","lowerLimit":"0.878","upperLimit":"1.937"}]}]},{"title":"Day 1826: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"2.54","lowerLimit":"1.908","upperLimit":"3.374"},{"groupId":"OG001","value":"1.37","lowerLimit":"0.903","upperLimit":"2.083"}]}]},{"title":"Day 366: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"3.62","lowerLimit":"3.025","upperLimit":"4.342"},{"groupId":"OG001","value":"1.08","lowerLimit":"0.949","upperLimit":"1.225"}]}]},{"title":"Day 731: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"2.79","lowerLimit":"2.180","upperLimit":"3.575"},{"groupId":"OG001","value":"0.68","lowerLimit":"0.557","upperLimit":"0.836"}]}]},{"title":"Day 1096: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"2.44","lowerLimit":"1.911","upperLimit":"3.125"},{"groupId":"OG001","value":"0.63","lowerLimit":"0.511","upperLimit":"0.788"}]}]},{"title":"Day 1461: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"2.46","lowerLimit":"1.832","upperLimit":"3.315"},{"groupId":"OG001","value":"0.90","lowerLimit":"0.656","upperLimit":"1.235"}]}]},{"title":"Day 1826: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"1.98","lowerLimit":"1.454","upperLimit":"2.694"},{"groupId":"OG001","value":"0.73","lowerLimit":"0.529","upperLimit":"0.997"}]}]},{"title":"Day 366: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"2.37","lowerLimit":"2.021","upperLimit":"2.778"},{"groupId":"OG001","value":"1.11","lowerLimit":"1.009","upperLimit":"1.232"}]}]},{"title":"Day 731: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"2.36","lowerLimit":"1.939","upperLimit":"2.876"},{"groupId":"OG001","value":"1.16","lowerLimit":"0.966","upperLimit":"1.385"}]}]},{"title":"Day 1096: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"2.35","lowerLimit":"1.916","upperLimit":"2.872"},{"groupId":"OG001","value":"1.19","lowerLimit":"1.010","upperLimit":"1.406"}]}]},{"title":"Day 1461: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"1.83","lowerLimit":"1.495","upperLimit":"2.249"},{"groupId":"OG001","value":"1.03","lowerLimit":"0.767","upperLimit":"1.371"}]}]},{"title":"Day 1826: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"1.67","lowerLimit":"1.328","upperLimit":"2.099"},{"groupId":"OG001","value":"0.88","lowerLimit":"0.632","upperLimit":"1.227"}]}]},{"title":"Day 366: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"3.10","lowerLimit":"2.573","upperLimit":"3.737"},{"groupId":"OG001","value":"1.16","lowerLimit":"1.033","upperLimit":"1.293"}]}]},{"title":"Day 731: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"2.14","lowerLimit":"1.673","upperLimit":"2.733"},{"groupId":"OG001","value":"0.71","lowerLimit":"0.598","upperLimit":"0.831"}]}]},{"title":"Day 1096: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"2.06","lowerLimit":"1.638","upperLimit":"2.592"},{"groupId":"OG001","value":"0.74","lowerLimit":"0.624","upperLimit":"0.867"}]}]},{"title":"Day 1461: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"1.99","lowerLimit":"1.507","upperLimit":"2.640"},{"groupId":"OG001","value":"0.99","lowerLimit":"0.775","upperLimit":"1.268"}]}]},{"title":"Day 1826: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"1.41","lowerLimit":"1.094","upperLimit":"1.823"},{"groupId":"OG001","value":"0.65","lowerLimit":"0.507","upperLimit":"0.827"}]}]},{"title":"Day 366: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"1.71","lowerLimit":"1.516","upperLimit":"1.931"},{"groupId":"OG001","value":"1.05","lowerLimit":"0.931","upperLimit":"1.182"}]}]},{"title":"Day 731: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"1.69","lowerLimit":"1.419","upperLimit":"2.010"},{"groupId":"OG001","value":"1.14","lowerLimit":"0.949","upperLimit":"1.368"}]}]},{"title":"Day 1096: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"1.84","lowerLimit":"1.519","upperLimit":"2.226"},{"groupId":"OG001","value":"1.08","lowerLimit":"0.845","upperLimit":"1.392"}]}]},{"title":"Day 1461: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"1.61","lowerLimit":"1.253","upperLimit":"2.075"},{"groupId":"OG001","value":"1.04","lowerLimit":"0.681","upperLimit":"1.577"}]}]},{"title":"Day 1826: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"1.67","lowerLimit":"1.318","upperLimit":"2.121"},{"groupId":"OG001","value":"1.19","lowerLimit":"0.818","upperLimit":"1.731"}]}]},{"title":"Day 366: Serotype EPA","categories":[{"measurements":[{"groupId":"OG000","value":"3.31","lowerLimit":"2.587","upperLimit":"4.232"},{"groupId":"OG001","value":"0.98","lowerLimit":"0.946","upperLimit":"1.019"}]}]},{"title":"Day 731: Serotype EPA","categories":[{"measurements":[{"groupId":"OG000","value":"2.25","lowerLimit":"1.793","upperLimit":"2.819"},{"groupId":"OG001","value":"1.14","lowerLimit":"0.838","upperLimit":"1.546"}]}]},{"title":"Day 1096: Serotype EPA","categories":[{"measurements":[{"groupId":"OG000","value":"2.33","lowerLimit":"1.864","upperLimit":"2.907"},{"groupId":"OG001","value":"1.14","lowerLimit":"0.844","upperLimit":"1.553"}]}]},{"title":"Day 1461: Serotype EPA","categories":[{"measurements":[{"groupId":"OG000","value":"2.11","lowerLimit":"1.568","upperLimit":"2.844"},{"groupId":"OG001","value":"1.17","lowerLimit":"0.712","upperLimit":"1.939"}]}]},{"title":"Day 1826: Serotype EPA","categories":[{"measurements":[{"groupId":"OG000","value":"1.86","lowerLimit":"1.376","upperLimit":"2.513"},{"groupId":"OG001","value":"1.29","lowerLimit":"0.848","upperLimit":"1.957"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Geometric Mean Titer (GMT) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by MOPA on Days 366, 731, 1096, and 1461","description":"GMTs of serotype-specific total IgG serum antibodies as measured by MOPA were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Data was planned to be analyzed for specified arms only. LLOQ values for O1A: 33, O2: 42, O4: 12, O6A: 62, O15: 75, O16: 17, O18A: 44, O25B: 58, O75: 14. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"PPI analysis set used. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this endpoint. Data for this endpoint was planned to be collected and analyzed only on the ExPEC10V dose selected for further clinical development based on Day 30 primary analysis. Since high-dose ExPEC10V was selected and Prevnar 13 was continued as comparator, only data from these groups is available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Days 366, 731, 1096, 1461","groups":[{"id":"OG000","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"51"}]}],"classes":[{"title":"Day 366: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"266.6","lowerLimit":"194.4","upperLimit":"365.5"},{"groupId":"OG001","value":"187.9","lowerLimit":"76.6","upperLimit":"460.5"}]}]},{"title":"Day 731: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"198.0","lowerLimit":"146.6","upperLimit":"267.5"},{"groupId":"OG001","value":"379.5","lowerLimit":"125.6","upperLimit":"1146.1"}]}]},{"title":"Day 1096: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"229.2","lowerLimit":"162.9","upperLimit":"322.4"},{"groupId":"OG001","value":"278.9","lowerLimit":"116.4","upperLimit":"667.8"}]}]},{"title":"Day 1461: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"241.0","lowerLimit":"160.6","upperLimit":"361.6"},{"groupId":"OG001","value":"362.3","lowerLimit":"53.0","upperLimit":"2478.0"}]}]},{"title":"Day 366: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"1700.5","lowerLimit":"1171.9","upperLimit":"2467.7"},{"groupId":"OG001","value":"186.1","lowerLimit":"74.2","upperLimit":"466.5"}]}]},{"title":"Day 731: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"468.2","lowerLimit":"325.6","upperLimit":"673.4"},{"groupId":"OG001","value":"261.3","lowerLimit":"132.0","upperLimit":"517.2"}]}]},{"title":"Day 1096: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"866.7","lowerLimit":"600.6","upperLimit":"1250.8"},{"groupId":"OG001","value":"236.5","lowerLimit":"104.7","upperLimit":"534.3"}]}]},{"title":"Day 1461: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"622.5","lowerLimit":"374.9","upperLimit":"1033.5"},{"groupId":"OG001","value":"288.4","lowerLimit":"NA","upperLimit":"2239.4","comment":"Lower limit of 95% CI could not be estimated as it was below LLOQ (42)."}]}]},{"title":"Day 366: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"269.8","lowerLimit":"211.3","upperLimit":"344.3"},{"groupId":"OG001","value":"155.8","lowerLimit":"98.4","upperLimit":"246.6"}]}]},{"title":"Day 731: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"279.7","lowerLimit":"225.2","upperLimit":"347.3"},{"groupId":"OG001","value":"229.2","lowerLimit":"92.0","upperLimit":"571.1"}]}]},{"title":"Day 1096: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"284.4","lowerLimit":"233.9","upperLimit":"345.7"},{"groupId":"OG001","value":"292.0","lowerLimit":"204.4","upperLimit":"417.2"}]}]},{"title":"Day 1461: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"242.0","lowerLimit":"180.6","upperLimit":"324.2"},{"groupId":"OG001","value":"216.3","lowerLimit":"101.2","upperLimit":"462.3"}]}]},{"title":"Day 366: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"620.2","lowerLimit":"471.0","upperLimit":"816.6"},{"groupId":"OG001","value":"287.6","lowerLimit":"91.7","upperLimit":"902.0"}]}]},{"title":"Day 731: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"483.7","lowerLimit":"357.0","upperLimit":"655.4"},{"groupId":"OG001","value":"368.0","lowerLimit":"104.3","upperLimit":"1298.3"}]}]},{"title":"Day 1096: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"548.5","lowerLimit":"397.1","upperLimit":"757.6"},{"groupId":"OG001","value":"635.9","lowerLimit":"156.7","upperLimit":"2581.5"}]}]},{"title":"Day 1461: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"538.7","lowerLimit":"374.0","upperLimit":"775.8"},{"groupId":"OG001","value":"921.4","lowerLimit":"200.1","upperLimit":"4243.2"}]}]},{"title":"Day 366: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"1062.4","lowerLimit":"770.4","upperLimit":"1465.1"},{"groupId":"OG001","value":"434.2","lowerLimit":"160.1","upperLimit":"1177.6"}]}]},{"title":"Day 731: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"846.5","lowerLimit":"606.0","upperLimit":"1182.4"},{"groupId":"OG001","value":"815.5","lowerLimit":"170.5","upperLimit":"3900.1"}]}]},{"title":"Day 1096: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"484.3","lowerLimit":"355.7","upperLimit":"659.5"},{"groupId":"OG001","value":"527.2","lowerLimit":"135.9","upperLimit":"2045.2"}]}]},{"title":"Day 1461: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"600.8","lowerLimit":"376.3","upperLimit":"959.3"},{"groupId":"OG001","value":"736.1","lowerLimit":"106.0","upperLimit":"5110.6"}]}]},{"title":"Day 366: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"440.9","lowerLimit":"304.1","upperLimit":"639.4"},{"groupId":"OG001","value":"113.1","lowerLimit":"58.3","upperLimit":"219.6"}]}]},{"title":"Day 731: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"375.6","lowerLimit":"263.5","upperLimit":"535.6"},{"groupId":"OG001","value":"140.7","lowerLimit":"47.6","upperLimit":"416.0"}]}]},{"title":"Day 1096: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"265.9","lowerLimit":"181.4","upperLimit":"389.7"},{"groupId":"OG001","value":"300.1","lowerLimit":"83.5","upperLimit":"1078.5"}]}]},{"title":"Day 1461: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"249.6","lowerLimit":"153.5","upperLimit":"405.7"},{"groupId":"OG001","value":"186.2","lowerLimit":"37.6","upperLimit":"921.8"}]}]},{"title":"Day 366: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"301.7","lowerLimit":"233.4","upperLimit":"390.1"},{"groupId":"OG001","value":"182.8","lowerLimit":"71.2","upperLimit":"469.7"}]}]},{"title":"Day 731: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"213.0","lowerLimit":"167.6","upperLimit":"270.7"},{"groupId":"OG001","value":"131.8","lowerLimit":"NA","upperLimit":"412.7","comment":"Lower limit of 95% CI could not be estimated as it was below LLOQ (44)."}]}]},{"title":"Day 1096: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"192.9","lowerLimit":"143.1","upperLimit":"260.2"},{"groupId":"OG001","value":"90.2","lowerLimit":"NA","upperLimit":"373.6","comment":"Lower limit of 95% CI could not be estimated as it was below LLOQ (44)."}]}]},{"title":"Day 1461: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"324.9","lowerLimit":"222.0","upperLimit":"475.4"},{"groupId":"OG001","value":"327.2","lowerLimit":"NA","upperLimit":"2698.0","comment":"Lower limit of 95% CI could not be estimated as it was below LLOQ (44)."}]}]},{"title":"Day 366: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"69.2","lowerLimit":"NA","upperLimit":"90.2","comment":"Lower limit of 95% CI could not be estimated as it was below LLOQ (58)."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Geometric mean, lower and upper limit of 95% CI could not be estimated as the value was below LLOQ (58)."}]}]},{"title":"Day 731: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"70.4","comment":"Geometric mean and lower limit of 95% CI could not be estimated as the value was below LLOQ (58)."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Geometric mean, lower, and upper limit of 95% CI could not be estimated as the value was below LLOQ (58)."}]}]},{"title":"Day 1096: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Geometric mean, lower, and upper limit of 95% CI could not be estimated as the value was below LLOQ (58)."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Geometric mean, lower, and upper limit of 95% CI could not be estimated as the value was below LLOQ (58)."}]}]},{"title":"Day 1461: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"59.9","comment":"Geometric mean and lower limit of 95% CI could not be estimated as the value was below LLOQ (58)."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"74.0","comment":"Geometric mean and lower limit of 95% CI could not be estimated as the value was below LLOQ (58)."}]}]},{"title":"Day 366: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"80.9","lowerLimit":"62.2","upperLimit":"105.2"},{"groupId":"OG001","value":"101.5","lowerLimit":"40.9","upperLimit":"251.5"}]}]},{"title":"Day 731: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"57.7","lowerLimit":"42.3","upperLimit":"78.7"},{"groupId":"OG001","value":"101.5","lowerLimit":"39.5","upperLimit":"260.6"}]}]},{"title":"Day 1096: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"83.0","lowerLimit":"58.7","upperLimit":"117.2"},{"groupId":"OG001","value":"100.9","lowerLimit":"33.3","upperLimit":"305.4"}]}]},{"title":"Day 1461: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"46.6","lowerLimit":"32.0","upperLimit":"67.9"},{"groupId":"OG001","value":"117.3","lowerLimit":"19.7","upperLimit":"698.4"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype Specific Antibodies as Measured by MOPA on Days 366, 731, 1096, and 1461","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by MOPA on Days 366, 731, 1096, 1461 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples by MOPA. GMR of fold change from baseline was calculated as the ratio of GMTs on Days 366, 731, 1096, 1461 and pre-vaccination (on Day 1). For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set used. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this endpoint. Data for this endpoint was planned to be collected and analyzed only on the ExPEC10V dose selected for further clinical development based on Day 30 primary analysis. Since high-dose ExPEC10V was selected and Prevnar 13 was continued as comparator, only data from these groups is available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline (Day 1, pre-vaccination) and Days 366, 731, 1096, 1461","groups":[{"id":"OG000","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"51"}]}],"classes":[{"title":"Day 366: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"0.90","lowerLimit":"0.738","upperLimit":"1.110"},{"groupId":"OG001","value":"0.62","lowerLimit":"0.401","upperLimit":"0.963"}]}]},{"title":"Day 731: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"0.71","lowerLimit":"0.591","upperLimit":"0.865"},{"groupId":"OG001","value":"0.91","lowerLimit":"0.401","upperLimit":"2.088"}]}]},{"title":"Day 1096: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"0.80","lowerLimit":"0.665","upperLimit":"0.953"},{"groupId":"OG001","value":"0.69","lowerLimit":"0.325","upperLimit":"1.459"}]}]},{"title":"Day 1461: Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"0.98","lowerLimit":"0.781","upperLimit":"1.225"},{"groupId":"OG001","value":"0.64","lowerLimit":"0.146","upperLimit":"2.786"}]}]},{"title":"Day 366: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"5.05","lowerLimit":"3.601","upperLimit":"7.072"},{"groupId":"OG001","value":"0.84","lowerLimit":"0.437","upperLimit":"1.604"}]}]},{"title":"Day 731: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"1.53","lowerLimit":"1.131","upperLimit":"2.057"},{"groupId":"OG001","value":"0.93","lowerLimit":"0.410","upperLimit":"2.095"}]}]},{"title":"Day 1096: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"2.63","lowerLimit":"1.932","upperLimit":"3.574"},{"groupId":"OG001","value":"0.76","lowerLimit":"0.513","upperLimit":"1.140"}]}]},{"title":"Day 1461: Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"2.13","lowerLimit":"1.386","upperLimit":"3.274"},{"groupId":"OG001","value":"0.96","lowerLimit":"0.398","upperLimit":"2.313"}]}]},{"title":"Day 366: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"1.67","lowerLimit":"1.343","upperLimit":"2.080"},{"groupId":"OG001","value":"1.23","lowerLimit":"0.367","upperLimit":"4.130"}]}]},{"title":"Day 731: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"1.62","lowerLimit":"1.313","upperLimit":"1.997"},{"groupId":"OG001","value":"2.04","lowerLimit":"0.672","upperLimit":"6.185"}]}]},{"title":"Day 1096: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"1.62","lowerLimit":"1.345","upperLimit":"1.947"},{"groupId":"OG001","value":"2.12","lowerLimit":"0.330","upperLimit":"13.573"}]}]},{"title":"Day 1461: Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"1.43","lowerLimit":"1.087","upperLimit":"1.880"},{"groupId":"OG001","value":"1.42","lowerLimit":"0.041","upperLimit":"49.404"}]}]},{"title":"Day 366: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"1.19","lowerLimit":"0.954","upperLimit":"1.475"},{"groupId":"OG001","value":"0.59","lowerLimit":"0.317","upperLimit":"1.083"}]}]},{"title":"Day 731: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"0.84","lowerLimit":"0.689","upperLimit":"1.018"},{"groupId":"OG001","value":"0.91","lowerLimit":"0.458","upperLimit":"1.808"}]}]},{"title":"Day 1096: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"0.91","lowerLimit":"0.711","upperLimit":"1.160"},{"groupId":"OG001","value":"1.47","lowerLimit":"0.337","upperLimit":"6.398"}]}]},{"title":"Day 1461: Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"0.761","upperLimit":"1.319"},{"groupId":"OG001","value":"2.59","lowerLimit":"0.139","upperLimit":"48.195"}]}]},{"title":"Day 366: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"2.86","lowerLimit":"2.140","upperLimit":"3.825"},{"groupId":"OG001","value":"0.95","lowerLimit":"0.594","upperLimit":"1.522"}]}]},{"title":"Day 731: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"2.06","lowerLimit":"1.549","upperLimit":"2.737"},{"groupId":"OG001","value":"1.81","lowerLimit":"0.904","upperLimit":"3.610"}]}]},{"title":"Day 1096: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"1.23","lowerLimit":"0.887","upperLimit":"1.707"},{"groupId":"OG001","value":"0.97","lowerLimit":"0.331","upperLimit":"2.850"}]}]},{"title":"Day 1461: Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"1.79","lowerLimit":"1.164","upperLimit":"2.753"},{"groupId":"OG001","value":"0.87","lowerLimit":"0.320","upperLimit":"2.343"}]}]},{"title":"Day 366: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"3.84","lowerLimit":"2.861","upperLimit":"5.155"},{"groupId":"OG001","value":"0.99","lowerLimit":"0.495","upperLimit":"1.962"}]}]},{"title":"Day 731: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"3.45","lowerLimit":"2.618","upperLimit":"4.534"},{"groupId":"OG001","value":"1.13","lowerLimit":"0.631","upperLimit":"2.031"}]}]},{"title":"Day 1096: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"2.39","lowerLimit":"1.796","upperLimit":"3.171"},{"groupId":"OG001","value":"1.80","lowerLimit":"0.891","upperLimit":"3.618"}]}]},{"title":"Day 1461: Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"2.53","lowerLimit":"1.726","upperLimit":"3.719"},{"groupId":"OG001","value":"1.31","lowerLimit":"0.419","upperLimit":"4.085"}]}]},{"title":"Day 366: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"1.27","lowerLimit":"1.008","upperLimit":"1.601"},{"groupId":"OG001","value":"0.93","lowerLimit":"0.464","upperLimit":"1.861"}]}]},{"title":"Day 731: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"0.86","lowerLimit":"0.695","upperLimit":"1.064"},{"groupId":"OG001","value":"0.78","lowerLimit":"0.516","upperLimit":"1.181"}]}]},{"title":"Day 1096: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"0.78","lowerLimit":"0.647","upperLimit":"0.949"},{"groupId":"OG001","value":"0.57","lowerLimit":"0.365","upperLimit":"0.901"}]}]},{"title":"Day 1461: Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"1.21","lowerLimit":"0.979","upperLimit":"1.491"},{"groupId":"OG001","value":"1.03","lowerLimit":"0.422","upperLimit":"2.519"}]}]},{"title":"Day 366: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"1.39","lowerLimit":"1.188","upperLimit":"1.630"},{"groupId":"OG001","value":"1.08","lowerLimit":"0.906","upperLimit":"1.276"}]}]},{"title":"Day 731: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"1.19","lowerLimit":"0.999","upperLimit":"1.428"},{"groupId":"OG001","value":"1.08","lowerLimit":"0.894","upperLimit":"1.308"}]}]},{"title":"Day 1096: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"0.99","lowerLimit":"0.918","upperLimit":"1.070"},{"groupId":"OG001","value":"1.00","lowerLimit":"0.996","upperLimit":"1.010"}]}]},{"title":"Day 1461: Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"1.05","lowerLimit":"0.921","upperLimit":"1.185"},{"groupId":"OG001","value":"1.05","lowerLimit":"0.896","upperLimit":"1.235"}]}]},{"title":"Day 366: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"1.43","lowerLimit":"1.160","upperLimit":"1.772"},{"groupId":"OG001","value":"1.20","lowerLimit":"0.496","upperLimit":"2.878"}]}]},{"title":"Day 731: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"1.12","lowerLimit":"0.886","upperLimit":"1.408"},{"groupId":"OG001","value":"1.17","lowerLimit":"0.457","upperLimit":"2.982"}]}]},{"title":"Day 1096: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"1.57","lowerLimit":"1.159","upperLimit":"2.117"},{"groupId":"OG001","value":"0.92","lowerLimit":"0.338","upperLimit":"2.479"}]}]},{"title":"Day 1461: Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"1.13","lowerLimit":"0.875","upperLimit":"1.462"},{"groupId":"OG001","value":"1.11","lowerLimit":"0.189","upperLimit":"6.553"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by MOPA on Days 366, 731, 1096, and 1461","description":"The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Days 366, 731, 1096, and 1461 for the serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75 was calculated as the ratio of titer values of serum antibody on Days 366, 731, 1096, 1461 and pre-vaccination (on day 1) that is, Day 366/Day 1, 731/Day 1, 1096/Day 1, 1461/Day 1. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set used. \"N\" (number of participants analyzed): participants evaluable for this endpoint and \"n\" (number analyzed): participants evaluable at specified categories. Data for this endpoint was planned to be collected and analyzed only on the ExPEC10V dose selected for further clinical development based on Day 30 primary analysis. Since high-dose ExPEC10V was selected and Prevnar 13 was continued as comparator, only data from these groups is available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline (Day 1, pre-vaccination) and Days 366, 731, 1096, and 1461","groups":[{"id":"OG000","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"classes":[{"title":"Day 366: Serotype O1A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","lowerLimit":"3.26","upperLimit":"17.97"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"36.94"}]}]},{"title":"Day 731: Serotype O1A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","lowerLimit":"1.88","upperLimit":"16.46"},{"groupId":"OG001","value":"14.3","lowerLimit":"0.36","upperLimit":"57.87"}]}]},{"title":"Day 1096: Serotype O1A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"4.11","upperLimit":"22.25"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 1461: Serotype O1A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","lowerLimit":"6.56","upperLimit":"33.65"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"60.24"}]}]},{"title":"Day 366: Serotype O1A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","lowerLimit":"2.39","upperLimit":"16.11"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"36.94"}]}]},{"title":"Day 731: Serotype O1A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"0.04","upperLimit":"9.09"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"40.96"}]}]},{"title":"Day 1096: Serotype O1A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.00","upperLimit":"6.49"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 1461: Serotype O1A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.00","upperLimit":"10.00"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"60.24"}]}]},{"title":"Day 366: Serotype O2: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","lowerLimit":"57.31","upperLimit":"80.08"},{"groupId":"OG001","value":"12.5","lowerLimit":"0.32","upperLimit":"52.65"}]}]},{"title":"Day 731: Serotype O2: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.0","lowerLimit":"19.54","upperLimit":"44.54"},{"groupId":"OG001","value":"28.6","lowerLimit":"3.67","upperLimit":"70.96"}]}]},{"title":"Day 1096: Serotype O2: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52.7","lowerLimit":"38.80","upperLimit":"66.35"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 1461: Serotype O2: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","lowerLimit":"33.99","upperLimit":"68.62"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"60.24"}]}]},{"title":"Day 366: Serotype O2: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52.2","lowerLimit":"39.80","upperLimit":"64.35"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"36.94"}]}]},{"title":"Day 731: Serotype O2: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","lowerLimit":"7.35","upperLimit":"27.42"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"40.96"}]}]},{"title":"Day 1096: Serotype O2: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","lowerLimit":"20.68","upperLimit":"46.71"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 1461: Serotype O2: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","lowerLimit":"16.85","upperLimit":"49.29"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"60.24"}]}]},{"title":"Day 366: Serotype O4: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","lowerLimit":"28.91","upperLimit":"53.08"},{"groupId":"OG001","value":"37.5","lowerLimit":"8.52","upperLimit":"75.51"}]}]},{"title":"Day 731: Serotype O4: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","lowerLimit":"23.55","upperLimit":"49.13"},{"groupId":"OG001","value":"71.4","lowerLimit":"29.04","upperLimit":"96.33"}]}]},{"title":"Day 1096: Serotype O4: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","lowerLimit":"25.41","upperLimit":"52.27"},{"groupId":"OG001","value":"66.7","lowerLimit":"22.28","upperLimit":"95.67"}]}]},{"title":"Day 1461: Serotype O4: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","lowerLimit":"14.64","upperLimit":"46.30"},{"groupId":"OG001","value":"50.0","lowerLimit":"6.76","upperLimit":"93.24"}]}]},{"title":"Day 366: Serotype O4: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","lowerLimit":"12.71","upperLimit":"33.31"},{"groupId":"OG001","value":"12.5","lowerLimit":"0.32","upperLimit":"52.65"}]}]},{"title":"Day 731: Serotype O4: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","lowerLimit":"7.22","upperLimit":"26.99"},{"groupId":"OG001","value":"28.6","lowerLimit":"3.67","upperLimit":"70.96"}]}]},{"title":"Day 1096: Serotype O4: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"4.11","upperLimit":"22.25"},{"groupId":"OG001","value":"33.3","lowerLimit":"4.33","upperLimit":"77.72"}]}]},{"title":"Day 1461: Serotype O4: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"1.80","upperLimit":"23.06"},{"groupId":"OG001","value":"50.0","lowerLimit":"6.76","upperLimit":"93.24"}]}]},{"title":"Day 366: Serotype O6A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","lowerLimit":"15.05","upperLimit":"36.49"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"36.94"}]}]},{"title":"Day 731: Serotype O6A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"2.81","upperLimit":"18.68"},{"groupId":"OG001","value":"14.3","lowerLimit":"0.36","upperLimit":"57.87"}]}]},{"title":"Day 1096: Serotype O6A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","lowerLimit":"6.50","upperLimit":"26.66"},{"groupId":"OG001","value":"16.7","lowerLimit":"0.42","upperLimit":"64.12"}]}]},{"title":"Day 1461: Serotype O6A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"4.81","upperLimit":"30.26"},{"groupId":"OG001","value":"25.0","lowerLimit":"0.63","upperLimit":"80.59"}]}]},{"title":"Day 366: Serotype O6A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","lowerLimit":"5.14","upperLimit":"21.57"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"36.94"}]}]},{"title":"Day 731: Serotype O6A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","lowerLimit":"1.06","upperLimit":"14.15"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"40.96"}]}]},{"title":"Day 1096: Serotype O6A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","lowerLimit":"2.02","upperLimit":"17.59"},{"groupId":"OG001","value":"16.7","lowerLimit":"0.42","upperLimit":"64.12"}]}]},{"title":"Day 1461: Serotype O6A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"1.80","upperLimit":"23.06"},{"groupId":"OG001","value":"25.0","lowerLimit":"0.63","upperLimit":"80.59"}]}]},{"title":"Day 366: Serotype O15: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.1","lowerLimit":"42.62","upperLimit":"67.08"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"36.94"}]}]},{"title":"Day 731: Serotype O15: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","lowerLimit":"37.50","upperLimit":"64.11"},{"groupId":"OG001","value":"57.1","lowerLimit":"18.41","upperLimit":"90.10"}]}]},{"title":"Day 1096: Serotype O15: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","lowerLimit":"16.14","upperLimit":"40.96"},{"groupId":"OG001","value":"33.3","lowerLimit":"4.33","upperLimit":"77.72"}]}]},{"title":"Day 1461: Serotype O15: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.6","lowerLimit":"31.38","upperLimit":"66.01"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"60.24"}]}]},{"title":"Day 366: Serotype O15: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"22.44","upperLimit":"45.71"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"36.94"}]}]},{"title":"Day 731: Serotype O15: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","lowerLimit":"13.62","upperLimit":"36.59"},{"groupId":"OG001","value":"28.6","lowerLimit":"3.67","upperLimit":"70.96"}]}]},{"title":"Day 1096: Serotype O15: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"10.43","upperLimit":"32.97"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 1461: Serotype O15: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","lowerLimit":"12.49","upperLimit":"43.26"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"60.24"}]}]},{"title":"Day 366: Serotype O16: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","lowerLimit":"52.17","upperLimit":"75.92"},{"groupId":"OG001","value":"37.5","lowerLimit":"8.52","upperLimit":"75.51"}]}]},{"title":"Day 731: Serotype O16: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","lowerLimit":"55.46","upperLimit":"80.46"},{"groupId":"OG001","value":"14.3","lowerLimit":"0.36","upperLimit":"57.87"}]}]},{"title":"Day 1096: Serotype O16: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","lowerLimit":"41.40","upperLimit":"69.08"},{"groupId":"OG001","value":"50.0","lowerLimit":"11.81","upperLimit":"88.19"}]}]},{"title":"Day 1461: Serotype O16: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.3","lowerLimit":"36.65","upperLimit":"71.17"},{"groupId":"OG001","value":"25.0","lowerLimit":"0.63","upperLimit":"80.59"}]}]},{"title":"Day 366: Serotype O16: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.1","lowerLimit":"34.83","upperLimit":"59.55"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"36.94"}]}]},{"title":"Day 731: Serotype O16: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.8","lowerLimit":"31.74","upperLimit":"58.46"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"40.96"}]}]},{"title":"Day 1096: Serotype O16: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.5","lowerLimit":"19.52","upperLimit":"45.55"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 1461: Serotype O16: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","lowerLimit":"19.13","upperLimit":"52.21"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"60.24"}]}]},{"title":"Day 366: Serotype O18A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","lowerLimit":"16.25","upperLimit":"38.06"},{"groupId":"OG001","value":"12.5","lowerLimit":"0.32","upperLimit":"52.65"}]}]},{"title":"Day 731: Serotype O18A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","lowerLimit":"6.04","upperLimit":"24.98"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"40.96"}]}]},{"title":"Day 1096: Serotype O18A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"1.14","upperLimit":"15.12"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 1461: Serotype O18A: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"8.44","upperLimit":"36.94"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"60.24"}]}]},{"title":"Day 366: Serotype O18A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","lowerLimit":"6.14","upperLimit":"23.32"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"36.94"}]}]},{"title":"Day 731: Serotype O18A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","lowerLimit":"1.06","upperLimit":"14.15"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"40.96"}]}]},{"title":"Day 1096: Serotype O18A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.00","upperLimit":"6.49"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 1461: Serotype O18A: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"0.70","upperLimit":"19.16"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"19.16"}]}]},{"title":"Day 366: Serotype O25B: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","lowerLimit":"8.36","upperLimit":"27.10"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"36.94"}]}]},{"title":"Day 731: Serotype O25B: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","lowerLimit":"4.99","upperLimit":"23.30"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"40.96"}]}]},{"title":"Day 1096: Serotype O25B: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"0.05","upperLimit":"9.89"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 1461: Serotype O25B: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","lowerLimit":"0.72","upperLimit":"19.68"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"60.24"}]}]},{"title":"Day 366: Serotype O25B: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","lowerLimit":"3.31","upperLimit":"18.22"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"36.94"}]}]},{"title":"Day 731: Serotype O25B: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"0.42","upperLimit":"11.91"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"40.96"}]}]},{"title":"Day 1096: Serotype O25B: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.00","upperLimit":"6.60"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"45.93"}]}]},{"title":"Day 1461: Serotype O25B: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.00","upperLimit":"10.28"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"60.24"}]}]},{"title":"Day 366: Serotype O75: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","lowerLimit":"18.69","upperLimit":"41.16"},{"groupId":"OG001","value":"25.0","lowerLimit":"3.19","upperLimit":"65.09"}]}]},{"title":"Day 731: Serotype O75: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","lowerLimit":"12.51","upperLimit":"35.27"},{"groupId":"OG001","value":"14.3","lowerLimit":"0.36","upperLimit":"57.87"}]}]},{"title":"Day 1096: Serotype O75: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","lowerLimit":"25.92","upperLimit":"53.12"},{"groupId":"OG001","value":"16.7","lowerLimit":"0.42","upperLimit":"64.12"}]}]},{"title":"Day 1461: Serotype O75: >= 2 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"4.81","upperLimit":"30.26"},{"groupId":"OG001","value":"25.0","lowerLimit":"0.63","upperLimit":"80.59"}]}]},{"title":"Day 366: Serotype O75: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","lowerLimit":"5.14","upperLimit":"21.57"},{"groupId":"OG001","value":"12.5","lowerLimit":"0.32","upperLimit":"52.65"}]}]},{"title":"Day 731: Serotype O75: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","lowerLimit":"4.99","upperLimit":"23.30"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"40.96"}]}]},{"title":"Day 1096: Serotype O75: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","lowerLimit":"10.63","upperLimit":"33.53"},{"groupId":"OG001","value":"16.7","lowerLimit":"0.42","upperLimit":"64.12"}]}]},{"title":"Day 1461: Serotype O75: >= 4 Fold Increase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"1.80","upperLimit":"23.06"},{"groupId":"OG001","value":"25.0","lowerLimit":"0.63","upperLimit":"80.59"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Correlation Between the Multiplex ECL-Based Immunoassay and the MOPA Functional Titers by Serotype on Day 30","description":"Correlation between the multiplex ECL-based immunoassay and the MOPA functional titers by serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75 on Day 30 was analyzed. Data was planned to be analyzed for specified arms only. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype.","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this outcome measure and \"n\" (number analyzed) signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"correlation coefficient","timeFrame":"Day 30","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"69"}]}],"classes":[{"title":"Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","lowerLimit":"0.24","upperLimit":"0.46"},{"groupId":"OG001","value":"0.20","lowerLimit":"-0.04","upperLimit":"0.42"}]}]},{"title":"Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","lowerLimit":"0.50","upperLimit":"0.66"},{"groupId":"OG001","value":"0.47","lowerLimit":"0.26","upperLimit":"0.64"}]}]},{"title":"Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","lowerLimit":"0.53","upperLimit":"0.68"},{"groupId":"OG001","value":"0.20","lowerLimit":"-0.03","upperLimit":"0.42"}]}]},{"title":"Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","lowerLimit":"0.45","upperLimit":"0.63"},{"groupId":"OG001","value":"0.30","lowerLimit":"0.07","upperLimit":"0.50"}]}]},{"title":"Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","lowerLimit":"0.45","upperLimit":"0.63"},{"groupId":"OG001","value":"0.41","lowerLimit":"0.20","upperLimit":"0.59"}]}]},{"title":"Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","lowerLimit":"0.63","upperLimit":"0.76"},{"groupId":"OG001","value":"0.41","lowerLimit":"0.19","upperLimit":"0.59"}]}]},{"title":"Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","lowerLimit":"0.51","upperLimit":"0.67"},{"groupId":"OG001","value":"0.19","lowerLimit":"-0.05","upperLimit":"0.41"}]}]},{"title":"Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","lowerLimit":"0.58","upperLimit":"0.72"},{"groupId":"OG001","value":"0.40","lowerLimit":"0.19","upperLimit":"0.58"}]}]},{"title":"Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"257"},{"groupId":"OG001","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","lowerLimit":"0.47","upperLimit":"0.64"},{"groupId":"OG001","value":"0.28","lowerLimit":"0.04","upperLimit":"0.49"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Geometric Mean Titers (GMTs) of Serotype-specific Total Immunoglobulin G (IgG) Serum Antibodies as Measured by Multiplex ECL Based Immunoassay on Days 15 and 181","description":"GMTs of serotype-specific total IgG serum antibodies as measured by ECL based immunoassay were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 and EPA were determined in serum from collected blood samples. Data was planned to be analyzed for specified arms only. LLOQ values for O1A: 69149, O2: 65287, O4: 67356, O6A: 150748, O8: 72196, O15: 66910, O16: 71586, O18A: 70519, O25B: 61990, O75: 133019, and EPA: 66165. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" ( number of participants analyzed) signifies participants evaluable for this outcome measure and \"n\" (number analyzed) signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"At Days 15 and 181","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"131"}]}],"classes":[{"title":"Serotype O1A: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6440111.0","lowerLimit":"5964513.8","upperLimit":"6953631.4"},{"groupId":"OG001","value":"1683620.1","lowerLimit":"1434083.1","upperLimit":"1976577.8"}]}]},{"title":"Serotype O2: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5984689.5","lowerLimit":"5506341.8","upperLimit":"6504592.4"},{"groupId":"OG001","value":"758680.9","lowerLimit":"637710.3","upperLimit":"902599.0"}]}]},{"title":"Serotype O4: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3674695.0","lowerLimit":"3268908.7","upperLimit":"4130853.6"},{"groupId":"OG001","value":"752878.3","lowerLimit":"648044.1","upperLimit":"874671.5"}]}]},{"title":"Serotype O6A: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5549559.4","lowerLimit":"5061238.2","upperLimit":"6084995.1"},{"groupId":"OG001","value":"1864516.2","lowerLimit":"1602306.3","upperLimit":"2169635.5"}]}]},{"title":"Serotype O8: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6259628.9","lowerLimit":"5787049.2","upperLimit":"6770800.1"},{"groupId":"OG001","value":"2402212.7","lowerLimit":"2080311.6","upperLimit":"2773923.8"}]}]},{"title":"Serotype O15: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5820591.1","lowerLimit":"5382542.2","upperLimit":"6294289.8"},{"groupId":"OG001","value":"1196527.5","lowerLimit":"1020092.0","upperLimit":"1403479.3"}]}]},{"title":"Serotype O16: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5328787.2","lowerLimit":"4876101.2","upperLimit":"5823499.4"},{"groupId":"OG001","value":"1094722.5","lowerLimit":"967329.6","upperLimit":"1238892.4"}]}]},{"title":"Serotype O18A: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4224096.2","lowerLimit":"3810089.9","upperLimit":"4683088.6"},{"groupId":"OG001","value":"1343124.1","lowerLimit":"1178653.4","upperLimit":"1530545.3"}]}]},{"title":"Serotype O25B: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2205580.7","lowerLimit":"1907527.9","upperLimit":"2550204.4"},{"groupId":"OG001","value":"369020.0","lowerLimit":"309515.7","upperLimit":"439964.0"}]}]},{"title":"Serotype O75: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3879088.3","lowerLimit":"3534225.0","upperLimit":"4257602.7"},{"groupId":"OG001","value":"1525428.5","lowerLimit":"1313220.7","upperLimit":"1771927.8"}]}]},{"title":"Serotype EPA: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"764611.5","lowerLimit":"606266.0","upperLimit":"964314.1"},{"groupId":"OG001","value":"76119.8","lowerLimit":"NA","upperLimit":"92444.3","comment":"NA stands for data not available for lower limit of the CI as titer value was below LLOQ (66165)."}]}]},{"title":"Serotype O1A: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5181579.3","lowerLimit":"4717321.1","upperLimit":"5691527.8"},{"groupId":"OG001","value":"1363698.1","lowerLimit":"1134292.4","upperLimit":"1639500.3"}]}]},{"title":"Serotype O2: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5104290.1","lowerLimit":"4630408.3","upperLimit":"5626669.7"},{"groupId":"OG001","value":"772833.5","lowerLimit":"647611.4","upperLimit":"922268.6"}]}]},{"title":"Serotype O4: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2464185.1","lowerLimit":"2180166.2","upperLimit":"2785204.2"},{"groupId":"OG001","value":"748466.8","lowerLimit":"626770.4","upperLimit":"893792.2"}]}]},{"title":"Serotype O6A: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4237338.6","lowerLimit":"3839748.2","upperLimit":"4676097.9"},{"groupId":"OG001","value":"1377697.3","lowerLimit":"1156472.5","upperLimit":"1641240.8"}]}]},{"title":"Serotype O8: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5341568.9","lowerLimit":"4901755.3","upperLimit":"5820845.0"},{"groupId":"OG001","value":"2347175.9","lowerLimit":"2014621.2","upperLimit":"2734625.6"}]}]},{"title":"Serotype O15: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4651707.1","lowerLimit":"4246266.4","upperLimit":"5095859.9"},{"groupId":"OG001","value":"1212443.2","lowerLimit":"1022590.8","upperLimit":"1437543.2"}]}]},{"title":"Serotype O16: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4002647.6","lowerLimit":"3633889.3","upperLimit":"4408826.6"},{"groupId":"OG001","value":"974253.6","lowerLimit":"851675.7","upperLimit":"1114473.6"}]}]},{"title":"Serotype O18A: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3510981.8","lowerLimit":"3167417.1","upperLimit":"3891812.4"},{"groupId":"OG001","value":"1440992.4","lowerLimit":"1251837.9","upperLimit":"1658728.5"}]}]},{"title":"Serotype O25B: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1448059.1","lowerLimit":"1242167.0","upperLimit":"1688078.3"},{"groupId":"OG001","value":"338325.5","lowerLimit":"276179.7","upperLimit":"414455.2"}]}]},{"title":"Serotype O75: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3483252.0","lowerLimit":"3157048.6","upperLimit":"3843160.4"},{"groupId":"OG001","value":"1605445.2","lowerLimit":"1367665.3","upperLimit":"1884565.2"}]}]},{"title":"Serotype EPA: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"415564.1","lowerLimit":"335178.0","upperLimit":"515229.3"},{"groupId":"OG001","value":"71976.3","lowerLimit":"NA","upperLimit":"86879.0","comment":"NA stands for data not available for lower limit of the CI as titer value was below LLOQ (66165)."}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype-specific Antibodies Measured by Multiplex ECL Based Immunoassay on Days 15 and 181","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by multiplex ECL based immunoassay on Days 15 and 181 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, and O75 were determined in serum from collected blood samples by ECL based immunoassay. GMR of fold change from baseline was calculated as the ratio of GMTs on Days 15 and 181 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" ( number of participants analyzed) signifies participants evaluable for this outcome measure and \"n\" (number analyzed) signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Baseline (Day 1, pre-vaccination), Days 15 and 181","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"131"}]}],"classes":[{"title":"Serotype O1A: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.40","lowerLimit":"3.932","upperLimit":"4.928"},{"groupId":"OG001","value":"0.99","lowerLimit":"0.967","upperLimit":"1.023"}]}]},{"title":"Serotype O2: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.96","lowerLimit":"7.052","upperLimit":"8.987"},{"groupId":"OG001","value":"0.99","lowerLimit":"0.933","upperLimit":"1.057"}]}]},{"title":"Serotype O4: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.45","lowerLimit":"4.825","upperLimit":"6.146"},{"groupId":"OG001","value":"1.02","lowerLimit":"0.988","upperLimit":"1.063"}]}]},{"title":"Serotype O6A: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.89","lowerLimit":"3.518","upperLimit":"4.298"},{"groupId":"OG001","value":"1.03","lowerLimit":"0.989","upperLimit":"1.070"}]}]},{"title":"Serotype O8: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.89","lowerLimit":"2.619","upperLimit":"3.194"},{"groupId":"OG001","value":"1.03","lowerLimit":"0.992","upperLimit":"1.072"}]}]},{"title":"Serotype O15: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.93","lowerLimit":"4.420","upperLimit":"5.505"},{"groupId":"OG001","value":"1.02","lowerLimit":"0.976","upperLimit":"1.070"}]}]},{"title":"Serotype O16: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.14","lowerLimit":"4.615","upperLimit":"5.715"},{"groupId":"OG001","value":"1.03","lowerLimit":"0.984","upperLimit":"1.078"}]}]},{"title":"Serotype O18A: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.63","lowerLimit":"3.266","upperLimit":"4.031"},{"groupId":"OG001","value":"1.06","lowerLimit":"1.023","upperLimit":"1.093"}]}]},{"title":"Serotype O25B: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.80","lowerLimit":"4.990","upperLimit":"6.748"},{"groupId":"OG001","value":"1.01","lowerLimit":"0.963","upperLimit":"1.068"}]}]},{"title":"Serotype O75: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.42","lowerLimit":"2.217","upperLimit":"2.644"},{"groupId":"OG001","value":"1.02","lowerLimit":"0.977","upperLimit":"1.071"}]}]},{"title":"Serotype O1A: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.54","lowerLimit":"3.186","upperLimit":"3.937"},{"groupId":"OG001","value":"0.85","lowerLimit":"0.778","upperLimit":"0.930"}]}]},{"title":"Serotype O2: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.79","lowerLimit":"6.020","upperLimit":"7.649"},{"groupId":"OG001","value":"1.10","lowerLimit":"0.964","upperLimit":"1.252"}]}]},{"title":"Serotype O4: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.68","lowerLimit":"3.284","upperLimit":"4.116"},{"groupId":"OG001","value":"1.02","lowerLimit":"0.948","upperLimit":"1.105"}]}]},{"title":"Serotype O6A: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.88","lowerLimit":"2.569","upperLimit":"3.222"},{"groupId":"OG001","value":"0.78","lowerLimit":"0.678","upperLimit":"0.894"}]}]},{"title":"Serotype O8: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.45","lowerLimit":"2.239","upperLimit":"2.681"},{"groupId":"OG001","value":"1.06","lowerLimit":"1.000","upperLimit":"1.130"}]}]},{"title":"Serotype O15: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.08","lowerLimit":"3.692","upperLimit":"4.514"},{"groupId":"OG001","value":"1.08","lowerLimit":"1.016","upperLimit":"1.150"}]}]},{"title":"Serotype O16: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.98","lowerLimit":"3.605","upperLimit":"4.385"},{"groupId":"OG001","value":"0.92","lowerLimit":"0.859","upperLimit":"0.982"}]}]},{"title":"Serotype O18A: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.91","lowerLimit":"2.657","upperLimit":"3.179"},{"groupId":"OG001","value":"1.16","lowerLimit":"1.088","upperLimit":"1.234"}]}]},{"title":"Serotype O25B: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.73","lowerLimit":"3.237","upperLimit":"4.300"},{"groupId":"OG001","value":"0.95","lowerLimit":"0.814","upperLimit":"1.102"}]}]},{"title":"Serotype O75: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","lowerLimit":"1.983","upperLimit":"2.307"},{"groupId":"OG001","value":"1.11","lowerLimit":"1.029","upperLimit":"1.196"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With a >= 2-Fold Increase in Serotype-specific Serum Antibody Titers Measured by Multiplex ECL Based Immunoassay on Days 15 and 181","description":"Percentage of participants with a \\>=2-fold increase from baseline in serotype specific serum antibody titers as measured by multiplex ECL based immunoassay on Days 15 and 181 were reported. The fold (\\>=2-fold increase from baseline to Days 15 and 181) for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, and O75 was calculated as the ratio of titer values of serum antibody on Days 15 and 181 and pre-vaccination (on Day 1 that is Day 15/Day 1 and Day 181/Day 1).","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this outcome measure and \"n\" (number analyzed) signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline (Day 1, pre-vaccination), Days 15 and 181","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"131"}]}],"classes":[{"title":">=2 fold increase: Serotype O1A: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","lowerLimit":"70.55","upperLimit":"81.39"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"2.78"}]}]},{"title":">=2 fold increase: Serotype O2: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","lowerLimit":"84.40","upperLimit":"92.52"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.18"}]}]},{"title":">=2 fold increase: Serotype O4: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","lowerLimit":"76.50","upperLimit":"86.37"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.19","upperLimit":"5.41"}]}]},{"title":">=2 fold increase: Serotype O6A: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.9","lowerLimit":"68.04","upperLimit":"79.21"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.18"}]}]},{"title":">=2 fold increase: Serotype O8: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.1","lowerLimit":"55.77","upperLimit":"68.06"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.19","upperLimit":"5.41"}]}]},{"title":">=2 fold increase: Serotype O15: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"82.2","lowerLimit":"76.93","upperLimit":"86.72"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.18"}]}]},{"title":">=2 fold increase: Serotype O16: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.2","lowerLimit":"81.29","upperLimit":"90.17"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.18"}]}]},{"title":">=2 fold increase: Serotype O18A: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","lowerLimit":"63.08","upperLimit":"74.80"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.18"}]}]},{"title":">=2 fold increase: Serotype O25B: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","lowerLimit":"71.40","upperLimit":"82.11"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.18"}]}]},{"title":">=2 fold increase: Serotype O75: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52.6","lowerLimit":"46.22","upperLimit":"58.86"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.19","upperLimit":"5.41"}]}]},{"title":">=2 fold increase: Serotype O1A: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","lowerLimit":"65.40","upperLimit":"76.84"},{"groupId":"OG001","value":"2.5","lowerLimit":"0.51","upperLimit":"7.02"}]}]},{"title":">=2 fold increase: Serotype O2: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","lowerLimit":"81.94","upperLimit":"90.62"},{"groupId":"OG001","value":"12.2","lowerLimit":"6.99","upperLimit":"19.32"}]}]},{"title":">=2 fold increase: Serotype O4: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","lowerLimit":"62.95","upperLimit":"74.64"},{"groupId":"OG001","value":"3.3","lowerLimit":"0.89","upperLimit":"8.12"}]}]},{"title":">=2 fold increase: Serotype O6A: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","lowerLimit":"58.10","upperLimit":"70.19"},{"groupId":"OG001","value":"6.5","lowerLimit":"2.85","upperLimit":"12.41"}]}]},{"title":">=2 fold increase: Serotype O8: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.9","lowerLimit":"49.54","upperLimit":"62.04"},{"groupId":"OG001","value":"3.3","lowerLimit":"0.89","upperLimit":"8.12"}]}]},{"title":">=2 fold increase: Serotype O15: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","lowerLimit":"74.13","upperLimit":"84.38"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.20","upperLimit":"5.75"}]}]},{"title":">=2 fold increase: Serotype O16: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.8","lowerLimit":"73.29","upperLimit":"83.67"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"2.95"}]}]},{"title":">=2 fold increase: Serotype O18A: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.4","lowerLimit":"56.09","upperLimit":"68.32"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.51","upperLimit":"6.96"}]}]},{"title":">=2 fold increase: Serotype O25B: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","lowerLimit":"59.30","upperLimit":"71.31"},{"groupId":"OG001","value":"10.6","lowerLimit":"5.75","upperLimit":"17.40"}]}]},{"title":">=2 fold increase: Serotype O75: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","lowerLimit":"44.48","upperLimit":"57.06"},{"groupId":"OG001","value":"4.9","lowerLimit":"1.81","upperLimit":"10.32"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With a >= 4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by Multiplex ECL Based Immunoassay on Days 15 and 181","description":"Percentage of participants with a \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by multiplex ECL based immunoassay on Days 15 and 181 were reported. The fold (\\>=4-fold increase from baseline to Days 15 and 181) for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, and O75 was calculated as the ratio of titer values of serum antibody on Days 15 and 181 and pre-vaccination (on Day 1 that is Day 15/Day 1 and Day 181/Day 1).","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding participants with major protocol deviations expected to impact the immunogenicity outcomes. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this outcome measure and \"n\" (number analyzed) signifies those participants who were evaluable at specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline (Day 1, pre-vaccination), Days 15 and 181","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"131"}]}],"classes":[{"title":">=4 fold increase: Serotype O1A: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","lowerLimit":"48.19","upperLimit":"60.79"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"2.78"}]}]},{"title":">=4 fold increase: Serotype O2: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.9","lowerLimit":"72.24","upperLimit":"82.83"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.18"}]}]},{"title":">=4 fold increase: Serotype O4: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","lowerLimit":"54.56","upperLimit":"66.92"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.18"}]}]},{"title":">=4 fold increase: Serotype O6A: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.8","lowerLimit":"43.48","upperLimit":"56.13"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"2.78"}]}]},{"title":">=4 fold increase: Serotype O8: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","lowerLimit":"30.43","upperLimit":"42.62"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.19","upperLimit":"5.41"}]}]},{"title":">=4 fold increase: Serotype O15: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.9","lowerLimit":"52.56","upperLimit":"65.02"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.18"}]}]},{"title":">=4 fold increase: Serotype O16: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","lowerLimit":"56.17","upperLimit":"68.44"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.18"}]}]},{"title":">=4 fold increase: Serotype O18A: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.4","lowerLimit":"41.14","upperLimit":"53.78"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"2.78"}]}]},{"title":">=4 fold increase: Serotype O25B: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","lowerLimit":"51.76","upperLimit":"64.25"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.18"}]}]},{"title":">=4 fold increase: Serotype O75: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"131"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","lowerLimit":"19.34","upperLimit":"30.28"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.19","upperLimit":"5.41"}]}]},{"title":">=4 fold increase: Serotype O1A: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","lowerLimit":"41.96","upperLimit":"54.55"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"2.98"}]}]},{"title":">=4 fold increase: Serotype O2: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.9","lowerLimit":"63.90","upperLimit":"75.47"},{"groupId":"OG001","value":"7.3","lowerLimit":"3.40","upperLimit":"13.44"}]}]},{"title":">=4 fold increase: Serotype O4: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43.5","lowerLimit":"37.35","upperLimit":"49.86"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.51","upperLimit":"6.96"}]}]},{"title":">=4 fold increase: Serotype O6A: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.2","lowerLimit":"33.18","upperLimit":"45.50"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.45"}]}]},{"title":">=4 fold increase: Serotype O8: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","lowerLimit":"21.98","upperLimit":"33.24"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.45"}]}]},{"title":">=4 fold increase: Serotype O15: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","lowerLimit":"46.23","upperLimit":"58.81"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.45"}]}]},{"title":">=4 fold increase: Serotype O16: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.8","lowerLimit":"43.50","upperLimit":"56.11"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"2.95"}]}]},{"title":">=4 fold increase: Serotype O18A: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","lowerLimit":"29.06","upperLimit":"41.10"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"2.95"}]}]},{"title":">=4 fold increase: Serotype O25B: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.3","lowerLimit":"38.12","upperLimit":"50.64"},{"groupId":"OG001","value":"6.5","lowerLimit":"2.85","upperLimit":"12.41"}]}]},{"title":">=4 fold increase: Serotype O75: Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"11.74","upperLimit":"21.09"},{"groupId":"OG001","value":"3.3","lowerLimit":"0.89","upperLimit":"8.12"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Geometric Mean Titers (GMTs) of Serotype-specific Total IgG Serum Antibodies Against Specified Antigens Measured by MOPA on Day 181","description":"GMTs of serotype-specific total IgG serum antibodies as measured by MOPA were reported. Serotypes: O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75 were determined in serum from collected blood samples. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. LLOQ values for O1A: 33, O2: 42, O4: 12, O6A: 62, O15: 75, O16: 17, O18A: 44, O25B: 58, O75: 14. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding those samples with major protocol deviations expected to impact the immunogenicity outcomes. Participants in this analysis set had to have at least a baseline antibody titer measurement. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"At Day 181","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"classes":[{"title":"Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"411.3","lowerLimit":"355.6","upperLimit":"475.7"},{"groupId":"OG001","value":"334.1","lowerLimit":"270.8","upperLimit":"412.3"}]}]},{"title":"Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"1684.8","lowerLimit":"1413.3","upperLimit":"2008.5"},{"groupId":"OG001","value":"352.1","lowerLimit":"284.7","upperLimit":"435.5"}]}]},{"title":"Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"591.2","lowerLimit":"512.8","upperLimit":"681.6"},{"groupId":"OG001","value":"204.3","lowerLimit":"173.2","upperLimit":"241.0"}]}]},{"title":"Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"747.6","lowerLimit":"643.4","upperLimit":"868.6"},{"groupId":"OG001","value":"379.7","lowerLimit":"291.9","upperLimit":"494.0"}]}]},{"title":"Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"1756.2","lowerLimit":"1502.7","upperLimit":"2052.5"},{"groupId":"OG001","value":"469.6","lowerLimit":"372.5","upperLimit":"592.2"}]}]},{"title":"Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"890.9","lowerLimit":"758.7","upperLimit":"1046.1"},{"groupId":"OG001","value":"144.5","lowerLimit":"115.9","upperLimit":"180.1"}]}]},{"title":"Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"423.9","lowerLimit":"370.3","upperLimit":"485.2"},{"groupId":"OG001","value":"199.7","lowerLimit":"158.7","upperLimit":"251.2"}]}]},{"title":"Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"103.1","lowerLimit":"88.9","upperLimit":"119.6"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"59.1","comment":"NA signifies geometric mean and lower limit of 95% CI could not be calculated as values were below LLOQ (58)."}]}]},{"title":"Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"160.4","lowerLimit":"138.8","upperLimit":"185.3"},{"groupId":"OG001","value":"66.6","lowerLimit":"52.9","upperLimit":"83.8"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by MOPA on Day 181","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by MOPA on Day 181 was reported. The fold (\\>=2-fold and \\>=4-fold) increase from baseline to Day 181 for the serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 was calculated as the ratio of titer values of serum antibody on Day 181 and pre-vaccination (on Day 1) that is, Day 181/Day 1. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"The PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding those samples with major protocol deviations expected to impact the immunogenicity outcomes. Participants in this analysis set had to have at least a baseline antibody titer measurement. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline (Day 1, pre-vaccination) and Day 181","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"classes":[{"title":"Serotype O1A: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"22.1","lowerLimit":"17.18","upperLimit":"27.66"},{"groupId":"OG001","value":"12.5","lowerLimit":"5.88","upperLimit":"22.41"}]}]},{"title":"Serotype O1A: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"5.42","upperLimit":"12.63"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.04","upperLimit":"7.50"}]}]},{"title":"Serotype O2: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"64.7","lowerLimit":"58.56","upperLimit":"70.55"},{"groupId":"OG001","value":"12.5","lowerLimit":"5.88","upperLimit":"22.41"}]}]},{"title":"Serotype O2: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"42.6","lowerLimit":"36.52","upperLimit":"48.92"},{"groupId":"OG001","value":"2.8","lowerLimit":"0.34","upperLimit":"9.68"}]}]},{"title":"Serotype O4: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"61.6","lowerLimit":"55.39","upperLimit":"67.59"},{"groupId":"OG001","value":"19.4","lowerLimit":"11.06","upperLimit":"30.47"}]}]},{"title":"Serotype O4: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"36.4","lowerLimit":"30.55","upperLimit":"42.63"},{"groupId":"OG001","value":"2.8","lowerLimit":"0.34","upperLimit":"9.68"}]}]},{"title":"Serotype O6A: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"31.4","lowerLimit":"25.78","upperLimit":"37.44"},{"groupId":"OG001","value":"9.7","lowerLimit":"4.00","upperLimit":"19.01"}]}]},{"title":"Serotype O6A: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"12.0","lowerLimit":"8.31","upperLimit":"16.62"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.04","upperLimit":"7.50"}]}]},{"title":"Serotype O15: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"71.7","lowerLimit":"65.79","upperLimit":"77.12"},{"groupId":"OG001","value":"23.6","lowerLimit":"14.40","upperLimit":"35.09"}]}]},{"title":"Serotype O15: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"51.2","lowerLimit":"44.89","upperLimit":"57.41"},{"groupId":"OG001","value":"5.6","lowerLimit":"1.53","upperLimit":"13.62"}]}]},{"title":"Serotype O16: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"79.8","lowerLimit":"74.42","upperLimit":"84.57"},{"groupId":"OG001","value":"25.4","lowerLimit":"13.08","upperLimit":"33.14"}]}]},{"title":"Serotype O16: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"49.6","lowerLimit":"43.27","upperLimit":"55.95"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"4.93"}]}]},{"title":"Serotype O18A: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"53.5","lowerLimit":"47.20","upperLimit":"59.70"},{"groupId":"OG001","value":"16.7","lowerLimit":"8.92","upperLimit":"27.30"}]}]},{"title":"Serotype O18A: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"22.9","lowerLimit":"17.89","upperLimit":"28.48"},{"groupId":"OG001","value":"2.8","lowerLimit":"0.34","upperLimit":"9.68"}]}]},{"title":"Serotype O25B: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"26.0","lowerLimit":"20.73","upperLimit":"31.77"},{"groupId":"OG001","value":"4.2","lowerLimit":"0.87","upperLimit":"11.70"}]}]},{"title":"Serotype O25B: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"11.6","lowerLimit":"7.98","upperLimit":"16.18"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.04","upperLimit":"7.50"}]}]},{"title":"Serotype O75: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"55.5","lowerLimit":"49.15","upperLimit":"61.66"},{"groupId":"OG001","value":"29.6","lowerLimit":"19.33","upperLimit":"41.59"}]}]},{"title":"Serotype O75: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"32.8","lowerLimit":"27.09","upperLimit":"38.93"},{"groupId":"OG001","value":"5.6","lowerLimit":"1.56","upperLimit":"13.80"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype-specific Antibodies Measured by MOPA on Day 181","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by MOPA on Day 181 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples by MOPA. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 181 and pre-vaccination (on Day 1). For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"The PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding those samples with major protocol deviations expected to impact the immunogenicity outcomes. Participants in this analysis set had to have at least a baseline antibody titer measurement. Here, \"N\" (number of participants analyzed) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Baseline (Day 1, pre-vaccination), Day 181","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"123"}]}],"classes":[{"title":"Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"1.07","lowerLimit":"0.948","upperLimit":"1.201"},{"groupId":"OG001","value":"0.80","lowerLimit":"0.671","upperLimit":"0.954"}]}]},{"title":"Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"3.94","lowerLimit":"3.285","upperLimit":"4.727"},{"groupId":"OG001","value":"0.80","lowerLimit":"0.658","upperLimit":"0.983"}]}]},{"title":"Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"3.16","lowerLimit":"2.716","upperLimit":"3.686"},{"groupId":"OG001","value":"1.15","lowerLimit":"0.988","upperLimit":"1.349"}]}]},{"title":"Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"1.41","lowerLimit":"1.244","upperLimit":"1.5994"},{"groupId":"OG001","value":"0.80","lowerLimit":"0.680","upperLimit":"0.938"}]}]},{"title":"Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"4.19","lowerLimit":"3.568","upperLimit":"4.919"},{"groupId":"OG001","value":"1.13","lowerLimit":"0.885","upperLimit":"1.431"}]}]},{"title":"Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"6.63","lowerLimit":"5.601","upperLimit":"7.844"},{"groupId":"OG001","value":"1.21","lowerLimit":"0.994","upperLimit":"1.483"}]}]},{"title":"Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"2.30","lowerLimit":"2.008","upperLimit":"2.641"},{"groupId":"OG001","value":"1.03","lowerLimit":"0.875","upperLimit":"1.223"}]}]},{"title":"Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"1.42","lowerLimit":"1.277","upperLimit":"1.571"},{"groupId":"OG001","value":"0.94","lowerLimit":"0.857","upperLimit":"1.038"}]}]},{"title":"Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"2.56","lowerLimit":"2.246","upperLimit":"2.920"},{"groupId":"OG001","value":"1.18","lowerLimit":"0.965","upperLimit":"1.442"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Number of Participants With Serious Adverse Events (SAEs) Related to Study Vaccine or Study Procedure From Day 182 up to End of Study (Day 1826)","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","populationDescription":"The FAS included all randomized participants with a vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 182 up to end of study (Day 1826)","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"138"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Geometric Mean Titers (GMTs) of Serotype-specific Antibodies Against Specified Antigens Measured by Multiplex ECL Based Immunoassay on Day 366","description":"GMTs of serotype-specific antibodies as measured by ECL based immunoassay were reported. GMTs for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 were determined. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"The PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding those samples with major protocol deviations expected to impact the immunogenicity outcomes. Participants in this analysis set had to have at least a baseline antibody titer measurement. Here, \"N\" (Overall number of participants analyzed) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"At Day 366","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"129"}]}],"classes":[{"title":"Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"4022674.3","lowerLimit":"3621999.8","upperLimit":"4467672.3"},{"groupId":"OG001","value":"1425709.7","lowerLimit":"1193504.1","upperLimit":"1703092.6"}]}]},{"title":"Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"4539197.6","lowerLimit":"4061044.2","upperLimit":"5073649.6"},{"groupId":"OG001","value":"945957.9","lowerLimit":"770610.6","upperLimit":"1161204.5"}]}]},{"title":"Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"1877926.0","lowerLimit":"1662018.9","upperLimit":"2121880.9"},{"groupId":"OG001","value":"781470.1","lowerLimit":"645829.6","upperLimit":"945598.4"}]}]},{"title":"Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"3366305.0","lowerLimit":"3030852.9","upperLimit":"3738884.7"},{"groupId":"OG001","value":"1746191.5","lowerLimit":"1476781.0","upperLimit":"2064750.9"}]}]},{"title":"Serotype O8","categories":[{"measurements":[{"groupId":"OG000","value":"4468182.7","lowerLimit":"4073515.2","upperLimit":"4901088.0"},{"groupId":"OG001","value":"2612423.8","lowerLimit":"2233155.6","upperLimit":"3056105.0"}]}]},{"title":"Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"3690523.9","lowerLimit":"3327526.1","upperLimit":"4093120.9"},{"groupId":"OG001","value":"1379883.1","lowerLimit":"1146231.7","upperLimit":"1661162.7"}]}]},{"title":"Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"2732322.4","lowerLimit":"2460092.5","upperLimit":"3034676.8"},{"groupId":"OG001","value":"909470.4","lowerLimit":"771204.3","upperLimit":"1072525.6"}]}]},{"title":"Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"2902883.8","lowerLimit":"2610124.6","upperLimit":"3228479.7"},{"groupId":"OG001","value":"1538291.3","lowerLimit":"1327257.2","upperLimit":"1782880.0"}]}]},{"title":"Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"1010150.2","lowerLimit":"874663.8","upperLimit":"1166623.5"},{"groupId":"OG001","value":"344740.3","lowerLimit":"281210.9","upperLimit":"422621.9"}]}]},{"title":"Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"2675947.8","lowerLimit":"2416208.1","upperLimit":"2963609.2"},{"groupId":"OG001","value":"1512970.1","lowerLimit":"1293159.3","upperLimit":"1770144.2"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by Multiplex ECL Based Immunoassay on Day 366","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by multiplex ECL based immunoassay on Day 366 was reported. The fold (\\>=2-fold and \\>=4- fold) increase from baseline to Day 366 for the serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 was calculated as the ratio of titer values of serum antibodies on Day 366 and pre-vaccination (on day 1) that is, Day 366/ Day 1. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"The PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding those samples with major protocol deviations expected to impact the immunogenicity outcomes. Participants in this analysis set had to have at least a baseline antibody titer measurement. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline (Day 1, pre-vaccination), Day 366","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"129"}]}],"classes":[{"title":"Serotype O1A: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"62.4","lowerLimit":"56.09","upperLimit":"68.32"},{"groupId":"OG001","value":"7.0","lowerLimit":"3.24","upperLimit":"12.83"}]}]},{"title":"Serotype O1A: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"34.9","lowerLimit":"29.06","upperLimit":"41.10"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"2.82"}]}]},{"title":"Serotype O2: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"81.6","lowerLimit":"76.26","upperLimit":"86.13"},{"groupId":"OG001","value":"18.6","lowerLimit":"12.30","upperLimit":"26.41"}]}]},{"title":"Serotype O2: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"66.3","lowerLimit":"60.11","upperLimit":"72.05"},{"groupId":"OG001","value":"3.9","lowerLimit":"1.27","upperLimit":"8.81"}]}]},{"title":"Serotype O4: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"60.0","lowerLimit":"53.70","upperLimit":"66.06"},{"groupId":"OG001","value":"11.6","lowerLimit":"6.66","upperLimit":"18.45"}]}]},{"title":"Serotype O4: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"32.5","lowerLimit":"26.84","upperLimit":"38.67"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.85","upperLimit":"7.75"}]}]},{"title":"Serotype O6: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"54.7","lowerLimit":"48.38","upperLimit":"60.96"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.48","upperLimit":"6.65"}]}]},{"title":"Serotype O6: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"22.0","lowerLimit":"17.11","upperLimit":"27.65"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.24"}]}]},{"title":"Serotype O8: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"51.0","lowerLimit":"44.67","upperLimit":"57.27"},{"groupId":"OG001","value":"10.1","lowerLimit":"5.48","upperLimit":"16.62"}]}]},{"title":"Serotype O8: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"18.4","lowerLimit":"13.87","upperLimit":"23.74"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.85","upperLimit":"7.75"}]}]},{"title":"Serotype O15: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"67.8","lowerLimit":"61.73","upperLimit":"73.53"},{"groupId":"OG001","value":"13.2","lowerLimit":"7.87","upperLimit":"20.26"}]}]},{"title":"Serotype O15: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"36.9","lowerLimit":"30.93","upperLimit":"43.11"},{"groupId":"OG001","value":"7.0","lowerLimit":"3.24","upperLimit":"12.83"}]}]},{"title":"Serotype O16: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"63.9","lowerLimit":"57.70","upperLimit":"69.82"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.48","upperLimit":"6.65"}]}]},{"title":"Serotype O16: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"27.5","lowerLimit":"22.07","upperLimit":"33.37"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.24"}]}]},{"title":"Serotype O18A: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"55.3","lowerLimit":"48.96","upperLimit":"61.50"},{"groupId":"OG001","value":"11.6","lowerLimit":"6.66","upperLimit":"18.45"}]}]},{"title":"Serotype O18A: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"24.3","lowerLimit":"19.18","upperLimit":"30.06"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"2.82"}]}]},{"title":"Serotype O25B: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"56.9","lowerLimit":"50.54","upperLimit":"63.03"},{"groupId":"OG001","value":"6.2","lowerLimit":"2.72","upperLimit":"11.85"}]}]},{"title":"Serotype O25B: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"30.6","lowerLimit":"24.99","upperLimit":"36.64"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.48","upperLimit":"6.65"}]}]},{"title":"Serotype O75: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"33.7","lowerLimit":"27.95","upperLimit":"39.89"},{"groupId":"OG001","value":"8.6","lowerLimit":"4.37","upperLimit":"14.86"}]}]},{"title":"Serotype O75: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"8.2","lowerLimit":"5.17","upperLimit":"12.31"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.02","upperLimit":"4.28"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype-specific Antibodies Measured by Multiplex ECL Based Immunoassay on Day 366","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by multiplex ECL based immunoassay on Day 366 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B, O75 were determined in serum from collected blood samples by ECL based immunoassay. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 366 and pre-vaccination (on Day 1). Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"The PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding those samples with major protocol deviations expected to impact the immunogenicity outcomes. Participants in this analysis set had to have at least a baseline antibody titer measurement. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Baseline (Day 1, pre-vaccination), Day 366","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"129"}]}],"classes":[{"title":"Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"2.77","lowerLimit":"2.497","upperLimit":"3.070"},{"groupId":"OG001","value":"0.83","lowerLimit":"0.758","upperLimit":"0.909"}]}]},{"title":"Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"6.05","lowerLimit":"5.330","upperLimit":"6.878"},{"groupId":"OG001","value":"1.21","lowerLimit":"1.087","upperLimit":"1.342"}]}]},{"title":"Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"2.82","lowerLimit":"2.536","upperLimit":"3.144"},{"groupId":"OG001","value":"1.04","lowerLimit":"0.951","upperLimit":"1.139"}]}]},{"title":"Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"2.31","lowerLimit":"2.102","upperLimit":"2.534"},{"groupId":"OG001","value":"0.95","lowerLimit":"0.875","upperLimit":"1.028"}]}]},{"title":"Serotype O8","categories":[{"measurements":[{"groupId":"OG000","value":"2.09","lowerLimit":"1.915","upperLimit":"2.277"},{"groupId":"OG001","value":"1.10","lowerLimit":"1.009","upperLimit":"1.202"}]}]},{"title":"Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"3.15","lowerLimit":"2.862","upperLimit":"3.468"},{"groupId":"OG001","value":"1.18","lowerLimit":"1.064","upperLimit":"1.312"}]}]},{"title":"Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"2.63","lowerLimit":"2.388","upperLimit":"2.906"},{"groupId":"OG001","value":"0.83","lowerLimit":"0.753","upperLimit":"0.920"}]}]},{"title":"Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"2.44","lowerLimit":"2.248","upperLimit":"2.658"},{"groupId":"OG001","value":"1.19","lowerLimit":"1.106","upperLimit":"1.286"}]}]},{"title":"Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"2.66","lowerLimit":"2.365","upperLimit":"2.983"},{"groupId":"OG001","value":"0.91","lowerLimit":"0.830","upperLimit":"1.003"}]}]},{"title":"Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"1.68","lowerLimit":"1.563","upperLimit":"1.809"},{"groupId":"OG001","value":"1.00","lowerLimit":"0.917","upperLimit":"1.088"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Geometric Mean Titers (GMTs) of Serotype-specific Total IgG Serum Antibodies Against Specified Antigens Measured by MOPA on Day 366","description":"GMTs of serotype-specific total IgG serum antibodies as measured by MOPA were reported. GMTs for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75 were determined in serum from collected blood samples. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. LLOQ values for O1A: 33, O2: 42, O4: 12, O6A: 62, O15: 75, O16: 17, O18A: 44, O25B: 58, O75: 14. Any titer less than LLOQ is replaced by half of LLOQ (0.5\\*LLOQ).","populationDescription":"The PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding those samples with major protocol deviations expected to impact the immunogenicity outcomes. Participants in this analysis set had to have at least a baseline antibody titer measurement. Here, \"N\" (Overall number of participants analyzed) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"At Day 366","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"129"}]}],"classes":[{"title":"Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"376.0","lowerLimit":"325.3","upperLimit":"434.5"},{"groupId":"OG001","value":"368.5","lowerLimit":"302.4","upperLimit":"449.1"}]}]},{"title":"Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"1167.9","lowerLimit":"994.6","upperLimit":"1371.5"},{"groupId":"OG001","value":"395.5","lowerLimit":"322.9","upperLimit":"484.5"}]}]},{"title":"Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"398.1","lowerLimit":"347.2","upperLimit":"456.5"},{"groupId":"OG001","value":"191.7","lowerLimit":"163.3","upperLimit":"225.0"}]}]},{"title":"Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"592.2","lowerLimit":"509.2","upperLimit":"688.9"},{"groupId":"OG001","value":"395.4","lowerLimit":"302.6","upperLimit":"516.7"}]}]},{"title":"Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"1125.8","lowerLimit":"958.3","upperLimit":"1322.7"},{"groupId":"OG001","value":"478.8","lowerLimit":"377.2","upperLimit":"607.7"}]}]},{"title":"Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"557.6","lowerLimit":"470.4","upperLimit":"660.9"},{"groupId":"OG001","value":"134.5","lowerLimit":"107.8","upperLimit":"167.8"}]}]},{"title":"Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"335.1","lowerLimit":"291.5","upperLimit":"385.1"},{"groupId":"OG001","value":"211.6","lowerLimit":"171.5","upperLimit":"261.1"}]}]},{"title":"Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"78.0","lowerLimit":"67.6","upperLimit":"90.0"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"NA signifies that geometric mean and 95% CI could not be calculated as the values were below LLOQ (58)."}]}]},{"title":"Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"126.5","lowerLimit":"109.7","upperLimit":"145.9"},{"groupId":"OG001","value":"78.6","lowerLimit":"62.6","upperLimit":"98.7"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Geometric Mean Ratio (GMR) of Fold Changes From Baseline for Serotype-specific Antibodies Measured by MOPA on Day 366","description":"GMR of fold changes from baseline for serotype specific antibodies as measured by MOPA on Day 366 were reported. GMR for each antigen serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 were determined in serum from collected blood samples by MOPA. GMR of fold change from baseline was calculated as the ratio of GMTs on Day 366 and pre-vaccination (on Day 1). For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"The PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding those samples with major protocol deviations expected to impact the immunogenicity outcomes. Participants in this analysis set had to have at least a baseline antibody titer measurement. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Baseline (Day 1, pre-vaccination), Day 366","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"129"}]}],"classes":[{"title":"Serotype O1A","categories":[{"measurements":[{"groupId":"OG000","value":"0.99","lowerLimit":"0.880","upperLimit":"1.104"},{"groupId":"OG001","value":"0.84","lowerLimit":"0.704","upperLimit":"1.013"}]}]},{"title":"Serotype O2","categories":[{"measurements":[{"groupId":"OG000","value":"2.70","lowerLimit":"2.292","upperLimit":"3.178"},{"groupId":"OG001","value":"0.78","lowerLimit":"0.653","upperLimit":"0.931"}]}]},{"title":"Serotype O4","categories":[{"measurements":[{"groupId":"OG000","value":"2.14","lowerLimit":"1.857","upperLimit":"2.474"},{"groupId":"OG001","value":"1.04","lowerLimit":"0.889","upperLimit":"1.222"}]}]},{"title":"Serotype O6A","categories":[{"measurements":[{"groupId":"OG000","value":"1.11","lowerLimit":"0.987","upperLimit":"1.259"},{"groupId":"OG001","value":"0.84","lowerLimit":"0.693","upperLimit":"1.009"}]}]},{"title":"Serotype O15","categories":[{"measurements":[{"groupId":"OG000","value":"2.66","lowerLimit":"2.251","upperLimit":"3.137"},{"groupId":"OG001","value":"0.98","lowerLimit":"0.736","upperLimit":"1.314"}]}]},{"title":"Serotype O16","categories":[{"measurements":[{"groupId":"OG000","value":"4.06","lowerLimit":"3.448","upperLimit":"4.782"},{"groupId":"OG001","value":"0.98","lowerLimit":"0.813","upperLimit":"1.174"}]}]},{"title":"Serotype O18A","categories":[{"measurements":[{"groupId":"OG000","value":"1.84","lowerLimit":"1.612","upperLimit":"2.097"},{"groupId":"OG001","value":"0.97","lowerLimit":"0.831","upperLimit":"1.135"}]}]},{"title":"Serotype O25B","categories":[{"measurements":[{"groupId":"OG000","value":"1.19","lowerLimit":"1.088","upperLimit":"1.294"},{"groupId":"OG001","value":"0.93","lowerLimit":"0.822","upperLimit":"1.060"}]}]},{"title":"Serotype O75","categories":[{"measurements":[{"groupId":"OG000","value":"2.09","lowerLimit":"1.837","upperLimit":"2.369"},{"groupId":"OG001","value":"1.40","lowerLimit":"1.137","upperLimit":"1.717"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With a >= 2-Fold and >=4-Fold Increase in Serotype-specific Serum Antibody Titers Measured by MOPA on Day 366","description":"Percentage of participants with a \\>=2-fold and \\>=4-fold increase from baseline in serotype specific serum antibody titers as measured by MOPA on Day 366 was reported. The \\>=2-fold and \\>=4-fold increase from baseline to Day 366 for the serotypes O1A, O2, O4, O6A, O15, O16, O18A, O25B and O75 was calculated as the ratio of titer values of serum antibody on Day 366 and pre-vaccination (on day 1) that is, Day 366/Day 1. For serotype O8 functional IgG serum antibodies were not evaluated as the assay was not able to detect vaccine-induced functional antibodies against the O8 serotype. Any titer less than LLOQ is replaced by value of LLOQ.","populationDescription":"The PPI analysis set included all randomized and vaccinated participants, for whom immunogenicity data were available excluding those samples with major protocol deviations expected to impact the immunogenicity outcomes. Participants in this analysis set had to have at least a baseline antibody titer measurement. Here, \"N\" (Number of participants analyzed) signifies participants evaluable for this endpoint.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline (Day 1, pre-vaccination), Day 366","groups":[{"id":"OG000","title":"Cohort 2: ExPEC10V High Dose","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1."},{"id":"OG001","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"129"}]}],"classes":[{"title":"Serotype O1A: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"22.6","lowerLimit":"17.60","upperLimit":"28.29"},{"groupId":"OG001","value":"12.3","lowerLimit":"5.80","upperLimit":"22.12"}]}]},{"title":"Serotype O1A: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"3.07","upperLimit":"9.15"},{"groupId":"OG001","value":"2.7","lowerLimit":"0.33","upperLimit":"9.55"}]}]},{"title":"Serotype O2: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"54.0","lowerLimit":"47.60","upperLimit":"60.24"},{"groupId":"OG001","value":"11.0","lowerLimit":"4.85","upperLimit":"20.46"}]}]},{"title":"Serotype O2: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"32.1","lowerLimit":"26.42","upperLimit":"38.29"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.03","upperLimit":"7.40"}]}]},{"title":"Serotype O4: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"48.0","lowerLimit":"41.70","upperLimit":"54.37"},{"groupId":"OG001","value":"11.0","lowerLimit":"4.85","upperLimit":"20.46"}]}]},{"title":"Serotype O4: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"23.0","lowerLimit":"17.97","upperLimit":"28.71"},{"groupId":"OG001","value":"2.7","lowerLimit":"0.33","upperLimit":"9.55"}]}]},{"title":"Serotype O6A: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"25.1","lowerLimit":"19.86","upperLimit":"30.94"},{"groupId":"OG001","value":"12.3","lowerLimit":"5.80","upperLimit":"22.12"}]}]},{"title":"Serotype O6A: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"9.2","lowerLimit":"5.90","upperLimit":"13.43"},{"groupId":"OG001","value":"6.8","lowerLimit":"2.26","upperLimit":"15.26"}]}]},{"title":"Serotype O15: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"57.9","lowerLimit":"51.58","upperLimit":"64.10"},{"groupId":"OG001","value":"21.9","lowerLimit":"13.08","upperLimit":"33.14"}]}]},{"title":"Serotype O15: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"37.3","lowerLimit":"31.31","upperLimit":"43.59"},{"groupId":"OG001","value":"6.8","lowerLimit":"2.26","upperLimit":"15.26"}]}]},{"title":"Serotype O16: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"67.5","lowerLimit":"61.30","upperLimit":"73.21"},{"groupId":"OG001","value":"21.9","lowerLimit":"13.08","upperLimit":"33.14"}]}]},{"title":"Serotype O16: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"49.6","lowerLimit":"43.27","upperLimit":"55.95"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.00","upperLimit":"4.93"}]}]},{"title":"Serotype O18A: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"38.5","lowerLimit":"32.45","upperLimit":"44.80"},{"groupId":"OG001","value":"9.9","lowerLimit":"4.06","upperLimit":"19.26"}]}]},{"title":"Serotype O18A: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"17.1","lowerLimit":"12.63","upperLimit":"22.29"},{"groupId":"OG001","value":"2.8","lowerLimit":"0.34","upperLimit":"9.81"}]}]},{"title":"Serotype O25B: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"15.9","lowerLimit":"11.59","upperLimit":"20.98"},{"groupId":"OG001","value":"8.2","lowerLimit":"3.08","upperLimit":"17.04"}]}]},{"title":"Serotype O25B: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"3.07","upperLimit":"9.15"},{"groupId":"OG001","value":"2.7","lowerLimit":"0.33","upperLimit":"9.55"}]}]},{"title":"Serotype O75: >=2 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"51.6","lowerLimit":"45.22","upperLimit":"57.94"},{"groupId":"OG001","value":"40.0","lowerLimit":"28.47","upperLimit":"52.41"}]}]},{"title":"Serotype O75: >=4 fold increase","categories":[{"measurements":[{"groupId":"OG000","value":"24.8","lowerLimit":"19.57","upperLimit":"30.63"},{"groupId":"OG001","value":"5.7","lowerLimit":"1.58","upperLimit":"13.99"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"3","timeFrame":"From Day 1 (post vaccination) up to Day 1826","description":"FAS included all randomized participants with a vaccine administration documented.","eventGroups":[{"id":"EG000","title":"Cohort 1: Low Dose ExPEC10V","description":"Participants aged greater than or equal to (\\>=) 60 to less than or equal to (\\<=) 85 years in stable health with or without a history of urinary tract infection (UTI) received a single 0.5 milliliter (mL) intramuscular (IM) injection of ExPEC10V low dose (88 micrograms polysaccharide per milliliter \\[mcg PS/mL\\]) on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":104,"seriousNumAffected":2,"seriousNumAtRisk":104,"otherNumAffected":60,"otherNumAtRisk":104},{"id":"EG001","title":"Cohort 1: Medium Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V medium dose (120 mcg PS/mL) on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":102,"seriousNumAffected":2,"seriousNumAtRisk":102,"otherNumAffected":61,"otherNumAtRisk":102},{"id":"EG002","title":"Cohort 1: High Dose ExPEC10V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":104,"seriousNumAffected":0,"seriousNumAtRisk":104,"otherNumAffected":71,"otherNumAtRisk":104},{"id":"EG003","title":"Cohort 1: ExPEC4V","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of ExPEC4V 40 mcg PS/mL on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":52,"seriousNumAffected":0,"seriousNumAtRisk":52,"otherNumAffected":24,"otherNumAtRisk":52},{"id":"EG004","title":"Cohort 1: Prevnar 13","description":"Participants aged \\>=60 to \\<= 85 years in stable health with or without a history of UTI received a single 0.5 mL IM injection of Prevnar 13 on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":54,"seriousNumAffected":1,"seriousNumAtRisk":54,"otherNumAffected":41,"otherNumAtRisk":54},{"id":"EG005","title":"Cohort 2: ExPEC10V","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of ExPEC10V high dose (176 mcg PS/mL) on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":278,"seriousNumAffected":9,"seriousNumAtRisk":278,"otherNumAffected":180,"otherNumAtRisk":278},{"id":"EG006","title":"Cohort 2: Placebo","description":"Participants aged \\>=60 years in stable health with a history of UTI received a single 0.5 mL IM injection of placebo (matched to ExPEC10V high dose) on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":138,"seriousNumAffected":6,"seriousNumAtRisk":138,"otherNumAffected":64,"otherNumAtRisk":138}],"seriousEvents":[{"term":"Abdominal Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":1,"numAtRisk":278},{"groupId":"EG006","numAffected":0,"numAtRisk":138}]},{"term":"Non-Cardiac Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":2,"numAtRisk":278},{"groupId":"EG006","numAffected":0,"numAtRisk":138}]},{"term":"Enterococcal Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":0,"numAtRisk":278},{"groupId":"EG006","numAffected":1,"numAtRisk":138}]},{"term":"Enterocolitis Infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":1,"numAtRisk":278},{"groupId":"EG006","numAffected":0,"numAtRisk":138}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":1,"numAtRisk":278},{"groupId":"EG006","numAffected":0,"numAtRisk":138}]},{"term":"Pyelonephritis Acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":0,"numAtRisk":278},{"groupId":"EG006","numAffected":1,"numAtRisk":138}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":1,"numAtRisk":278},{"groupId":"EG006","numAffected":0,"numAtRisk":138}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":0,"numAtRisk":278},{"groupId":"EG006","numAffected":1,"numAtRisk":138}]},{"term":"Lumbar Vertebral Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":0,"numAtRisk":278},{"groupId":"EG006","numAffected":1,"numAtRisk":138}]},{"term":"Intervertebral Disc Protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":104},{"groupId":"EG001","numAffected":1,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":0,"numAtRisk":278},{"groupId":"EG006","numAffected":1,"numAtRisk":138}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":1,"numAtRisk":54},{"groupId":"EG005","numAffected":1,"numAtRisk":278},{"groupId":"EG006","numAffected":0,"numAtRisk":138}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":0,"numAtRisk":278},{"groupId":"EG006","numAffected":1,"numAtRisk":138}]},{"term":"Calculus Urinary","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":1,"numAtRisk":278},{"groupId":"EG006","numAffected":0,"numAtRisk":138}]},{"term":"Chronic Kidney Disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":0,"numAtRisk":278},{"groupId":"EG006","numAffected":1,"numAtRisk":138}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":1,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":1,"numAtRisk":278},{"groupId":"EG006","numAffected":0,"numAtRisk":138}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":0,"numAtRisk":278},{"groupId":"EG006","numAffected":1,"numAtRisk":138}]}],"otherEvents":[{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":2,"numAtRisk":54},{"groupId":"EG005","numAffected":0,"numAtRisk":278},{"groupId":"EG006","numAffected":0,"numAtRisk":138}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":4,"numAtRisk":104},{"groupId":"EG003","numAffected":1,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":3,"numAtRisk":278},{"groupId":"EG006","numAffected":3,"numAtRisk":138}]},{"term":"Nausea (Solicited)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":104},{"groupId":"EG001","numAffected":9,"numAtRisk":102},{"groupId":"EG002","numAffected":11,"numAtRisk":104},{"groupId":"EG003","numAffected":1,"numAtRisk":52},{"groupId":"EG004","numAffected":2,"numAtRisk":54},{"groupId":"EG005","numAffected":40,"numAtRisk":278},{"groupId":"EG006","numAffected":8,"numAtRisk":138}]},{"term":"Erythema (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":104},{"groupId":"EG001","numAffected":19,"numAtRisk":102},{"groupId":"EG002","numAffected":19,"numAtRisk":104},{"groupId":"EG003","numAffected":1,"numAtRisk":52},{"groupId":"EG004","numAffected":5,"numAtRisk":54},{"groupId":"EG005","numAffected":60,"numAtRisk":278},{"groupId":"EG006","numAffected":1,"numAtRisk":138}]},{"term":"Fatigue (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":104},{"groupId":"EG001","numAffected":29,"numAtRisk":102},{"groupId":"EG002","numAffected":24,"numAtRisk":104},{"groupId":"EG003","numAffected":8,"numAtRisk":52},{"groupId":"EG004","numAffected":13,"numAtRisk":54},{"groupId":"EG005","numAffected":98,"numAtRisk":278},{"groupId":"EG006","numAffected":31,"numAtRisk":138}]},{"term":"Fever (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":3,"numAtRisk":104},{"groupId":"EG003","numAffected":1,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":15,"numAtRisk":278},{"groupId":"EG006","numAffected":3,"numAtRisk":138}]},{"term":"Injection Site Pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":104},{"groupId":"EG001","numAffected":5,"numAtRisk":102},{"groupId":"EG002","numAffected":3,"numAtRisk":104},{"groupId":"EG003","numAffected":2,"numAtRisk":52},{"groupId":"EG004","numAffected":1,"numAtRisk":54},{"groupId":"EG005","numAffected":7,"numAtRisk":278},{"groupId":"EG006","numAffected":0,"numAtRisk":138}]},{"term":"Pain/Tenderness (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":46,"numAtRisk":104},{"groupId":"EG001","numAffected":52,"numAtRisk":102},{"groupId":"EG002","numAffected":60,"numAtRisk":104},{"groupId":"EG003","numAffected":15,"numAtRisk":52},{"groupId":"EG004","numAffected":39,"numAtRisk":54},{"groupId":"EG005","numAffected":132,"numAtRisk":278},{"groupId":"EG006","numAffected":20,"numAtRisk":138}]},{"term":"Swelling (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":104},{"groupId":"EG001","numAffected":15,"numAtRisk":102},{"groupId":"EG002","numAffected":14,"numAtRisk":104},{"groupId":"EG003","numAffected":2,"numAtRisk":52},{"groupId":"EG004","numAffected":2,"numAtRisk":54},{"groupId":"EG005","numAffected":44,"numAtRisk":278},{"groupId":"EG006","numAffected":2,"numAtRisk":138}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":104},{"groupId":"EG001","numAffected":4,"numAtRisk":102},{"groupId":"EG002","numAffected":1,"numAtRisk":104},{"groupId":"EG003","numAffected":3,"numAtRisk":52},{"groupId":"EG004","numAffected":3,"numAtRisk":54},{"groupId":"EG005","numAffected":1,"numAtRisk":278},{"groupId":"EG006","numAffected":0,"numAtRisk":138}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":1,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":7,"numAtRisk":278},{"groupId":"EG006","numAffected":10,"numAtRisk":138}]},{"term":"Blood Pressure Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":104},{"groupId":"EG001","numAffected":0,"numAtRisk":102},{"groupId":"EG002","numAffected":0,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":2,"numAtRisk":54},{"groupId":"EG005","numAffected":1,"numAtRisk":278},{"groupId":"EG006","numAffected":0,"numAtRisk":138}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":104},{"groupId":"EG001","numAffected":3,"numAtRisk":102},{"groupId":"EG002","numAffected":2,"numAtRisk":104},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":54},{"groupId":"EG005","numAffected":7,"numAtRisk":278},{"groupId":"EG006","numAffected":6,"numAtRisk":138}]},{"term":"Myalgia (Solicited)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":104},{"groupId":"EG001","numAffected":36,"numAtRisk":102},{"groupId":"EG002","numAffected":37,"numAtRisk":104},{"groupId":"EG003","numAffected":10,"numAtRisk":52},{"groupId":"EG004","numAffected":21,"numAtRisk":54},{"groupId":"EG005","numAffected":84,"numAtRisk":278},{"groupId":"EG006","numAffected":23,"numAtRisk":138}]},{"term":"Headache (Solicited)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":104},{"groupId":"EG001","numAffected":25,"numAtRisk":102},{"groupId":"EG002","numAffected":25,"numAtRisk":104},{"groupId":"EG003","numAffected":11,"numAtRisk":52},{"groupId":"EG004","numAffected":10,"numAtRisk":54},{"groupId":"EG005","numAffected":74,"numAtRisk":278},{"groupId":"EG006","numAffected":34,"numAtRisk":138}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Days 1 and 15 samples in all arms were first tested with qualified MOPA. Only later timepoints Day 30 onwards used validated MOPA once available. As high-dose ExPEC10V regimen was selected to move forward in clinical development, low, medium-dose ExPEC10V, and ExPEC4V arms were not tested with validated MOPA at Days 1 and 15. Hence, at Days 30 and 181, GMRs and 2-and 4-fold changes cannot be calculated as MOPA results from Day 1 versus Days 30 and 181 were derived using different MOPA assay."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days."},"pointOfContact":{"title":"Trial Physician","organization":"Janssen Research & Development, LLC","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-10-19","uploadDate":"2024-05-30T05:37","filename":"Prot_000.pdf","size":1980399},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-12-08","uploadDate":"2026-04-17T06:33","filename":"SAP_002.pdf","size":1716260}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"interventionBrowseModule":{"meshes":[{"id":"C538862","term":"13-valent pneumococcal vaccine"}]}},"hasResults":true}